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Parkinson’s	  disease	  is	  a	  progressively	  debilitating	  disease	  that	  affects	  about	  1%	  of	  the	  
world’s	  population,	  and	  does	  not	  differentiate	  between	  genders	  or	  races.	  	  The	  disease	  is	  
caused	  by	  the	  death	  of	  dopaminergic	  neurons	  in	  the	  basal	  ganglia	  nuclei,	  especially	  
those	  in	  the	  substantia	  nigra	  pars	  compacta.	  	  Subsequent	  loss	  of	  dopamine	  production	  
engenders	  the	  cardinal	  symptoms	  of	  bradykinesia,	  rigidity,	  akinesia,	  and	  postural	  
instability	  found	  in	  all	  patients	  with	  Parkinson’s	  disease.	  	  	  While	  there	  are	  several	  types	  
of	  Parkinson’s	  disease,	  the	  majority	  of	  the	  cases	  are	  made	  up	  of	  the	  idiopathic	  and	  
Levodopa	  responsive	  type.	  	  The	  current	  consensus	  on	  treatment	  is	  to	  use	  medications	  
until	  the	  patient	  becomes	  refractory	  to	  all	  medicines.	  	  It	  is	  only	  at	  this	  point	  will	  the	  
surgical	  option	  deep	  brain	  stimulation	  be	  considered.	  	  While	  this	  procedure	  comes	  with	  
a	  higher	  risk	  of	  post	  surgery	  complications,	  the	  benefits	  it	  offers	  patients	  with	  advanced	  
Parkinson’s	  disease	  are	  far	  superior	  to	  those	  offered	  patients	  by	  medications.	  	  	  It	  
reasons	  then	  that	  patients	  would	  benefit	  more	  if	  they	  received	  this	  treatment	  earlier	  in	  





long	  term	  effects	  on	  quality	  of	  life	  of	  deep	  brain	  stimulation	  will	  be	  compared	  with	  
those	  of	  medications	  to	  assess	  whether	  it	  is	  worthwhile	  to	  use	  this	  treatment	  for	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MC	   	   	   	  Motor	  cortex	  
MCP	   	   	   	  Midcommissural	  point	  
	  
MER	   	   	   	  Microelectrode	  Recording	  
	  
MPP+	   	   	   1-­‐methyl-­‐4-­‐phenylpyridinium	  
	  
MPTP	   	   	   	  1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine	  
	  
MRI	   	   	   Magnetic	  resonance	  imaging	  
OHDA	   	   	   	  6-­‐hydroxydopamine	  
	  
OMD	   	   	   3-­‐O-­‐methyl	  dopa	  
OT	   	   	   	  Optic	  tract	  
	  
PC	   	   	   	  Posterior	  Commissure	  
	  
PD	   	   	   	  Parkinson’s	  Disease/parkinsonism	  
	  





PPN	   	   	   	  Pedunculopontine	  Nucleus	  
	  
Put	   	   	   	  Putamen	  Nucleus	  
	  
QALY	   	   	   Quality	  of	  life	  
RAS	   	   	   	  Reticular	  Activating	  System	  
	  
SN	   	   	   	  Substantia	  Nigra	  
	  
SNpc/SNc	   	   	  Substantia	  Nigra	  Pars	  Compacta	  
	  
SNpr/SNr	   	   	  Substantia	  Nigra	  Pars	  Reticulate	  
	  
SPECT	   	   	   Single	  photon	  emission	  computed	  tomography	  
Sth/STN	   	   	  Subthalamic	  Nucleus	  
	  
Striatum	   	   	  Caudate	  Nucleus	  and	  Putamen	  Nucleus	  
	  
TH	   	   	   	  Tyrosine	  hydroxylase	  
	  
Thal	   	   	   	  Thalamus	  
UPDRS	  	   	   Unified	  Parkinson’s	  Disease	  Rating	  Scale	  
VA	   	   	   Ventral	  Anterior	  Nucleus	  of	  Thalamus	  
	  
VIM	   	   	   Ventral	  Intermediate	  Nucleus	  of	  Thalamus	  
	  
VL	   	   	   Ventral	  Lateral	  Nucleus	  of	  Thalamus	  
	  
VP	   	   	   Ventral	  Posterior	  Nucleus	  of	  Thalamus	  
	  
VOA	   	   	   Ventralis	  Oralis	  Anterior	  
	  
VOP	   	   	   Ventralis	  Oralis	  Posterior	  
	  
	  





	   	   	   	   	   Introduction:	  
Parkinson’s	  disease	  (PD),	  the	  second	  most	  common	  neurodegenerative	  disorder	  after	  to	  
Alzheimer	  ’s	  disease,	  is	  an	  incurable	  debilitating	  motor	  related	  condition	  (George	  et	  al.,	  
2009).	  	  It	  is	  caused	  by	  a	  gradual	  progressive	  degeneration	  of	  nigrostriatal	  neurons	  and	  
subsequent	  loss	  of	  dopamine.	  	  As	  the	  disease	  progresses,	  about	  10%	  of	  the	  remaining	  
dopaminergic	  cells	  die	  each	  year.	  	  This	  may	  explain	  why	  patients	  do	  well	  initially	  with	  
medications	  but	  become	  unresponsive	  to	  them	  later	  on.	  	  Patients	  then	  start	  manifesting	  
other	  non-­‐dopaminergic	  and	  neuropsychiatric	  symptoms.	  	  At	  this	  stage	  of	  development,	  
treatments	  through	  surgery	  and	  deep	  brain	  stimulation	  are	  used	  in	  place	  of	  medications	  
(Siegel,	  2011).	  
	  
Epidemiology	  of	  Parkinson’s	  disease:	  
The	  frequency	  of	  PD	  differs	  depending	  on	  the	  diagnostic	  criteria,	  study	  population,	  and	  
epidemiologic	  methods	  used.	  	  In	  one	  study	  involving	  a	  joint	  analysis	  of	  five	  European	  
communities,	  the	  overall	  prevalence	  of	  PD	  was	  1.6%	  in	  population	  over	  65	  and	  3.5%	  in	  
those	  older	  than	  85	  (de	  Lau	  et	  al.	  2006).	  	  	  In	  another	  prospective	  study	  involving	  142,902	  
healthcare	  professionals,	  the	  incidence	  of	  PD	  was	  at	  18.6/100,000	  person-­‐years	  (Chen	  
H.	  et	  al.,	  2003).	  	  The	  incidence	  for	  men	  –	  43.2	  per	  100,000	  person-­‐years	  –	  was	  higher	  
than	  that	  for	  women	  –	  10.7	  per	  100,000	  person-­‐years	  (Chen	  H.	  et	  al.,	  2003).	  	  In	  a	  third	  





maintenance	  organization,	  588	  newly	  diagnosed	  cases	  of	  PD	  were	  identified,	  giving	  an	  
annualized	  incidence,	  adjusted	  for	  age	  and	  gender,	  of	  13.4/100,000(Van	  Den	  Eeden	  et	  
al.,	  2003).	  	  In	  this	  latter	  study,	  only	  4	  %	  of	  cases	  were	  younger	  than	  50	  years	  old,	  and	  the	  
incidence	  was	  higher	  amongst	  men	  than	  women	  (19/100,000	  versus	  9.9/100,000).	  	  	  
However,	  male	  preponderance	  of	  PD	  has	  not	  been	  observed	  in	  all	  epidemiologic	  studies,	  
meaning	  that	  men	  merely	  have	  a	  higher	  risk	  for	  PD	  than	  women.	  	  
	  
This	  may	  be	  due	  to	  the	  substantia	  nigra	  (neuronal	  deaths	  in	  this	  brain	  region	  are	  
responsible	  for	  causing	  PD)	  being	  one	  of	  the	  numerous	  areas	  of	  the	  brain	  dependent	  on	  
sexual	  differentiation.	  	  In	  the	  male	  substantia	  nigra,	  the	  number	  of	  dopamine	  producing	  
neurons	  is	  controlled	  by	  the	  SRY	  gene,	  a	  sex	  determining	  gene	  on	  the	  Y	  chromosome.	  	  
This	  gene	  codes	  for	  and	  increases	  the	  levels	  of	  the	  enzyme	  tyrosine	  hydroxylase	  (TH),	  
which	  catalyzes	  the	  reaction	  for	  producing	  dopamine.	  	  Absence	  or	  deficiency	  of	  the	  SRY	  
gene	  will	  result	  in	  a	  very	  low	  level	  of	  TH	  in	  the	  male	  substantia	  nigra.	  	  Since	  thelevels	  of	  
TH	  in	  female	  substantia	  nigra	  are	  also	  low,	  but	  do	  not	  result	  in	  motor	  dysfunction	  for	  
females,	  it	  is	  hypothesized	  that	  the	  SRY	  gene	  compensates	  for	  an	  unknown	  factor	  
present	  only	  in	  true	  XX	  chromosomal	  females	  and	  maintains	  a	  level	  of	  TH	  needed	  for	  
normal	  male	  functioning	  (Dewing	  et	  al.,	  2006).	  
	  
In	  general,	  the	  prevalence	  (number	  of	  cases	  at	  a	  particular	  point	  in	  time)	  of	  PD	  in	  





for	  people	  over	  60	  years	  old.	  Worldwide,	  there	  are	  about	  five	  million	  people	  with	  PD	  (de	  
Lau	  et	  al.,	  2006).	  	  Cross	  culturally,	  PD	  may	  be	  less	  common	  in	  African	  and	  Asian	  people	  
than	  in	  Caucasian	  peoples;	  results,	  however,	  are	  conflicting.	  	  Reported	  differences	  may	  
result	  from	  discrepancies	  in	  survey	  response	  rates,	  survival,	  and	  case-­‐ascertainment	  
rather	  than	  from	  real	  differences	  in	  PD	  prevalence	  across	  ethnic	  groups	  (de	  Lau	  et	  al.,	  	  
2006).	  
Estimates	  of	  the	  incidence	  (number	  of	  new	  cases	  per	  year)	  range	  from	  8	  to	  18.6	  per	  
100,000	  person-­‐years.	  	  Onset	  of	  PD	  is	  rarely	  seen	  before	  age	  50	  years	  and	  a	  sharp	  
increase	  of	  incidence	  is	  seen	  after	  60	  years	  old	  (de	  Lau	  et	  al.,	  2006).	  
	  
Symptoms	  of	  Parkinson’s	  disease:	  
	  
PD	  has	  traditionally	  been	  considered	  as	  a	  motor	  system	  disorder	  but	  is	  a	  complex	  
disease	  with	  nonmotor	  symptoms	  that	  include	  neuropsychiatric,	  cognitive,	  and	  sensory	  
problems.	  	  PD	  is	  characterized	  partly	  by	  the	  four	  cardinal	  motor	  symptoms	  of	  resting	  
tremor,	  bradykinesia,	  rigidity,	  and	  postural	  instability	  (Pereira	  et	  al.,	  2005).	  	  The	  rest	  
tremor,	  usually	  described	  as	  “pill-­‐rolling”,	  has	  a	  frequency	  of	  the	  tremors	  is	  usually	  
between	  4	  and	  5	  Hz	  (Findley	  et	  al.,	  1981).	  	  It	  is	  most	  noticeable	  at	  a	  later	  stage	  of	  PD	  and	  
when	  the	  patient	  is	  not	  conducting	  any	  voluntary	  purposeful	  actions.	  	  It	  is	  worsened	  by	  
anxiety,	  emotional	  excitement	  or	  stress	  (Hunker	  et	  al.,	  1990).	  	  	  The	  tremor	  usually	  starts	  	  
unilaterally	  in	  the	  hand	  and	  then	  spread	  to	  the	  other	  hand	  (Scott	  et	  al.,	  1970).	  	  While	  the	  





et	  al.,	  1990).	  	  Bradykinesia,	  or	  the	  general	  slowness	  of	  movement,	  usually	  affects	  the	  
arms	  and	  legs.	  	  In	  arms,	  bradykinesia	  starts	  distally	  with	  decreased	  finger	  dexterity	  and	  
spread	  to	  shoulders.	  	  Bradykinesia	  of	  the	  legs	  results	  in	  dragging,	  shuffling	  steps,	  a	  
feeling	  of	  unsteadiness,	  and	  gait	  freezing	  (Scott	  et	  al.,	  1970).	  	  Rigidity	  is	  defined	  as	  
increased	  resistance	  to	  passive	  motion,	  and	  is	  found	  in	  90%	  of	  all	  PD	  patients	  (Hughes	  et	  
al.,	  1993).	  	  It	  usually	  starts	  on	  one	  side	  of	  the	  body,	  and	  spread	  to	  the	  opposite	  side,	  but	  
is	  usually	  asymmetrical	  in	  most	  patients	  (Scott	  et	  al.,	  1970).	  	  In	  the	  arms,	  PD	  can	  
manifest	  as	  either	  cogwheel	  rigidity	  -­‐	  a	  ratchety	  pattern	  of	  resistance	  and	  relaxation	  of	  
the	  arm	  as	  the	  patient	  tries	  to	  flex	  the	  elbow	  (Deuschl	  et	  al.,	  1998)	  –	  or	  as	  lead-­‐pipe	  
rigidity,	  which	  is	  a	  tonic	  resistance	  that	  is	  present	  during	  all	  passive	  movements	  (Deuschl	  
et	  al.,	  1998).	  	  Other	  rigidity	  manifestations	  include	  decreased	  arm	  swing	  with	  walking,	  
stiffness	  and	  pain	  in	  other	  parts	  of	  the	  body	  (Deuschl	  et	  al.,	  1998).	  	  Unlike	  the	  other	  
three	  mentioned	  cardinal	  symptoms,	  postural	  instability	  does	  not	  appear	  until	  later	  in	  
the	  course	  of	  the	  disease;	  if	  PD	  patients	  fall	  early	  on,	  they	  may	  have	  other	  syndromes	  
that	  mimic	  PD,	  such	  as	  progressive	  supranuclear	  palsy	  or	  multiple	  system	  atrophy	  
(Tolosa	  et	  al.,	  2006).	  	  Postural	  instability	  reflects	  on	  the	  impairment	  of	  the	  central	  
nervous	  system	  mediated	  postural	  reflexes,	  causing	  patients	  to	  feel	  imbalanced	  and	  
have	  an	  increased	  tendency	  to	  fall	  and	  hurt	  themselves	  (Muslimovic	  et	  al.,	  2008).	  	  	  
Unfortunately,	  this	  symptom	  is	  the	  most	  resistant	  one	  to	  dopaminergic	  therapies	  (Koller	  





Other	  motor	  symptoms	  stem	  from	  the	  four	  cardinal	  ones	  and	  include	  craniofacial,	  
visual,	  musculoskeletal,	  and	  gait	  problems	  (Langston	  et	  al.,	  2006).	  Craniofacial	  problems	  
include	  masked	  facial	  expression,	  decreased	  spontaneous	  eye	  blinking	  rate,	  speech	  
impairment,	  dysphagia	  [difficulty	  in	  swallowing	  (Spiegel,	  2011)],	  and	  sialorrhea	  [drooling	  
(Langston	  et	  al.,	  2006)].	  	  Visual	  problems	  include	  blurred	  vision,	  impaired	  contrast	  
sensitivity,	  hypometric	  saccades,	  impaired	  vestibulo-­‐ocular	  reflex	  [a	  reflex	  that	  keeps	  
the	  line	  of	  sight	  stable	  in	  space	  while	  the	  head	  is	  moving	  (Kaminski	  et	  al.,	  1997)],	  
impaired	  upward	  gaze	  and	  convergence	  [simultaneous	  inward	  movement	  of	  both	  eyes	  
toward	  each	  other],	  and	  eyelid	  opening	  apraxia	  [inability	  to	  open	  eyelids	  voluntarily]	  	  
(Langston	  et	  al.,	  2006).	  Musculoskeletal	  problems	  include	  micrographia	  [abnormally	  
small	  and	  cramped	  handwriting	  (O’Sullivan,2007)],	  dystonia	  [a	  movement	  disorder	  
characterized	  by	  involuntary,	  sustained	  muscle	  contractions	  that	  result	  in	  twisting	  and	  
repetitive	  movements	  or	  abnormal	  postures	  (Fahn	  et	  al.,	  1998)],	  myoclonus	  [brief,	  
shock-­‐like,	  involuntary	  movements	  caused	  by	  muscular	  contractions	  or	  inhibitions	  
(Marsden	  et	  al.,	  1982)],	  stooped	  posture,	  camptocormia	  [severe	  forward	  bending	  of	  the	  
thoracolumbar	  spine	  (Langston	  et	  al.,	  2006)],	  kyphosis,	  scoliosis,	  and	  difficulty	  turning	  in	  
bed.	  	  Gait	  problems	  include	  shuffling	  or	  short	  stepped	  gait,	  freezing	  aka	  akinesia,	  and	  







As	  PD	  progresses,	  non-­‐motor	  symptoms	  manifest;	  these	  include	  cognitive	  dysfunction,	  
dementia,	  pscyhosis,	  hallucinations,	  mood	  disorders	  of	  depression,	  anxiety,	  and	  apathy,	  
sleep	  disturbances,	  fatigue,	  autonomous	  dysfunction,	  olfactory	  problems,	  pain	  and	  
sensory	  disturbances,	  and	  seborrhea	  (Langston	  et	  al.,	  2006;	  Lim	  et	  al.,	  2009;	  Barone	  et	  
al.,	  2009).	  	  While	  both	  cognitive	  dysfunction	  and	  dementia	  are	  common	  in	  PD	  patients,	  
dementia	  do	  not	  manifest	  until	  late	  in	  the	  course	  of	  PD.	  This	  dementia	  is	  associated	  with	  
psychomotor	  retardation,	  memory	  difficulty,	  and	  altered	  personality	  (Forsaa	  et	  al.,	  
2010).	  	  In	  community-­‐based	  studies,	  the	  prevalence	  of	  dementia	  in	  PD	  patient	  is	  41	  
percent	  and	  in	  longitudinal	  studies,	  the	  cumulative	  incidence	  is	  78%	  (Forsaa	  et	  al.,	  
2010).	  	  Older	  age	  and	  severity	  of	  PD	  motor	  symptoms	  increases	  risk	  of	  dementia;	  other	  
risk	  factors	  include	  a	  later	  age	  of	  onset	  of	  PD,	  longer	  duration	  of	  PD	  symptoms,	  
hallucinations,	  depression,	  and	  family	  history	  (Forsaa	  et	  al.,	  2010).	  As	  for	  cognitive	  
dysfunctions,	  PD	  patients	  usually	  complain	  of	  problems	  with	  executive	  function	  
[decision	  making	  or	  multi-­‐tasking],	  memory	  retrieval,	  and	  visuo-­‐spatial	  misperceptions.	  	  
Psychosis	  occurs	  in	  20	  to	  40	  percent	  of	  PD	  patients	  (Aarsland	  et	  al.,	  2007),	  and	  can	  be	  
attributable	  to	  underlying	  Lewy	  body	  disease,	  and	  to	  antiparkinsonian	  drug	  therapy	  
(Cummings,	  1991).	  	  Psychotic	  symptoms	  may	  persist	  but	  generally	  resolve	  when	  the	  
medications	  are	  discontinued	  (Goetz,	  1989).	  	  As	  for	  hallucinations,	  PD	  patients	  can	  have	  
auditory,	  olfactory,	  tactile,	  and	  visual	  ones,	  with	  visual	  hallucinations	  the	  most	  common	  
(Fenelon	  et	  al.,	  2000).	  	  The	  prevalence	  and	  severity	  of	  hallucinations	  increase	  as	  the	  





of	  spousal	  infidelity,	  theft,	  and	  intruders	  in	  the	  house;	  delusions	  are	  least	  responsive	  to	  
medications	  (Goetz	  et	  al.,	  2005).	  	  Psychoses	  are	  the	  greatest	  risk	  factor	  for	  nursing	  home	  
placement,	  and	  increases	  both	  caregiver	  burden	  and	  risk	  of	  mortality	  (Aarsland	  et	  al.,	  
2007).	  	  Common	  risk	  factors	  for	  psychosis	  in	  PD	  include	  the	  use	  of	  high	  doses	  of	  
antiparkinsonian	  drugs,	  dementia,	  advanced	  age,	  impaired	  vision,	  depression,	  sleep	  
disorders,	  and	  longer	  disease	  duration	  (Biglan	  et	  al.,	  2007).	  	  
	  
Anxiety	  is	  the	  next	  most	  common	  psychiatric	  disorder	  and	  is	  found	  in	  29	  to	  38	  percent	  
of	  PD	  patients	  (Maricle	  et	  al.,	  1995).	  	  It	  is	  associated	  with	  worsened	  mood,	  on-­‐off	  
fluctuations	  from	  Levodopa	  use,	  and	  “off	  periods”	  [improves	  with	  Levodopa	  use]	  
(Maricle	  et	  al.,	  1995).	  	  Apathy,	  defined	  as	  the	  loss	  of	  motivation,	  is	  associated	  with	  
frontal	  lobe	  and	  limbic	  system	  dysfunction	  (Rejinders	  et	  al.,	  2010).	  	  Sleep	  disorders,	  the	  
most	  troublesome	  non-­‐motor	  symptoms	  during	  early	  and	  late	  stage	  PD,	  affect	  between	  	  
74	  and	  98	  percent	  of	  PD	  patients	  (Partinem	  et	  al.,	  1997),	  and	  include	  frequent	  
awakening	  during	  the	  night,	  early	  morning	  awakenings,	  and	  restless	  leg	  syndrome	  
(Wetter	  et	  al.,	  1997).	  	  In	  PD	  patients,	  the	  prevalence	  of	  excessive	  daytime	  somnolence	  
ranges	  from	  33	  to	  76	  percent	  (Hogl	  et	  al.,	  2003).	  	  Fatigue	  is	  also	  a	  common	  problem,	  and	  
its	  prevalence	  in	  PD	  patients	  ranges	  from	  33	  to	  58	  percent	  (Herlofson	  et	  al.,	  2003).	  
Fatigue	  is	  especially	  common	  in	  early	  stage,	  untreated,	  and	  non-­‐depressed	  PD	  patients,	  





Autonomic	  dysfunction	  symptoms	  include	  orthostatic	  hypotension,	  constipation,	  
dysphagia,	  excessive	  sweating,	  urinary	  difficulties,	  and	  sexual	  dysfunctions	  (Allan	  et	  al.,	  
2007).	  	  Orthostatic	  hypotension,	  which	  is	  a	  form	  of	  low	  blood	  pressure	  where	  a	  person’s	  
blood	  pressure	  falls	  when	  standing	  up	  or	  stretching	  (Freeman	  et	  al.,	  2011),	  affects	  58	  
percent	  of	  PD	  patients	  (Senard	  et	  al.,	  1997).	  	  Sexual	  dysfunctions	  range	  from	  
underactivity	  to	  hypersexuality	  (Allan	  et	  al.,	  2007).	  	  Underactivity	  manifests	  as	  
decreased	  interest	  and	  drive,	  erectile	  dysfunction,	  vaginal	  tightness,	  dryness,	  and	  an	  
inability	  to	  achieve	  orgasm	  (Koller	  et	  al.,	  1990).	  	  Hypersexuality	  can	  be	  associated	  with	  
both	  pharmacological	  and	  surgical	  PD	  therapies	  (Voon	  et	  al.,	  2006).	  	  Another	  common	  
non-­‐motor	  PD	  symptom	  is	  olfactory	  dysfunction	  –	  deficits	  in	  odor	  identification,	  
discrimination,	  and	  detection.	  	  However,	  PD	  patients	  usually	  do	  not	  notice	  this	  problem	  
(Tissingh	  et	  al.,	  2001).	  	  Lastly,	  pain	  is	  reported	  in	  46	  percent	  of	  all	  PD	  patients	  (Goetz	  et	  
al.,	  1986).	  It	  is	  one	  of	  the	  most	  troublesome	  non-­‐motor	  symptoms	  in	  both	  early	  and	  late	  
stage	  PD	  and	  tends	  to	  correlate	  with	  motor	  symptom	  fluctuations	  (Palitis	  et	  al.,	  2010).	  	  	  
	  
Causes	  of	  Parkinson’s	  Disease:	  
	  
Other	  key	  pathological	  features	  –	  which	  can	  only	  be	  confirmed	  post	  mortem	  –	  are	  the	  
loss	  of	  nigral	  neurons	  (and	  loss	  of	  pigmentation	  in	  this	  area),	  and	  the	  presence	  of	  
insoluble	  proteinaceous	  cytoplasmic	  inclusions,	  also	  known	  as	  Lewy	  bodies	  and	  Lewy	  
neuritis,	  in	  the	  remaining	  cells	  (George	  et	  al.,	  2009).	  	  These	  inclusions	  are	  rich	  in	  the	  





The	  motor	  symptoms	  are	  caused	  by	  a	  loss	  of	  dopamine	  producing	  cells	  within	  the	  
substantia	  nigra	  pars	  compacta,	  in	  the	  interconnections	  between	  the	  substantia	  nigra	  
and	  the	  striatum	  [caudate	  and	  putamen	  nuclei]	  (Spiegel	  2011).	  	  Along	  with	  the	  globus	  
pallidus	  and	  subthalamic	  nuclei,	  the	  substantia	  nigra,	  the	  caudate	  and	  putamen	  nuclei	  
make	  up	  the	  basal	  ganglia	  (Spiegel	  2011).	  	  In	  PD,	  not	  all	  of	  the	  basal	  ganglia	  nuclei	  are	  
affected	  equally;	  the	  putamen	  and	  caudate	  loses	  95%,	  and	  80%	  of	  dopaminergic	  inputs,	  
respectively,	  from	  the	  substantia	  nigra	  pars	  compacta	  (George	  et	  al.,	  2009).	  	  Recent	  
research,	  however,	  has	  shown	  that	  other	  brain	  nuclei	  are	  damaged	  before	  the	  
substantia	  nigra	  is	  involved	  (George	  et	  al.,	  2009).	  	  This	  is	  because	  the	  first	  appearance	  of	  
disease	  related	  symptoms	  correlates	  with	  functional	  deficits	  in	  the	  lower	  brainstem	  and	  
olfactory	  bulb.	  	  The	  problem	  then	  progresses	  up	  the	  brainstem	  to	  produce	  classical	  PD.	  	  
These	  changes	  include	  loss	  of	  smell,	  REM	  sleep	  disturbances,	  restless	  leg	  syndrome,	  
constipation,	  having	  a	  soft	  or	  hoarse	  voice,	  dizziness	  or	  vertigo,	  and	  stooping	  or	  
hunching	  over.	  	  It	  is	  believed	  that	  changes	  in	  other	  nuclei	  are	  secondary	  to	  the	  primary	  
disease,	  which	  will	  progress	  until	  cortical	  and	  cognitive	  changes	  develop	  (George	  et	  al.,	  
2009).	  
	  
Although	  the	  pathology	  of	  PD	  was	  not	  well	  understood	  until	  the	  early	  20th	  century,	  
remarkable	  advances	  have	  shed	  light	  on	  some	  of	  the	  mechanisms	  behind	  the	  condition.	  	  





factors.	  The	  true	  cause	  of	  the	  loss	  of	  dopaminergic	  neurons,	  however,	  remains	  a	  
mystery.	  
	  
Genetic	  Causes	  of	  Parkinson’s	  Disease:	  
	  
While	  90%	  of	  Parkinson’s	  disease	  cases	  arise	  sporadically,	  the	  remainder	  is	  genetic	  and	  
only	  1%	  is	  due	  to	  familial	  onset.	  Sporadic	  Parkinson’s	  disease	  occurs	  at	  a	  later	  onset	  age	  
of	  60	  but	  familial	  onset	  develops	  at	  a	  younger	  age	  of	  less	  than	  50.	  	  Mutations	  in	  six	  gene	  
loci	  (Table	  1)	  have	  been	  identified	  to	  cause	  a	  PD	  pathological	  phenotype	  (George	  et	  al.,	  
2009).	  Mutations	  in	  the	  alpha-­‐synuclein	  (a-­‐syn),	  Parkin,	  PTEN	  [Phosphatase	  and	  tensin	  
homolog]	  -­‐Induced	  putative	  Kinase	  1	  (PINK1),	  JD-­‐1,	  leucine	  rich	  repeat	  kinase	  2	  (LRRK2),	  
and	  ATP	  13A2	  genes	  all	  contribute	  to	  familial	  PD.	  
	  
The	  alpha	  synuclein	  protein	  is	  found	  in	  the	  neurons	  and	  glia	  of	  the	  central	  nervous	  
system.	  	  The	  protein	  is	  both	  a	  protein	  trafficking	  chaperone	  and	  a	  neurotransmitter	  
modulator	  that	  regulates	  vesicle	  handling	  (recycling	  and	  docking),	  synaptic	  transmission	  
and	  re-­‐uptake.	  	  If	  the	  gene	  is	  mutated	  such	  that	  no	  alpha	  synuclein	  protein	  is	  produced,	  
there	  will	  be	  a	  deficit	  in	  the	  expression	  of	  synaptic-­‐associated	  proteins,	  and	  a	  reduction	  
in	  synaptic	  vesicles	  but	  manifests	  only	  subtle	  behavioral	  deficits.	  On	  the	  other	  hand,	  
nucleotide	  substitutions	  (A53T	  mutation),	  point	  mutations	  (A30P,	  E46K),	  whole	  gene	  
duplications	  and	  triplications	  increase	  the	  age	  of	  onset	  of	  Parkinson’s	  disease,	  muscle	  





The	  PARK2	  gene	  codes	  for	  the	  parkin	  protein,	  an	  E3	  ubiquitin	  ligase,	  which	  is	  responsible	  
for	  attaching	  chains	  to	  target	  proteins	  for	  degradation.	  	  Parkin	  mutations	  are	  the	  most	  
common	  cause	  of	  genetic	  parkinsonism,	  and	  are	  specifically	  linked	  to	  autosomal	  
recessive	  juvenile	  parkinsonism.	  	  Other	  parkin	  gene	  mutations	  (deletions,	  
multiplications,	  rearrangements,	  etc.)	  cause	  a	  wide	  range	  of	  clinical	  Parkinson	  disease	  
phenotypes	  with	  early	  onset,	  slow	  progression,	  and	  neuronal	  death	  without	  Lewy	  body	  
formation.	  	  It	  is	  not	  clear	  how	  mutations	  in	  the	  parkin	  gene	  cause	  parkinsonism	  because	  	  
dopaminergic	  neurons	  still	  survived	  in	  parkin	  knockout	  mice.	  
	  
PINK	  1	  is	  a	  mitochondrial	  serine/threonine	  kinase	  coded	  by	  the	  PINK1	  gene.	  The	  kinase	  
is	  supposed	  to	  protect	  cells	  from	  stress-­‐induced	  mitochondrial	  dysfunction	  by	  recruiting	  
the	  parkin	  protein	  to	  induce	  autophagy	  of	  diseased	  mitochondria.	  	  Mutations	  of	  the	  
PINK1	  gene	  are	  second	  to	  parkin	  mutations	  in	  the	  induction	  of	  early	  onset	  parkinsonism.	  
	  
The	  PARK	  8	  gene	  encodes	  for	  the	  LRRK2	  protein	  that	  interacts	  with	  the	  mitochondrial	  
outer	  membrane	  and	  the	  parkin	  protein.	  	  LRRK2	  mutants	  are	  implicated	  in	  autosomal	  
dominant	  PD	  and	  result	  in	  the	  simplification	  of	  the	  dendritic	  tree.	  (Paisan-­‐Ruiz	  et	  al.,	  
2004)	  These	  mutants	  are	  also	  found	  in	  sporadic	  and	  familial	  types	  of	  Parkinson’s	  
disease.	  	  Among	  all	  types	  of	  LRRK2	  gene	  mutations,	  the	  Gly2019Ser	  mutation	  in	  the	  





American	  Caucasians.	  	  This	  mutation	  is	  also	  found	  in	  20%	  of	  Ashkenazi	  Jewish	  PD	  and	  
40%	  of	  all	  PD	  cases	  of	  the	  North	  African	  Berber	  Arabs	  (Manolio	  et	  al.,	  2010).	  
	  
DJ-­‐1,	  a	  protein	  encoded	  by	  the	  PARK	  7	  gene,	  serves	  as	  a	  positive	  regulator	  of	  androgen	  
receptor-­‐dependent	  transcription,	  a	  redox-­‐sensitive	  chaperone,	  and	  a	  sensor	  for	  
oxidative	  stress,	  ultimately	  to	  protect	  neurons	  against	  oxidative	  stress	  and	  cell	  death.	  	  
DJ-­‐1	  mutants	  are	  linked	  with	  early	  onset	  autosomal	  recessive	  familial	  Parkinson’s	  
disease	  and	  not	  found	  in	  late	  onset	  PD.	  	  As	  for	  the	  UCH-­‐L1	  and	  ATP13A2	  genes,	  mutant	  
products	  are	  associated	  with	  parkinsonism	  and	  further	  research	  is	  required	  to	  
















Environmental	  Causes	  of	  Parkinson’s	  disease:	  
	  
In	  1983,	  the	  compound	  MPTP	  (1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine)	  was	  found	  
to	  cause	  parkinsonism	  symptoms	  in	  heroin	  addicts.	  	  After	  ingestion	  of	  the	  compound,	  
initial	  cell	  death	  starts	  within	  a	  few	  hours,	  peaks	  at	  five	  days,	  with	  two	  phases	  lasting	  21-­‐
28	  days.	  	  Chronic	  usage	  of	  MPTP	  causes	  aggregation	  of	  alpha-­‐synuclein	  within	  the	  
substantia	  nigra.	  	  Animal	  studies	  reveal	  that	  a	  lack	  of	  alpha-­‐synuclein	  offers	  protection	  
against	  MPTP,	  which	  is	  a	  compound	  that	  travels	  inside	  the	  neurons	  and	  has	  a	  high	  
affinity	  for	  dopamine	  re-­‐uptake	  transporters.	  Once	  inside	  the	  neurons,	  MPTP	  is	  reduced	  
to	  MPP+	  (1-­‐methyl-­‐4-­‐phenylpyridinium)	  by	  monoamine	  oxidase	  B;	  MPP+	  then	  affects	  
mitochondrial	  metabolism	  by	  inhibiting	  complex	  I	  and	  inducing	  release	  of	  cytochrome	  c	  
from	  the	  inner	  membrane	  of	  the	  mitochondria.	  	  This	  model	  is	  the	  keystone	  of	  the	  
oxidative	  stress	  hypothesis	  of	  PD	  (George	  et	  al.,	  2009).	  
	  
Amphetamines	  inhibit	  dopamine	  uptake,	  and	  cause	  a	  marked	  elevation	  of	  extracellular	  
dopamine.	  	  Amphetamine	  derivatives	  damage	  catecholamine	  neurons,	  induce	  
alterations	  in	  striatal	  dopamine,	  and	  have	  specific	  effects	  on	  tyrosine	  hydroxylase	  
positive	  cells,	  and	  leads	  to	  oxidative	  catalysts	  for	  PD.	  	  Cocaine	  elevates	  hydrogen	  and	  
lipid	  peroxidation	  products	  up	  to	  50	  hours.	  	  Any	  of	  the	  aforementioned	  effects	  will	  lead	  
to	  increased	  dopamine	  turnover,	  and	  cause	  a	  toxic	  cascade	  of	  free	  radicals	  that	  can	  





expression	  of	  alpha-­‐synuclein	  mRNA,	  and	  alpha-­‐synuclein	  protein	  levels	  in	  dopaminergic	  
neurons	  (George	  et	  al.	  2009).	  
	  
Environmental	  exposure	  to	  pesticides	  increases	  risk	  of	  developing	  PD	  by	  70%	  (George	  et	  
al.,	  2009).	  Pesticides	  such	  as	  Paraquat	  and	  Rotenone	  cause	  parkinsonism	  symptoms.	  	  
Paraquat	  is	  a	  potential	  neurotoxin	  that	  can	  cross	  the	  blood	  brain	  barrier.	  Once	  the	  
pesticide	  passes	  that	  barrier,	  it	  can	  be	  reduced	  to	  form	  free	  radicals	  that	  mimics	  the	  
neurotoxic	  metabolite	  MPP+,	  resulting	  in	  the	  selective	  destruction	  of	  dopaminergic	  
neurons.	  
	  
Later	  consequences	  of	  Paraquat	  include	  loss	  of	  tyrosine	  hydroxylase	  (TH)	  positive	  
neurons,	  loss	  of	  striatal	  terminal	  projects,	  a	  decrease	  in	  dopamine	  transporters,	  and	  an	  
accelerated	  fibrilization	  of	  alpha	  synuclein	  protein.	  	  Rotenone	  causes	  PD	  symptoms	  in	  
another	  way.	  	  It	  causes	  neurodegeneration	  in	  the	  substantia	  nigra,	  formation	  of	  Lewy	  
bodies	  in	  both	  dopaminergic	  and	  non-­‐dopaminergic	  systems;	  this	  causes	  unsteady	  gait	  
and	  bradykinesia.	  	  	  At	  chronic	  low	  doses,	  rotenone	  increases	  oxidative	  stress	  markers,	  
an	  increased	  expression	  of	  alpha	  synuclein,	  and	  Lewy	  body	  formation.	  	  This	  pesticide	  
also	  induces	  cell	  death	  via	  inhibition	  of	  mitochondrial	  metallo-­‐protein	  complexes,	  which	  
increases	  oxidative	  phosphorylation	  dysfunction	  (George	  et	  al.,	  2009).	  





Figure	  1:	  Oxidative	  Stress	  Theory	  (George	  et	  al.,	  2009).	  
	  
Figure	  1:	  Oxidative	  Stress	  Theory	  (George	  et	  al.,	  2009).	  
A	  unified	  picture	  of	  how	  genetic	  mutations,	  dopamine,	  iron	  dyshomeostasis,	  
and	  production	  of	  reactive	  species	  contribute	  to	  neuronal	  cell	  death.	  PD	  is	  believed	  to	  
result	  from	  a	  combination	  of	  these	  factors.	  	  Legend:	  Mutated	  genes	  that	  contribute	  to	  
PD:	  PARKIN,	  UCH-­‐L1,	  LRRK2,	  PINK1,	  DJ-­‐1	  (Table	  1);	  Fe:	  Iron;	  6-­‐OHDA:	  6-­‐
hydroxydopamine,	  H2O2:	  hydrogen	  peroxide,	  MAO:	  Monoamine	  Oxidase;	  OH:	  
hydroxyl	  radical	   	   	  
	  
	  
In	  this	  model	  (Figure	  1),	  damage	  results	  from	  an	  imbalance	  between	  the	  production	  of	  





the	  damages.	  In	  PD,	  mitochondria	  and	  dopamine	  are	  the	  major	  sources	  of	  reactive	  
species	  (RS),	  such	  as	  superoxide	  radicals,	  peroxynitrite	  (ONOO-­‐),	  hydrogen	  peroxides,	  
and	  hydroxyl	  radicals.	  	  Dopamine	  is	  highly	  reactive	  and	  produces	  RS	  in	  the	  following	  two	  
ways.	  	  First,	  dopamine	  can	  be	  oxidized	  into	  hydrogen	  peroxide,	  6-­‐OHDA	  [6-­‐
hydroxydopamine],	  quinine	  intermediates,	  and	  RS;	  all	  these	  amplify	  the	  amount	  of	  
reactive	  species	  products	  in	  the	  substantia	  nigra.	  Secondly,	  dopamine	  is	  degraded	  by	  
MAO-­‐B	  [Mono	  Amine	  Oxidase	  B]via	  deamination	  into	  hydrogen	  peroxide,	  which	  also	  
contributes	  to	  amplifying	  amounts	  of	  RS.	  	  High	  concentrations	  of	  RS	  products	  lead	  to	  
caspase	  activation	  and	  therefore,	  neuronal	  death.	  	  	  	  
	  
Normally,	  these	  reactive	  species	  are	  cleared	  by	  anti-­‐oxidative	  enzymatic	  activity	  of	  
catalases,	  copper/zinc	  superoxide	  dismutases,	  and	  glutathione	  peroxidases	  (GSH).	  	  
Absence	  of	  any	  of	  these	  enzymes	  leaves	  the	  cell	  more	  vulnerable	  to	  oxidative	  stress;	  
excess	  of	  the	  enzymes	  does	  the	  opposite.	  	  These	  enzymes	  are	  found	  in	  all	  types	  of	  cells	  
of	  the	  human	  body,	  but	  neuronal	  cells	  have	  an	  unusually	  low	  number	  of	  them	  (George	  
et	  al.,	  2009).	  	  Additionally,	  neuronal	  membranes	  are	  rich	  in	  free	  polyunsaturated	  side	  
chains	  that	  are	  highly	  susceptible	  to	  attack,	  leading	  to	  leaky	  membranes.	  Thus,	  the	  	  
substantia	  nigra	  and	  other	  basal	  ganglia	  nuclei	  are	  particularly	  vulnerable	  to	  oxidative	  









Iron	  toxicity	  (Figure	  1)	  has	  been	  implicated	  in	  the	  development	  of	  Parkinson’s	  disease.	  	  
Iron	  is	  essential	  to	  cellular	  respiration	  pathways,	  normal	  neural	  maturation,	  and	  serves	  
as	  the	  core	  component	  of	  metallo-­‐proteins,	  as	  well	  as	  neurotransmission	  and	  
myelination	  processes.	  	  Iron	  is	  also	  a	  co-­‐factor	  for	  many	  enzymatic	  reactions,	  including	  
the	  one	  for	  producing	  dopamine.	  	  Tyrosine	  hyroxylase	  is	  the	  non-­‐heme	  iron	  enzyme	  
responsible	  for	  hydroxylating	  tyrosine	  to	  form	  L-­‐DOPA	  in	  the	  brain	  (George	  et	  al.,	  2009).	  	  
	  
Unlike	  other	  parts	  of	  the	  body,	  the	  brain	  can	  adapt	  to	  high	  iron	  levels	  (60mg)	  by	  
redistributing	  iron	  to	  regions	  of	  high	  iron	  requirement	  (substantia	  nigra,	  globus	  pallidus,	  
caudate,	  and	  putamen	  nuclei)	  and	  has	  high	  amounts	  of	  the	  iron	  storage	  proteins	  –	  
ferritin	  and	  neuromelanin.	  	  Ferritin	  binds	  free	  cytosolic	  iron	  and	  reduces	  it	  to	  the	  ferric	  
state,	  thereby	  reducing	  the	  amount	  of	  free	  iron	  available	  for	  generating	  reactive	  
species.	  	  Ferritin	  is	  found	  in	  microglia,	  oligodendrocytes,	  and	  neurons.	  	  Neuromelanin	  is	  
another	  iron	  storage	  protein	  that	  is	  found	  in	  regions	  of	  high	  metabolic	  turnover,	  such	  	  
as	  dopamine	  producing	  neurons	  in	  the	  substantia	  nigra	  and	  the	  noradrenaline	  neurons	  
in	  the	  locus	  ceruleus.	  Normally,	  this	  protein	  prevents	  degeneration	  of	  nigral	  neurons	  by	  
binding	  transition	  metals	  and	  other	  dopamine	  oxidative	  products	  abundant	  in	  the	  
substantia	  nigra.	  	  In	  PD	  patients,	  it	  is	  found	  that	  neuromelanin	  are	  saturated.	  	  Thus,	  it	  is	  
possible	  that	  iron	  dyshomeostasis	  might	  cause	  PD	  but	  no	  actual	  link	  has	  been	  found.	  	  





mutations	  near	  iron	  binding	  site	  of	  TH	  (tyrosine	  hydroxylase)	  molecule,	  is	  found	  in	  cases	  
of	  L-­‐DOPA	  responsive	  PD.	  (George	  et	  al.,	  2009)	  
	  
In	  addition	  to	  iron,	  manganese	  is	  also	  associated	  with	  PD.	  	  A	  few	  years	  ago,	  it	  was	  
reported	  that	  ore	  miners	  with	  an	  overexposure	  to	  manganese	  and	  manganese	  toxicity	  
had	  a	  high	  prevalence	  of	  the	  parkinsonian	  symptoms	  of	  gait	  and	  speech	  abnormalities.	  	  
Manganese	  affects	  primarily	  the	  globus	  pallidus,	  with	  only	  minor	  damage	  to	  the	  
substantia	  nigra;	  it	  also	  contributes	  to	  oxidative	  stress	  by	  reducing	  anti-­‐oxidants	  such	  as	  
glutathione,	  catalase,	  and	  thiols,	  thus	  increasing	  intracellular	  levels	  of	  	  
free	  iron	  and	  reactive	  species	  (George	  et	  al.,	  2009).	  
	  
Factors	  that	  Protect	  Against	  Parkinson’s	  Disease:	  
	  
Oddly	  enough,	  cigarette	  smoking	  protects	  patients	  from	  PD.	  This	  is	  supported	  by	  data	  
from	  numerous	  large	  cohort	  studies	  and	  meta-­‐analyses	  (Noyce	  et	  al.,	  2012;	  Chen	  et	  al.,	  
2010;	  Ritz	  et	  al.,	  2007;	  Lin	  et	  al.,	  2012).	  	  	  	  According	  to	  a	  meta-­‐analysis	  report	  (Noyce	  et	  
al.,	  2012),	  the	  risk	  of	  PD	  was	  significantly	  lower	  for	  current	  smokers	  than	  never	  smokers.	  	  
It	  was	  hypothesized	  that	  nicotine	  in	  cigarettes	  has	  a	  neuroprotective	  effect	  (Quik	  et	  al.,	  
2004).	  	  An	  alternative	  theory	  proposes	  that	  since	  dopamine	  is	  an	  integral	  part	  of	  the	  
brain’s	  reward	  system,	  people	  who	  later	  fall	  victim	  to	  PD	  do	  not	  participate	  in	  reward-­‐
seeking	  behaviors,	  such	  as	  smoking,	  because	  their	  basal	  ganglia	  dopamine	  levels	  are	  





associated	  with	  a	  lower	  risk	  of	  PD	  include	  coffee,	  caffeine	  (Liu	  et	  al.,	  2012),	  ibuprofen	  
(Gao	  et	  al.,	  2011),	  and	  moderate	  to	  vigorous	  physical	  activity	  (Logroscino	  et	  al.,	  2006).	  	  
Meta-­‐analyses	  on	  other	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  yield	  conflicting	  results	  
on	  their	  ability	  to	  protect	  against	  PD	  (Rees	  et	  al.,	  2011).	  	  	  
	  
TREATMENT	  OF	  PARKINSON’S	  DISEASE:	  
	  
Before	  initiating	  treatment,	  all	  patients	  must	  be	  evaluated	  individually	  for	  a	  number	  of	  
factors,	  which	  include	  the	  patient’s	  PD	  signs	  and	  symptoms,	  age	  of	  onset,	  stage	  of	  
disease,	  degree	  of	  functional	  disability,	  neuropsychiatric	  problems,	  and	  level	  of	  physical	  
activity	  and	  productivity.	  	  These	  factors	  are	  assessed	  by	  the	  use	  of	  the	  Unified	  
Parkinson’s	  Disease	  Rating	  Scale	  or	  UPDRS	  (Appendix	  1).	  
	  
The	  UPDRS	  is	  a	  scale	  used	  for	  tracking	  the	  progression	  of	  PD	  in	  patients,	  and	  is	  made	  up	  
of	  six	  parts	  (Goetz	  et	  al.,	  2006).	  	  Part	  I	  evaluates	  mental	  activity,	  behavior,	  and	  mood.	  	  
Part	  II	  is	  a	  patient	  self	  evaluation	  of	  the	  activities	  of	  daily	  life	  including	  speech,	  
swallowing,	  handwriting,	  dressing,	  hygiene,	  falling,	  salivating,	  turning	  in	  bed,	  walking,	  
and	  cutting	  food.	  	  Unlike	  Part	  II,	  part	  III	  is	  a	  clinician-­‐scored	  motor	  evaluation.	  	  Part	  IV	  
evaluates	  if	  the	  patient	  had	  any	  recent	  complications	  from	  the	  treatments.	  	  Part	  V	  
consists	  of	  the	  modified	  Hoehn	  and	  Yahr	  Staging	  (Goetz	  et	  al.,	  2006),	  which	  is	  an	  older	  
system	  used	  since	  1967;	  scores	  range	  from	  1	  to	  5,	  with	  1	  being	  the	  most	  benign	  and	  5	  





is	  almost	  the	  same	  as	  Part	  II	  except	  it	  is	  not	  a	  patient	  self	  report.	  	  A	  lower	  score	  reflects	  
that	  the	  patient	  is	  at	  an	  earlier	  stage	  of	  the	  disease	  while	  a	  higher	  score	  shows	  that	  PD	  
has	  progressed	  to	  a	  later	  stage	  (Appendix	  1).	  	  	  	  
	  
Current	  treatments	  for	  PD	  can	  be	  classified	  as	  pharmacological,	  surgical,	  and	  non-­‐
pharmacological.	  	  Pharmacological	  treatments	  can	  be	  further	  divided	  into	  symptomatic	  
and	  neuroprotective	  but	  almost	  all	  available	  medications	  fall	  into	  the	  former	  category.	  
Unfortunately,	  none	  of	  the	  symptomatic	  medications	  reverse	  or	  even	  slow	  the	  natural	  
progression	  of	  the	  disease.	  	  Non-­‐pharmacological	  treatments	  consist	  of	  educating	  
patients	  about	  the	  disease,	  physical	  and	  speech	  therapies,	  and	  exercise.	  	  Surgical	  
therapies	  include	  deep	  brain	  stimulation,	  thalamotomy,	  pallidotomy,	  	  
subthalamotomy,	  neural	  transplantation,	  glial	  cell	  line	  derived	  neurotrophic	  factor	  
infusion,	  gene	  therapy,	  and	  duodenal	  L-­‐DOPA	  infusion.	  
	  
Symptomatic	  Pharmacological	  Therapy:	  
	  
The	  choice	  to	  start	  symptomatic	  medical	  therapy	  for	  Parkinson’s	  disease	  patients	  is	  
mainly	  determined	  by	  the	  degree	  to	  which	  the	  patient	  is	  functionally	  impaired	  (Olanow	  
et	  al.,	  2001).	  Other	  influences	  include	  the	  effect	  of	  disease	  on	  the	  dominant	  hand;	  the	  
degree	  to	  which	  the	  disease	  interferes	  with	  work,	  activities	  of	  daily	  living,	  or	  social	  and	  
leisure	  functions;	  the	  presence	  of	  significant	  bradykinesia	  or	  gait	  disturbances;	  and	  





symptomatic	  treatments	  include	  L-­‐DOPA,	  MAO-­‐B	  inhibitors,	  dopamine	  agonists,	  
catechol-­‐O-­‐methyl	  transferase	  (COMT)	  inhibitors,	  anticholinergics,	  and	  amantadine	  
(Ahlskog	  et	  al.,	  2003).	  These	  treatments	  are	  also	  believed	  to	  be	  neuroprotective	  




The	  medication	  Levodopa,	  also	  known	  as	  L-­‐DOPA	  (L-­‐3,	  4-­‐dihydroxy-­‐phenylalanine),	  is	  
currently	  the	  most	  effective	  drug	  for	  treating	  symptoms	  of	  idiopathic	  or	  Lewy	  body	  
Parkinson’s	  disease.	  Levodopa	  is	  most	  effective	  for	  managing	  akinetic	  symptoms,	  and	  
should	  be	  started	  when	  these	  symptoms	  become	  disabling	  and	  are	  uncontrolled	  by	  
other	  antiparkinsonian	  drugs.	  Tremors	  and	  rigidity	  also	  respond	  to	  the	  drug	  but	  postural	  
instability	  does	  not	  (George	  et	  al.,	  2009).	  
	  
L-­‐DOPA	  can	  be	  made	  synthetically	  and	  biologically	  (Figure	  2,	  Moussa	  et	  al.,	  2006).	  	  
Naturally,	  L-­‐DOPA	  is	  made	  from	  the	  amino	  acid	  L-­‐tyrosine	  by	  the	  enzyme	  TH.	  	  Normally,	  
L-­‐DOPA	  is	  a	  precursor	  to	  and	  can	  be	  converted	  into	  the	  catecholamine	  
neurotransmitters	  (dopamine,	  epinephrine,	  norepinephrine)	  in	  both	  the	  central	  and	  
peripheral	  nervous	  systems.	  	  Unlike	  its	  product	  dopamine,	  L-­‐DOPA	  can	  cross	  the	  	  
blood	  brain	  barrier	  and	  is	  used	  to	  increase	  dopamine	  concentrations	  in	  the	  affected	  
neural	  regions	  (Moussa	  et	  al.,	  2006).	  	  Once	  L-­‐DOPA	  has	  entered	  the	  central	  nervous	  





a	  required	  cofactor	  in	  this	  reaction	  and	  may	  be	  administered	  along	  with	  L-­‐DOPA	  in	  the	  
form	  of	  pyridoxine	  (Moussa	  et	  al.,	  2006).	  	  	  





Figure	  2:	  Dopamine	  Synthesis	  and	  its	  Metabolism	  by	  Monoamine	  Oxidases	  A	  and	  B	  
(Moussa	  et	  al.,	  2006)	  	  	  	  	  	  	  
	  
Left:	  peripheral	  system;	  Right:	  Past	  the	  blood	  brain	  barrier	  and	  into	  the	  central	  
nervous	  system;	  In	  the	  peripheral	  system,	  L-­‐DOPA	  can	  be	  converted	  into	  either	  
dopamine	  or	  3-­‐O-­‐methyldopa	  (OMD)	  by	  the	  enzymes	  COMT	  or	  DDC;	  since	  L-­‐DOPA	  is	  
needed	  inside	  the	  blood	  brain	  barrier,	  the	  medications	  entacapone	  or	  benzerazide	  
carbidopa	  are	  given	  with	  L-­‐DOPA	  to	  block	  its	  conversion	  into	  mentioned	  products,	  
which	  cannot	  cross	  the	  blood	  brain	  barrier.	  	  L-­‐DOPA	  can	  cross	  the	  blood	  brain	  barrier,	  
and	  once	  inside	  is	  converted	  into	  dopamine,	  which	  is	  then	  released	  into	  the	  synapse	  
to	  bind	  dopamine1	  (D1)	  and	  dopamine2	  (D2)	  receptors	  in	  the	  striatum.	  	  MAO	  serves	  
to	  degrade	  dopamine	  at	  the	  axon	  terminals;	  in	  PD	  where	  there	  is	  already	  a	  deficit	  of	  
dopamine,	  MAO	  activity	  is	  not	  desired.	  	  Thus,	  MAO	  inhibitors	  had	  been	  used	  as	  a	  
treatment	  for	  PD	  to	  increase	  the	  available	  dopamine	  concentration	  that	  can	  reach	  the	  





The	  same	  reaction	  also	  occurs	  in	  the	  peripheral	  nervous	  system,	  and	  usually	  results	  in	  
hyperdopaminergia	  (Moussa	  et	  al.,	  2006).	  	  This	  condition	  is	  one	  of	  causes	  of	  the	  many	  
adverse	  reactions	  seen	  with	  sole	  L-­‐DOPA	  use.	  In	  order	  to	  minimize	  the	  side	  effects	  from	  
using	  L-­‐DOPA	  alone,	  a	  peripheral	  DOPA	  decarboxylase	  inhibitor	  such	  as	  carbidopa	  is	  
combined	  with	  L-­‐DOPA	  to	  prevent	  the	  synthesis	  of	  dopamine	  in	  systemic	  circulation	  and	  
liver.	  	  L-­‐DOPA	  and	  carbidopa	  combination	  medicines	  are	  marketed	  as	  Sinemet,	  Lodosyn,	  
Parcopa,	  Atamet,	  or	  Stalevo,	  with	  Sinemet	  most	  commonly	  used.	  	  Sinemet	  comes	  in	  
formulations	  of	  10/100,	  25/100,	  25/250	  mg	  (ratios	  of	  carbidopa/levodopa)	  	  [Parkinson	  
Study	  Group,	  2004].	  
	  
In	  spite	  of	  the	  combination	  medicines,	  there	  are	  still	  many	  side	  effects	  induced	  by	  their	  
use.	  	  Nausea,	  somnolence,	  vomiting,	  dizziness	  and	  headaches	  are	  common	  but	  not	  very	  
serious	  early	  side	  effects	  (Table	  2,	  Pedrosa	  et	  al.,	  2013).	  The	  most	  serious	  ones,	  
especially	  in	  elderly	  patients,	  comprise	  of	  orthostatic	  hypotension,	  confusion,	  visual	  or	  
auditory	  hallucinations,	  delusions,	  agitation,	  and	  psychosis.	  	  L-­‐DOPA	  also	  induces	  mild	  to	  
moderate	  elevation	  in	  serum	  homocysteine	  levels,	  which	  raises	  the	  risk	  of	  hip	  fractures	  
in	  elderly	  patients	  (Vergani	  et	  al.,	  2010).	  	  Elevated	  methylmalonic	  acid	  levels	  induced	  by	  
L-­‐DOPA	  use	  puts	  patients	  at	  high	  risk	  for	  sensorimotor	  peripheral	  neuropathy.	  	  Other	  
side	  effects	  that	  affect	  patients’	  quality	  of	  life	  include	  arrhythmias,	  gastrointestinal	  
bleeding,	  disorientation,	  confusion,	  excessive	  libido,	  insomnia,	  narcolepsy,	  and	  





induce	  the	  more	  severe	  side	  effects	  of	  end-­‐of-­‐dose	  deterioration	  of	  function,	  on/off	  
oscillations	  [aka	  on/off	  phenomenon]	  (Figure	  3,	  Tetrud	  et	  al.,	  2007),	  freezing	  during	  
movement,	  drug	  resistance,	  possible	  serotonin	  depletion,	  and	  dopamine	  dysregulation	  
syndrome	  (Stacy	  et	  al.,	  2005).	  Another	  side	  effect	  of	  L-­‐DOPA	  use	  is	  acute	  akinesia.	  	  It	  is	  a	  
sudden	  exacerbation	  of	  PD	  characterized	  by	  akinetic	  state	  that	  lasts	  several	  days	  and	  
does	  not	  respond	  to	  treatment	  with	  anti-­‐PD	  medications;	  acute	  akinesia	  is	  not	  the	  same	  
as	  wearing	  off	  effects	  (Muller	  et	  al.,	  2006).	  
	  
To	  minimize	  the	  mentioned	  adverse	  events,	  treatment	  is	  started	  with	  the	  smallest	  
pharmacologically	  effective	  dose	  and	  then	  carefully	  titrated	  up	  to	  a	  level	  that	  the	  
patient	  can	  tolerate	  without	  side	  effects.	  	  The	  dosage	  must	  be	  smaller	  for	  elderly	  
patients	  or	  those	  with	  dementia	  because	  of	  their	  increased	  susceptibility	  to	  psychiatric	  
side	  effects	  (Koller	  et	  al.,	  1999).	  	  For	  patients	  taking	  levodopa	  medication	  for	  the	  first	  
time,	  each	  dose	  is	  taken	  with	  a	  meal	  to	  avoid	  nausea.	  	  However,	  for	  those	  who	  have	  
advanced	  PD,	  the	  medicine	  can	  be	  taken	  without	  food	  to	  maximize	  the	  therapeutic	  
effects	  of	  the	  drug	  (Koller	  et	  al.,	  1999).	  
	  
Along	  with	  L-­‐tyrosine	  and	  L-­‐phenylalanine,	  L-­‐DOPA	  is	  a	  precursor	  to	  the	  biological	  
pigment	  melanin	  that	  is	  found	  in	  the	  dopaminergic	  neurons.	  	  Loss	  of	  dopamine	  results	  in	  
the	  characteristic	  discoloration	  of	  the	  substantia	  nigra	  and	  other	  basal	  ganglia	  nuclei.	  	  In	  





the	  enzyme	  COMT	  to	  3-­‐O-­‐methyldopa	  (OMD)	  (Figure	  2)	  and	  then	  further	  to	  vanillic	  acid	  
in	  the	  peripheral	  nervous	  system	  (George	  et	  al.,	  2009).	  





L-­‐DOPA	  induced	  complications:	  
	  
Figure	  3:	  L-­‐DOPA	  on-­‐off	  phenomena.	  	  Figure	  from	  (European	  Parkinson’s	  Disease	  
Association,	  2012)	  
	  
Figure	  3:	  In	  the	  early	  stages	  of	  PD,	  the	  clinical	  benefits	  of	  L-­‐DOPA	  long-­‐lasting	  despite	  
its	  short	  half-­‐life.	  However,	  the	  progressive	  reduction	  of	  dopaminergic	  neurons	  as	  the	  
disease	  progresses	  results	  in	  a	  loss	  of	  buffering	  capacity,	  and	  synaptic	  levels	  of	  
dopamine	  start	  to	  reflect	  the	  fluctuating	  plasma	  levels	  of	  L-­‐DOPA.	  	  Thus,	  motor	  
symptoms	  begin	  to	  reemerge	  before	  the	  next	  scheduled	  dose,	  as	  shown	  in	  this	  figure	  
and	  patients	  start	  to	  experience	  wearing-­‐off	  periods.	  	  Peak	  dose	  dyskinesia	  usually	  
occurs	  at	  the	  time	  of	  peak	  L-­‐DOPA	  dose,	  and	  is	  characterized	  by	  stereotypical	  choreic	  
movements.	  Less	  commonly,	  'diphasic	  dyskinesia'	  can	  occur	  at	  low	  levodopa	  plasma	  
concentrations	  (bottom	  two	  thirds	  of	  graph),	  both	  at	  the	  beginning	  of	  a	  dose	  (as	  the	  
plasma	  concentration	  is	  increasing)	  and	  at	  the	  end	  of	  a	  dose	  (as	  the	  concentration	  is	  
decreasing).	  Clinically,	  this	  type	  of	  dyskinesia	  typically	  presents	  primarily	  as	  
stereotypic,	  large-­‐amplitude,	  rhythmic,	  involuntary	  movements	  of	  the	  upper	  and	  
lower	  limbs.	  "Off"-­‐state	  dyskinesia	  usually	  presents	  as	  dystonia,	  with	  twisting,	  
posturing,	  or	  cramping	  (most	  commonly	  in	  the	  feet)	  	  	  	  [Stacy	  et	  al.,	  2005;	  Muller	  et	  al.,	  
2006;	  Tetrud	  et	  al.,	  2007].	  
	  
	  
Complications	  due	  to	  L-­‐DOPA	  use	  usually	  start	  after	  several	  years	  of	  using	  it.	  	  These	  
include	  motor	  fluctuations	  (wearing-­‐off	  phenomena),	  involuntary	  movements	  of	  
dyskinesia,	  abnormal	  cramps	  and	  postures	  of	  the	  extremities	  and	  trunk	  (dystonia).	  	  





using	  L-­‐DOPA	  for	  any	  time	  between	  five	  and	  ten	  years.	  	  In	  a	  controlled	  study	  (need	  
reference	  here)	  of	  patients	  using	  L-­‐DOPA,	  thirty	  percent	  of	  the	  patients	  developed	  
motor	  complications	  after	  only	  two	  years	  of	  use	  at	  normal	  dosage	  (Block	  et	  al.,	  1997).	  	  	  
However,	  if	  L-­‐DOPA	  is	  used	  at	  low	  dosages,	  only	  twenty	  percent	  of	  the	  patients	  
developed	  the	  motor	  complications	  after	  five	  years.	  	  Motor	  complications	  are	  more	  
common	  in	  patients	  with	  young	  onset	  PD	  than	  patients	  with	  an	  older	  onset.	  	  In	  a	  
population	  based	  study	  (Kumar	  N.	  et	  al.,	  2005)	  that	  compared	  patients	  who	  were	  
diagnosed	  with	  PD	  at	  40-­‐59	  years	  old	  with	  those	  diagnosed	  at	  over	  70	  years	  old,	  the	  
corresponding	  five-­‐year	  incidence	  of	  dyskinesia	  was	  50%	  versus	  16%.	  	  
	  
A	  retrospective	  study	  of	  pramipexole	  and	  L-­‐DOPA	  on	  early	  Parkinson	  disease	  patients	  
showed	  that	  early	  occurrence	  of	  motor	  fluctuations	  is	  associated	  with	  higher	  cumulative	  
L-­‐DOPA	  doses.	  Later	  onset	  of	  motor	  fluctuations	  in	  PD	  is	  associated	  with	  initial	  
treatment	  with	  pramipexole	  rather	  than	  L-­‐DOPA.	  (Guridi	  et	  al.,	  2012)	  
	  
It	  is	  thought	  that	  increases	  in	  motor	  fluctuations	  (Figure	  3,	  Tetrud	  et	  al.,	  2007)	  over	  time	  
are	  due	  to	  the	  progressive	  degeneration	  of	  nigrostriatal	  dopamine	  terminals,	  which	  
increasingly	  limits	  normal	  physiologic	  uptake	  and	  release	  of	  dopamine.	  	  	  This	  leads	  to	  a	  
reduced	  buffering	  of	  natural	  fluctuations	  in	  plasma	  L-­‐DOPA	  levels	  that	  occur	  due	  to	  L-­‐





There	  is	  also	  a	  longstanding	  concern	  that	  L-­‐DOPA	  causes	  motor	  fluctuation	  and	  
dyskinesia	  by	  its	  potential	  to	  promote	  oxidative	  stress	  and	  accelerated	  
neurodegeneration,	  rather	  than	  by	  changes	  in	  L-­‐DOPA	  pharmacodynamics	  that	  occur	  
with	  natural	  progression	  of	  the	  underlying	  disease.	  So,	  initiation	  of	  L-­‐DOPA	  should	  be	  
delayed	  until	  symptoms	  significantly	  interfere	  with	  daily	  functions.	  	  Others	  contend	  that	  
unnecessary	  delay	  would	  deprive	  patients	  of	  therapeutic	  benefit	  early	  in	  disease,	  when	  
potential	  for	  sustained	  improvement	  is	  the	  greatest	  (Marras	  et	  al.,	  2008).	  	  The	  current	  
consensus	  is	  that	  the	  lowest	  effective	  LDOPA	  dose	  should	  be	  used,	  either	  singly	  or	  in	  
combination	  with	  other	  treatments	  for	  patients	  with	  Parkinson’s	  disease,	  and	  after	  




It	  is	  unclear	  if	  L-­‐DOPA	  is	  neuroprotective	  or	  neurotoxic.	  	  In	  one	  theory,	  prolonged	  use	  of	  
L-­‐DOPA	  directly	  hastens	  the	  degeneration	  of	  dopaminergic	  neurons	  in	  the	  substantia	  
nigra	  by	  promoting	  the	  generation	  of	  free	  radicals	  and	  oxidative	  stress.	  This	  is	  one	  
reason	  for	  delaying	  the	  use	  of	  L-­‐DOPA.	  Delayed	  use	  would	  postpone	  the	  appearance	  of	  
motor	  complications	  such	  as	  dyskinesia	  and	  motor	  fluctuations.	  	  This	  is	  supported	  by	  a	  
SPECT	  (single	  photon	  emission	  computed	  tomography)	  study	  (Toth	  et	  al.,	  2010)	  of	  the	  
effect	  of	  L-­‐DOPA	  on	  basal	  ganglia	  uptake	  of	  dopamine.	  	  In	  this	  study,	  SPECT	  imaging	  data	  
from	  a	  sub-­‐study	  of	  116	  patients	  showed	  that	  patients	  using	  L-­‐DOPA	  had	  greater	  





DOPA	  is	  neurotoxic.	  	  In	  1998,	  the	  consensus	  (Agid	  et	  al.,	  1998)	  on	  L-­‐DOPA	  was	  that	  there	  
is	  no	  evidence	  showing	  L-­‐DOPA	  to	  be	  a	  cause	  of	  neuronal	  death	  in	  animal	  models	  of	  
Parkinson’s	  disease.	  	  The	  relevance	  of	  in	  vitro	  studies	  of	  L-­‐DOPA	  toxicity	  to	  clinical	  use	  is	  
highly	  uncertain.	  There	  is	  no	  evidence	  that	  chronic	  administration	  of	  L-­‐DOPA	  
exacerbates	  degenerative	  process	  of	  PD.	  Late	  motor	  complications	  could	  be	  due	  to	  the	  
combination	  of	  progressive	  degeneration	  of	  DA	  neurons	  and	  reversible	  effects	  of	  L-­‐
DOPA	  	  (George	  et	  al.,	  2009).	  
	  
Other	  experiments,	  especially	  the	  Early	  versus	  Late	  Levodopa	  (ELLDOPA)	  trial,	  offer	  
evidence	  that	  contradicts	  the	  first	  theory	  (Fahn	  et	  al.,	  2004).	  	  The	  results	  from	  the	  
ELLDOPA	  trial	  show	  that	  LDOPA	  either	  slows	  progression	  of	  PD	  or	  has	  prolonged	  benefit	  
even	  after	  drug	  is	  stopped.	  The	  trial	  used	  361	  patients	  with	  newly	  diagnosed	  PD	  and	  
randomly	  assigned	  them	  to	  either	  one	  of	  3	  Sinemet	  (L-­‐DOPA	  plus	  carbidopa	  
combination	  medicine)	  doses	  given	  three	  times	  daily	  or	  to	  placebo	  for	  40	  weeks,	  
followed	  by	  withdrawal	  of	  treatment	  for	  2	  weeks.	  	  At	  42	  weeks,	  all	  groups	  using	  L-­‐DOPA	  
showed	  significantly	  less	  worsening	  in	  symptoms	  of	  PD	  (Fahn	  et	  al.,	  2004),	  as	  measured	  
by	  the	  Unified	  Parkinson’s	  Disease	  Rating	  Scale	  (UPDRS),	  than	  did	  those	  in	  the	  placebo	  
group.	  Patients	  on	  high	  L-­‐DOPA	  dose	  (600	  mg/d)	  had	  the	  lowest	  UPDRS	  scores	  (lower	  
the	  better)	  but	  had	  significantly	  more	  dyskinesia.	  Hypertonia,	  infection,	  headache,	  and	  





suggests	  that	  use	  of	  L-­‐DOPA	  for	  40	  weeks	  was	  neuroprotective.	  	  Ultimately,	  it	  is	  still	  
unclear	  whether	  L-­‐DOPA	  is	  neurotoxic	  or	  neuroprotective	  (Fahn	  et	  al.,	  2006).	  
	  
Monoamine	  Oxidase	  B	  Inhibitors:	  
	  
L-­‐monoamine	  oxidases	  (MAO),	  which	  catalyze	  the	  oxidative	  deamination	  of	  
monoamines,	  are	  a	  family	  of	  enzymes	  usually	  bound	  to	  the	  outer	  membrane	  of	  the	  
mitochondria	  in	  most	  cell	  types	  in	  the	  body.	  	  In	  humans,	  there	  are	  two	  types	  of	  MAO,	  
MAO-­‐A	  and	  MAO-­‐B	  (Figure	  2).	  	  While	  both	  types	  of	  MAO	  break	  down	  dopamine,	  
tyramine,	  and	  tryptamine	  equally,	  MAO-­‐A	  is	  more	  specific	  for	  serotonin,	  melatonin,	  
noradrenaline,	  and	  adrenaline	  while	  MAO-­‐B	  is	  more	  specific	  for	  phenethylamine	  and	  	  
benzylamine.	  	  	  
	  
Because	  of	  the	  vital	  role	  that	  MAOs	  play	  in	  the	  inactivation	  of	  monoamine	  
neurotransmitters,	  excessive	  or	  insufficient	  MAO	  function	  is	  probably	  responsible	  for	  
various	  psychiatric	  and	  neurological	  disorders.	  	  MAO	  dysfunction	  has	  been	  linked	  with	  
depression,	  schizophrenia,	  substance	  abuse,	  and	  PD.	  	  Thus,	  monoamine	  oxidase	  
inhibitors	  are	  one	  of	  the	  major	  classes	  of	  drugs	  prescribed	  for	  the	  aforementioned	  
disorders.	  	  MAO-­‐A	  inhibitors	  act	  as	  antidepressant	  and	  antianxiety	  agents,	  whereas	  	  
MAO-­‐B	  inhibitors	  are	  used	  alone	  or	  in	  combination	  to	  treat	  PD	  and	  Alzheimer’s	  disease.	  	  





Rasagiline	  is	  used	  as	  a	  symptomatic	  treatment	  for	  PD.	  While	  animal	  model	  experiments	  
(Parkinson	  Study	  Group,	  2004)	  showed	  that	  the	  drug	  has	  neuroprotective	  properties,	  
human	  trials	  yielded	  inconsistent	  findings.	  
	  
Selegiline,	  a	  selective	  MAO-­‐B	  inhibitor	  (does	  not	  cause	  hypertensive	  crisis	  when	  
ingesting	  tyramine-­‐containing	  foods),	  is	  modestly	  effective	  as	  a	  symptomatic	  treatment	  
for	  PD	  (Parkinson	  Study	  Group,	  2004),	  and	  may	  have	  neuroprotective	  properties.	  	  
Selegiline	  enhances	  the	  effect	  of	  L-­‐DOPA	  by	  slowing	  its	  oxidative	  metabolism,	  but	  may	  
increase	  L-­‐DOPA	  induced	  side	  effects	  such	  as	  dyskinesia	  and	  psychiatric	  toxicity.	  	  
Selegiline	  mono-­‐therapy	  does	  not	  produce	  a	  functionally	  significant	  benefit.	  	  While	  past	  
studies	  showed	  Selegiline	  to	  have	  little	  positive	  effect	  on	  PD,	  it	  can	  still	  be	  used	  for	  
patients	  in	  the	  early	  stages	  of	  PD	  as	  a	  means	  of	  treating	  very	  mild	  symptoms,	  such	  as	  
tremors,	  and	  staving	  off	  the	  need	  for	  L-­‐DOPA	  (Ives	  et	  al.,	  2004).	  The	  patient	  should	  be	  
warned	  Selegiline	  have	  weaker	  symptomatic	  effects	  than	  L-­‐DOPA	  and	  dopamine	  
agonists;	  thus,	  other	  medications	  are	  needed	  as	  PD	  progresses	  (Caslake	  et	  al.,	  2009).	  	  
Side	  effects	  of	  Selegiline	  include	  nausea,	  headache,	  insomnia,	  and	  confusion	  (Table	  2).	  	  
Since	  the	  elderly	  are	  especially	  vulnerable	  to	  these	  adverse	  events,	  Selegiline	  is	  
contraindicated	  in	  patients	  with	  late	  onset	  PD.	  Selegiline	  also	  should	  not	  be	  used	  with	  
SSRI,	  or	  Tricyclics.	  	  	  	  
	  





Dopamine	  Receptor	  Agonists:	  
	  
Dopamine	  receptor	  agonists	  (DA)	  are	  compounds	  that	  can	  activate	  the	  dopamine	  
receptors	  and	  are	  used	  for	  treating	  low	  dopamine	  conditions.	  	  Unlike	  Sinemet,	  these	  
drugs	  are	  direct	  agonists	  of	  the	  dopamine	  receptors	  that	  do	  not	  require	  metabolic	  
conversion,	  do	  not	  compete	  with	  amino	  acids	  for	  transport	  across	  the	  gut	  or	  into	  the	  
brain,	  and	  do	  not	  depend	  upon	  neuronal	  uptake	  and	  release.	  	  An	  additional	  advantage	  
over	  immediate-­‐release	  forms	  of	  L-­‐DOPA	  is	  a	  longer	  duration	  of	  action	  of	  most	  of	  these	  
agents.	  	  DA	  are	  used	  as	  monotherapies	  for	  patients	  younger	  than	  60	  years	  old	  to	  avoid	  
L-­‐DOPA	  neurotoxicity;	  L-­‐DOPA	  is	  used	  for	  patients	  60	  years	  old	  or	  older	  (George	  et	  al.,	  
2009).	  	  DAs	  can	  be	  divided	  into	  ergoline	  or	  non-­‐ergoline	  derivates;	  ergoline	  DAs	  are	  not	  
recommended	  as	  a	  first-­‐line	  treatment	  due	  to	  several	  severe	  side	  effects	  such	  as	  
valvular	  heart	  disease	  and	  orthostatic	  hypotension.	  	  Non-­‐ergoline	  DAs	  are	  regarded	  as	  
efficacious	  and	  safe;	  hence,	  is	  recommended	  as	  therapy	  for	  younger	  patients	  in	  
combination	  with	  L-­‐DOPA	  or	  as	  a	  monotherapy	  (Pedrosa	  et	  al.,	  2013).	  	  
	  
The	  ones	  most	  commonly	  used	  for	  PD	  patients	  in	  the	  United	  States	  consist	  of	  
Bromocriptine,	  Pramipexole,	  Ropinirole,	  Rotigotine,	  Piribedil,	  and	  Apomorphine.	  
Lisuride	  is	  not	  available	  in	  the	  United	  States.	  	  Apomorphine	  is	  administered	  parenterally	  
as	  rescue	  therapy	  for	  sudden	  akinetic	  episodes.	  	  Injectable	  Apomorphine	  is	  used	  for	  
treating	  motor	  fluctuations	  in	  PD.	  	  Controlled	  trials	  showed	  that	  Bromocriptine,	  





complicated	  by	  motor	  fluctuations	  and	  dyskinesia.	  	  However,	  only	  Pramipexole,	  
Ropinirole,	  transdermal	  Rotigotine,	  and	  Pergolide	  are	  effective	  as	  monotherapy	  in	  
patient	  with	  early	  PD.	  	  DAs	  are	  ineffective	  in	  patients	  who	  have	  shown	  no	  therapeutic	  
response	  to	  L-­‐DOPA.	  
	  
In	  16	  trials	  comparing	  DAs	  with	  L-­‐DOPA,	  patients	  using	  DA	  are	  less	  likely	  to	  develop	  
dyskinesia,	  dystonia,	  or	  motor	  fluctuations	  than	  those	  using	  L-­‐DOPA.	  	  However,	  
symptomatic	  control	  of	  PD	  is	  better	  with	  L-­‐DOPA	  than	  with	  DAs.	  	  Early	  DA	  monotherapy	  
postpones	  future	  onset	  of	  motor	  complications,	  because	  DA	  is	  less	  potent	  than	  L-­‐DOPA.	  	  
Few	  patients	  with	  progressive	  disease	  can	  be	  satisfactorily	  maintained	  on	  DA	  




The	  side	  effects	  of	  DAs	  are	  similar	  to	  those	  of	  L-­‐DOPA,	  and	  include	  nausea,	  vomiting,	  
sleepiness,	  orthostatic	  hypotension,	  confusion,	  and	  hallucinations	  (Table	  2).	  Peripheral	  
edema	  is	  common	  with	  chronic	  use	  of	  DAs	  but	  is	  rare	  in	  patients	  using	  L-­‐DOPA	  alone.	  	  
These	  adverse	  events	  are	  more	  likely	  to	  cause	  patients	  on	  DA	  than	  those	  on	  L-­‐DOPA	  to	  
discontinue	  treatment.	  	  	  
	  
Moreover,	  the	  use	  of	  DA	  as	  a	  class	  may	  lead	  to	  dopaminergic	  dysregulation	  syndrome	  





(3.4%)	  and	  impulse	  control	  disorders	  (George	  et	  al.,	  2009).	  	  DDS	  typically	  involves	  male	  
patients	  with	  early	  onset	  PD	  who	  take	  increasing	  quantities	  of	  DA	  drugs	  despite	  
increasingly	  severe	  drug-­‐induced	  dyskinesia.	  DDS	  is	  associated	  with	  cyclical	  mood	  
disorder	  characterized	  by	  hypomania	  or	  manic	  psychosis.	  	  DA	  therapy	  is	  also	  associated	  
with	  increased	  risk	  of	  impulse	  control	  disorders	  including	  pathological	  gambling,	  
compulsive	  sexual	  behavior,	  or	  compulsive	  buying.	  	  In	  a	  retrospective	  case	  series	  of	  11	  
patients	  who	  are	  on	  DA	  therapy	  and	  have	  a	  gambling	  problem,	  pathologic	  gambling	  
resolved	  with	  tapering	  down	  the	  dosage	  or	  discontinuation	  of	  DA	  therapy	  (Voon	  et	  al.,	  
2007;	  Weintraub	  et	  al.,	  2010).	  
	  
DA	  withdrawal	  syndrome	  is	  found	  in	  patients	  who	  had	  a	  dose	  reduction	  or	  had	  abruptly	  
stopped	  taking	  DA.	  Effects	  resemble	  those	  of	  cocaine	  withdrawal:	  anxiety,	  panic	  attacks,	  
depression,	  sweating,	  nausea,	  pain,	  fatigue,	  dizziness,	  drug	  craving.	  These	  effects	  are	  
refractory	  to	  other	  antiparkinsonian	  medications	  including	  L-­‐DOPA	  and	  respond	  only	  to	  
resuming	  DA.	  	  Most	  DAs	  decrease	  prolactin,	  leading	  to	  decreased	  milk	  production.	  	  So,	  
DA	  is	  contraindicated	  in	  women	  who	  breast	  feed	  (Giovannoni	  et	  al.,	  2000).	  
	  
Transdermal	  rotigotine	  induce	  skin	  site	  reactions	  that	  are	  transient	  and	  mild	  to	  
moderate	  in	  severity.	  	  Pergolide,	  one	  of	  the	  ergoline	  DAs,	  carries	  a	  high	  risk	  of	  valvular	  
heart	  disease	  and	  has	  been	  removed	  from	  the	  American	  market	  since	  2007	  (Pedrosa	  et	  





therapies.	  	  Side	  effects	  of	  apomorphine	  are	  usually	  mild,	  mostly	  cutaneous	  reactions	  
and	  neuropsychiatric	  problems.	  	  The	  drug	  also	  causes	  chest	  pain,	  angina,	  and	  orthostatic	  
hypotension	  (peaks	  20	  minutes	  after	  dosing	  and	  lasts	  at	  least	  90	  min)	  	  	  	  (Deleu	  D	  et	  al.,	  




The	  enzyme	  catechol-­‐O-­‐methyltransferase	  (COMT)	  is	  involved	  in	  the	  inactivation	  of	  the	  
catecholamine	  transmitters	  (dopamine,	  epinephrine,	  norepinephrine).	  	  L-­‐DOPA,	  a	  
precursor	  of	  the	  catecholamines,	  is	  also	  deactivated	  by	  the	  COMT	  enzyme	  (Figure	  2).	  	  
This	  enzyme	  plays	  a	  significant	  role	  in	  causing	  the	  peripheral	  nervous	  system	  side	  effects	  
found	  in	  PD.	  	  Hence,	  COMT	  inhibitors,	  such	  as	  Tolcapone	  and	  Entacapone	  (Figure	  2,	  
Table	  2),	  are	  important	  for	  saving	  and	  prolonging	  the	  effects	  of	  L-­‐DOPA.	  	  This	  
medication	  works	  only	  when	  it	  is	  administered	  in	  conjunction	  with	  a	  DOPA	  
decarboxylase	  inhibitor;	  monotherapies	  are	  ineffective.	  	  COMT	  inhibitors	  are	  used	  
especially	  for	  treating	  patients	  with	  motor	  fluctuations	  (Figure	  3)	  who	  experience	  end-­‐
of-­‐dose	  wearing	  off	  periods.	  When	  given	  to	  patients	  without	  motor	  fluctuations,	  the	  
drug	  does	  not	  improve	  UPDRS	  motor	  scores,	  but	  is	  associated	  with	  several	  improved	  




The	  COMT	  inhibitor	  Tolcapone	  causes	  increased	  dopaminergic	  stimulation,	  and	  gives	  





orthostatic	  hypotension	  (Table	  2).	  These	  effects	  are	  managed	  by	  lowering	  the	  L-­‐DOPA	  
dose	  before	  or	  after	  addition	  of	  Tolcapone.	  Rare	  adverse	  reactions	  include	  diarrhea	  (in	  
5%	  of	  patients),	  orange	  discoloration	  of	  urine,	  and	  hepatotoxicity.	  	  The	  side	  effects	  of	  




Dopamine	  and	  acetylcholine	  are	  normally	  in	  a	  state	  of	  electrochemical	  balance	  in	  the	  
basal	  ganglia	  (Katzenschlager	  et	  al.,	  2003).	  In	  PD,	  dopamine	  depletion	  induces	  a	  state	  of	  
cholinergic	  sensitivity	  such	  that	  cholinergic	  drugs	  exacerbate	  and	  anticholinergic	  drugs	  
improve	  PD	  symptoms.	  	  
	  
The	  anticholinergics	  Trihexyphenidyl	  and	  Benztropine	  are	  most	  useful	  as	  monotherapy	  
for	  younger	  patients	  (under	  age	  70)	  who	  have	  disturbing	  tremor	  but	  without	  significant	  
akinesia	  or	  gait	  disturbance.	  These	  drugs	  may	  also	  be	  useful	  for	  patients	  who	  have	  more	  
advanced	  disease	  with	  persistent	  tremors	  despite	  treatment	  with	  L-­‐DOPA	  or	  DAs	  (Lang	  




Anticholinergics	  are	  contraindicated	  for	  the	  elderly	  and	  cognitively	  impaired	  patients	  
because	  they	  are	  particularly	  susceptible	  to	  memory	  impairment,	  confusion,	  and	  
hallucinations.	  Peripheral	  antimuscarinic	  side	  effects	  of	  anticholinergics	  include	  dry	  





tachycardia.	  	  Because	  of	  them,	  anticholinergics	  are	  contraindicated	  if	  patient	  has	  




Amantadine	  is	  an	  antiviral	  agent	  with	  mild	  anti-­‐PD	  activity.	  While	  its	  mechanism	  is	  
unknown,	  Amantadine	  is	  known	  to	  increase	  dopamine	  release,	  inhibit	  dopamine	  
reuptake,	  stimulate	  dopamine	  receptors,	  and	  exert	  central	  anticholinergic	  effects.	  	  The	  
drug	  is	  good	  as	  a	  short-­‐term	  monotherapy	  in	  those	  with	  mild	  PD.	  	  There	  is	  little	  benefit	  
when	  Amantadine	  is	  added	  to	  L-­‐DOPA,	  but	  much	  improvement	  when	  L-­‐DOPA	  is	  added	  
to	  Amantadine	  (Godwen-­‐Austen,	  1970).	  
	  
Peripheral	  adverse	  events	  of	  Amantadine	  include	  (Table	  2)	  livedo	  reticularis	  [a	  lace-­‐like	  
purplish	  discoloration	  of	  skin	  caused	  by	  swelling	  of	  the	  small	  veins	  under	  the	  skin,	  owing	  
to	  obstruction	  of	  capillaries	  (Rapini,	  2007)],	  reversible	  corneal	  edema,	  ankle	  edema,	  
anxiety,	  agitation,	  insomnia,	  worsening	  of	  preexisting	  seizure	  disorders	  and	  psychiatric	  
symptoms	  (Pedrosa,	  2013).	  Confusion,	  hallucinations,	  and	  nightmares	  occur	  
infrequently	  and	  unpredictably,	  even	  after	  long	  periods	  of	  use	  without	  side	  effects.	  
These	  effects	  are	  more	  likely	  to	  happen	  when	  Amantadine	  is	  used	  in	  combination	  with	  











Low	  dose	  estrogen	  is	  helpful	  only	  as	  an	  adjunctive	  therapy	  for	  postmenopausal	  women	  
with	  motor	  fluctuations	  on	  antiparkinsonian	  medications.	  Administration	  of	  Premarin	  
0.625	  mg	  daily	  for	  8	  weeks	  significantly	  improved	  “on”	  time	  and	  motor	  control	  in	  such	  
women,	  but	  offered	  no	  global	  improvement	  on	  scale	  rating	  activities	  of	  daily	  living.	  
Benefits	  attributable	  to	  estrogen	  use	  may	  be	  related	  to	  overall	  sense	  of	  well	  being.	  
	  
Neuroprotective	  Pharmacological	  Therapy:	  
	  
Neuroprotective	  therapy	  has	  not	  been	  proven	  yet,	  but	  is	  based	  on	  the	  theory	  that	  the	  
three	  to	  four	  hundred	  thousand	  vulnerable	  dopaminergic	  neurons	  in	  the	  substantia	  
nigra	  can	  be	  protected	  from	  the	  complex	  degenerative	  process	  that	  induces	  premature	  
cell	  death	  and	  loss	  of	  dopamine.	  	  Once	  proven,	  these	  medications	  could	  be	  used	  for	  
patients	  in	  early	  stages	  of	  the	  disease	  or	  for	  those	  who	  are	  at	  genetic	  risk.	  	  	  
	  
There	  are	  many	  potential	  neuroprotective	  agents	  that	  are	  currently	  undergoing	  further	  
research.	  	  Of	  the	  group	  –	  L-­‐DOPA,	  the	  MAO	  inhibitors	  Selegiline	  and	  Rasagiline,	  DAs,	  and	  
the	  complex	  I	  mitochondrial	  fortifier	  Coenzyme	  Q10,	  Vitamin	  E,	  Riluzole,	  Uric	  acid	  –	  
Rasagiline	  and	  Coenzyme	  Q10	  appear	  to	  be	  the	  most	  promising	  (Olanow	  et	  al.,	  2009;	  









Neuroprotective	  Dopamine	  Agonists:	  Pramipexole,	  Ropinirole	  
	  
Theoretically,	  DAs	  are	  neuroprotective	  because	  they	  are	  antioxidants	  and	  free	  radical	  
scavengers	  and	  also	  because	  of	  feedback	  reduction	  of	  endogenous	  dopamine	  turnover.	  
It	  is	  hypothesized	  that	  if	  dopamine	  agonists	  are	  used	  in	  early	  stages	  of	  PD,	  they	  may	  
slow	  the	  progression	  of	  underlying	  neurodegeneration	  (Schapira	  et	  al.,	  2004).	  
	  
One	  potential	  biologic	  marker	  uses	  single	  photo	  emission	  computed	  tomography	  
(SPECT)	  with	  dopamine	  transporter	  ligand	  [123I]	  beta-­‐CIT	  (B-­‐CIT)	  as	  an	  anatomic	  
measure	  of	  nigrostriatal	  integrity	  and	  as	  a	  surrogate	  marker	  of	  PD	  progression.	  Earlier	  
investigation	  of	  natural	  course	  of	  PD	  shows	  a	  5%	  to	  10%	  reduction	  of	  B-­‐CIT	  uptake	  per	  
year	  in	  heterogeneous	  mix	  of	  patients	  with	  PD	  (Fahn	  et	  al.,	  2004).	  
	  
In	  a	  CALM-­‐PD	  study	  comparing	  Pramipexole	  and	  L-­‐DOPA,	  82	  PD	  patients	  were	  evaluated	  
over	  four	  years.	  Those	  using	  Pramipexole	  demonstrated	  less	  decline	  in	  striatal	  B-­‐CIT	  
uptake	  over	  4	  years	  than	  those	  using	  L-­‐DOPA.	  However,	  no	  differences	  in	  UPDRS	  scores	  
were	  found	  between	  the	  two	  groups	  (The	  Parkinson	  Study	  Group,	  2000).	  
	  
In	  another	  study,	  162	  patients	  were	  assigned	  to	  either	  L-­‐DOPA	  or	  Ropinirole,	  and	  
evaluated	  with	  the	  use	  of	  PET	  scanning,	  and	  the	  levodopa-­‐decarboxylase	  ligand	  18F-­‐





significantly	  less	  decline	  in	  18F-­‐dopa	  uptake	  than	  those	  using	  L-­‐DOPA.	  	  Ropinirole	  is	  
more	  neuroprotective	  than	  L-­‐DOPA	  (Rascol	  O	  et	  al.,	  2000).	  
	  
Despite	  of	  these	  study	  results,	  it	  is	  still	  uncertain	  whether	  these	  imaging	  studies	  reflect	  
actual	  changes	  in	  the	  underlying	  pathology	  of	  Parkinson’s	  disease	  or	  the	  differential	  
pharmacologic	  "regulatory"	  changes	  that	  are	  directly	  attributable	  to	  the	  drugs	  
themselves	  (Agid	  et	  al.,	  1998).	  
Coenzyme	  Q10	  
	  
In	  a	  trial	  with	  80	  patients	  subjected	  to	  either	  Coenzyme	  Q10	  or	  placebo,	  and	  followed	  
for	  progression	  of	  PD	  as	  measured	  by	  UPDRS,	  treatment	  with	  the	  highest	  dosage	  (1200	  
mg)	  of	  Coenzyme	  Q10	  is	  associated	  with	  a	  lower	  rate	  of	  disability	  progression	  over	  16	  
months	  compared	  to	  treatment	  with	  placebo.	  However,	  the	  results	  of	  the	  trial	  were	  not	  
statistically	  significant,	  and	  thus,	  it	  is	  not	  clear	  if	  coenzyme	  Q10	  is	  truly	  beneficial	  for	  PD	  




Riluzole,	  Vitamin	  E,	  and	  Uric	  acid	  had	  been	  candidates	  for	  neuroprotective	  research.	  	  
However,	  there	  is	  no	  current	  evidence	  that	  any	  of	  the	  three	  candidates	  are	  
neuroprotective.	  	  While	  high	  levels	  of	  uric	  acid	  had	  been	  associated	  with	  lower	  risk	  of	  





















	  Neural	  transplantation	  is	  an	  alternative	  treatment	  with	  mixed	  results	  that	  requires	  
further	  research.	  	  The	  idea	  of	  neural	  transplants	  is	  to	  place	  dopamine-­‐producing	  cells	  in	  
or	  near	  the	  sites	  in	  the	  brain	  where	  there	  is	  no	  dopamine	  production.	  	  	  Two	  randomized	  
controlled	  trials	  found	  no	  clear	  benefit	  for	  embryonic	  neural	  transplantation	  (Freed	  et	  
al.,	  2001;	  Olanow	  et	  al.,	  2003).	  	  	  Histopathologic	  evaluation	  of	  postmortem	  brains	  from	  
patients	  with	  PD	  who	  had	  neural	  implants	  also	  yielded	  conflicting	  results	  (Li	  et	  al.,	  2008;	  
Kordower	  et	  al.,	  2008;	  Braak	  et	  al.,	  2008).	  	  	  Postmortem	  analyses	  performed	  11	  to	  16	  
years	  after	  transplantation	  in	  three	  patients	  with	  Parkinson’s	  disease	  found	  Lewy	  body	  
pathology	  in	  transplanted	  neurons.	  	  It	  is	  hypothesized	  that	  unknown	  factors	  in	  
progressive	  neurodegeneration	  in	  PD	  caused	  the	  spread	  of	  disease	  from	  host	  to	  graft	  
cells.	  	  Another	  postmortem	  study	  done	  9	  to	  14	  years	  after	  transplantation	  in	  5	  PD	  
patients	  revealed	  surviving	  grafts	  that	  included	  dopaminergic	  and	  serotonergic	  	  
neurons	  without	  pathology	  (Mendez	  et	  al.,	  2008).	  	  Thus,	  neural	  transplant	  is	  not	  a	  
preferred	  treatment	  compared	  with	  other	  options.	  	  	  
	  
Gene	  Therapy:	  	  
Gene	  therapy	  in	  PD	  consists	  of	  creating	  new	  cells	  that	  can	  produce	  dopamine	  to	  protect	  
the	  neural	  system	  or	  modify	  genes	  related	  to	  the	  disease.	  These	  cells	  are	  then	  





Embryonic	  dopaminergic	  cells	  cannot	  be	  used	  because	  these	  cells	  are	  technically	  
difficult	  to	  obtain	  and	  modifications	  can	  only	  be	  made	  on	  somatic	  and	  not	  germ	  line	  
cells.	  It	  is	  only	  with	  the	  modifications	  of	  the	  transplanted	  cell	  can	  there	  be	  a	  change	  in	  
the	  expression	  of	  the	  genes	  (George	  et	  al.,	  2009).	  	  
	  
Current	  methods	  of	  gene	  therapy	  are	  classified	  as	  either	  symptomatic	  or	  disease	  
modifying.	  	  Symptomatic	  gene	  therapy	  includes	  increasing	  ectopic	  dopamine	  
production,	  augmenting	  the	  reduced	  dopamine	  production	  that	  occurs	  with	  PD,	  and	  
targeting	  the	  excess	  activity	  of	  the	  subthalamic	  nucleus	  that	  results	  from	  loss	  of	  
dopaminergic	  input.	  This	  can	  be	  achieved	  by	  inducing	  the	  production	  of	  the	  inhibitory	  
neurotransmitter,	  gamma-­‐amino	  butyric	  acid	  (GABA),	  thereby	  converting	  the	  output	  of	  
the	  STN	  from	  excitatory	  to	  inhibitory	  (Kaplitt	  et	  al.,	  2007).	  Disease	  modifying	  therapies	  
include	  glial	  cell	  line	  derived	  neurotrophic	  factor	  (GDNF)	  infusion,	  regulation	  of	  alpha-­‐
synuclein	  production,	  and	  Parkin	  gene	  expression.	  Gene	  therapy	  is	  currently	  in	  early	  
stages	  of	  research,	  and	  while	  results	  seem	  promising,	  further	  study	  is	  required.	  	  	  	  
	  
GDNF	  INFUSION:	  
This	  treatment	  involves	  the	  direct	  infusion	  of	  GDNF	  into	  the	  brain.	  	  Again,	  current	  
research	  has	  yielded	  conflicting	  results.	  	  In	  a	  phase	  II	  open	  label	  trial	  of	  safety	  and	  
tolerability	  involving	  five	  patients,	  GDNF	  infusion	  significantly	  improved	  the	  patients’	  





2003).	  	  However,	  no	  benefits	  from	  GDNF	  infusion	  was	  found	  in	  a	  larger	  randomized	  
controlled	  trial	  comparing	  intraputamenal	  infusion	  of	  GDNF	  and	  placebo	  in	  34	  patients	  
followed	  for	  six	  months	  (Lang	  et	  al.,	  2006).	  
	  
OVERVIEW	  OF	  SURGICAL	  TREATMENTS	  FOR	  PARKINSON’S	  DISEASE:	  
	  
Surgical	  procedures,	  which	  are	  established	  treatments	  for	  PD	  patients	  when	  they	  
become	  refractory	  to	  most	  medications,	  encompass	  ablative	  brain	  surgery	  and	  deep	  
brain	  stimulation	  (DBS).	  	  Despite	  of	  their	  efficacy	  of	  controlling	  PD	  symptoms,	  surgical	  
treatments	  do	  not	  cure	  PD.	  	  Ablative	  brain	  surgery,	  also	  known	  as	  brain	  lesioning,	  is	  an	  
invasive	  procedure	  where	  the	  target	  of	  choice	  is	  destroyed	  to	  alleviate	  pathologic	  
symptoms.	  	  The	  ventral	  intermediate	  nucleus	  of	  the	  thalamus,	  the	  subthalamic	  nucleus,	  
and	  the	  globus	  pallidus	  are	  the	  usual	  targets	  of	  brain	  lesioning	  because	  of	  their	  
involvements	  in	  the	  dopaminergic	  pathways	  damaged	  by	  PD	  (Ponce	  et	  al.,	  2010).	  	  Due	  
to	  the	  irreversible	  nature	  of	  neural	  ablations,	  they	  have	  mostly	  been	  replaced	  by	  DBS,	  
which	  is	  an	  alternative	  surgical	  procedure	  where	  the	  targets	  are	  stimulated	  by	  electrical	  
impulses	  to	  relieve	  the	  patient	  of	  PD	  symptoms.	  	  	  These	  impulses	  can	  be	  adjusted	  to	  
minimize	  and	  reverse	  any	  initial	  side	  effects	  (Vergani	  et	  al.,	  2010).	  	  	  
	  
What	  are	  Thalamotomy,	  Pallidotomy,	  Subthalamotomy,	  and	  Deep	  Brain	  Stimulation?	  
	  
The	  name	  of	  the	  brain	  lesioning	  procedure	  depends	  on	  the	  name	  of	  the	  target.	  	  Thus,	  





are	  known	  as	  thalamotomy,	  subthalamotomy,	  and	  pallidotomy	  respectively.	  	  These	  
three	  nuclei	  are	  also	  targets	  of	  DBS	  treatment.	  
	  
Thalamotomy	  is	  good	  for	  relieving	  motor	  symptoms	  such	  as	  tremor	  but	  not	  any	  other	  
PD	  symptoms.	  	  While	  the	  procedure	  was	  one	  of	  the	  earliest	  surgical	  treatments	  for	  PD,	  
it	  is	  now	  used	  only	  if	  nothing	  else	  is	  available	  due	  to	  its	  side	  effects,	  which	  are	  
exacerbated	  if	  thalamotomy	  is	  done	  on	  both	  sides	  of	  the	  brain.	  	  Common	  temporary	  
side	  effects	  include	  confusion,	  weakness,	  disturbed	  speech,	  and	  balance	  problems.	  	  
Severe	  adverse	  effects	  include	  permanent	  speech	  or	  balance	  problems,	  paralysis,	  
cognitive	  problems,	  bleeding,	  and	  infections	  (Follett	  et	  al.,	  2010).	  	  	  
	  
Pallidotomy	  is	  preferred	  over	  thalamotomy	  for	  treating	  more	  PD	  symptoms	  and	  having	  
relatively	  less	  side	  effects.	  	  This	  procedure	  is	  good	  for	  reducing	  tremors,	  muscle	  rigidity,	  
bradykinesia,	  and	  improving	  balance	  and	  speech	  problems.	  	  The	  procedure	  carries	  the	  
risk	  of	  stroke,	  cognitive	  impairment,	  seizures,	  and	  infections.	  	  Pallidotomy	  is	  used	  when	  
patients	  with	  advanced	  PD	  develop	  severe	  motor	  fluctuations,	  disabling	  tremors,	  and	  
other	  symptoms	  refractory	  to	  medication	  control.	  	  This	  surgical	  treatment	  is	  
contraindicated	  if	  the	  patients	  are	  unresponsive	  to	  L-­‐DOPA	  (Follett	  et	  al.,2010).	  	  	  
	  
Subthalamotomy	  is	  another	  surgical	  procedure	  that	  is	  used	  for	  patients	  with	  advanced	  





subthalamic	  nucleus	  can	  be	  ablated	  unilaterally	  or	  bilaterally.	  	  A	  2009	  study	  comparing	  
unilateral	  and	  bilateral	  subthalmotomy	  showed	  no	  difference	  between	  the	  two	  
techniques	  in	  terms	  of	  their	  ability	  to	  relieve	  motor	  symptoms	  that	  are	  refractory	  to	  PD	  
medications	  (Alvarez	  et	  al.,	  2009).	  	  The	  adverse	  events	  of	  subthalamotomy	  are	  similar	  to	  
those	  of	  pallidotomy.	  
	  
Deep	  brain	  stimulation	  is	  the	  surgical	  procedure	  used	  most	  frequently	  nowadays.	  	  A	  
medical	  device	  called	  a	  brain	  pacemaker	  is	  implanted	  in	  one	  of	  the	  aforementioned	  
targets;	  electrical	  impulses	  are	  sent	  through	  the	  pacemaker	  to	  control	  pathological	  
symptoms.	  	  While	  deep	  brain	  stimulation	  effects	  are	  similar	  to	  those	  of	  brain	  lesioning,	  
these	  effects	  are	  adjustable	  and	  reversible.	  	  However,	  this	  surgical	  procedure	  is	  not	  
suitable	  for	  all	  PD	  patients.	  	  Factors	  that	  contraindicate	  DBS	  include	  PD	  that	  is	  not	  
responsive	  to	  L-­‐DOPA	  or	  dopamine	  agonists,	  difficulties	  with	  speech,	  walking,	  or	  balance	  
that	  are	  not	  relieved	  by	  medications,	  confusion,	  memory	  problems,	  any	  psychiatric	  
disorders,	  depression,	  anxiety,	  and	  patient	  age	  over	  70	  years	  old	  (McIntosh	  et	  al.,	  2011).	  	  	  
	  
History	  of	  Surgical	  Treatments	  
	  
Surgical	  ablations,	  which	  encompass	  thalamotomy,	  pallidotomy,	  and	  subthalamotomy,	  
are	  seldom	  used	  today	  due	  to	  their	  irreversible	  nature	  unless	  deep	  brain	  stimulation	  is	  





Despite	  the	  current	  consensus,	  surgical	  ablation	  has	  been	  around	  for	  a	  hundred	  years	  
(Fasano	  et	  al.,	  2012).	  	  
	  
Surgical	  ablation	  was	  first	  pioneered	  by	  Dr.	  Victor	  Horsely	  in	  1909	  when	  he	  resected	  part	  
of	  the	  precentral	  gyrus	  or	  motor	  cortex	  in	  a	  patient	  with	  athetoid	  movements.	  While	  the	  
procedure	  was	  successful	  in	  halting	  the	  patient’s	  abnormal	  movements,	  it	  was	  
abandoned	  because	  the	  patient	  also	  developed	  dyspraxia	  and	  paralysis	  of	  the	  limb.	  	  
Difficulty	  in	  locating	  the	  motor	  cortex	  was	  another	  reason	  for	  abandoning	  the	  
procedure;	  moreover,	  not	  only	  did	  patients	  continue	  to	  suffer	  from	  rigidity	  and	  akinesia,	  
but	  they	  also	  developed	  post-­‐operative	  epilepsy.	  	  Finally,	  people	  back	  then	  believed	  that	  
the	  human	  consciousness	  resided	  in	  the	  basal	  ganglia,	  and	  that	  utmost	  care	  was	  needed	  
to	  protect	  it	  (CNS	  Clinic	  Jordan,	  2010).	  	  Basal	  ganglia	  surgery	  remained	  unpopular	  until	  
1939,	  when	  Dr.	  Meyers	  successfully	  used	  it	  to	  improve	  the	  symptoms	  of	  a	  patient	  with	  
post-­‐encephalitic	  PD.	  	  	  In	  the	  1940s	  and	  1950s,	  Dr.	  Meyers	  focused	  more	  on	  the	  basal	  
ganglia	  and	  reported	  a	  60%	  improvement	  in	  rigidity	  and	  tremor	  following	  the	  combined	  
section	  of	  pallido-­‐fugal	  fibers,	  resection	  of	  the	  caudate	  head,	  and	  anterior	  capsulotomy	  





	   	  
Figure	  4.	  The	  stereotactic	  frame	  with	  the	  MRI	  Localizer	  Box	  (CNS	  Clinic	  Jordan,	  2010).	  
The	  plastic	  box	  is	  used	  to	  add	  coordinate	  points	  the	  surgeon	  can	  use	  to	  locate	  objects	  
in	  the	  frame’s	  three-­‐dimensional	  space.	  This	  frame	  has	  greatly	  increased	  the	  safety	  of	  
modern	  surgical	  treatments,	  and	  is	  a	  staple	  of	  all	  neural	  ablative	  surgeries	  and	  deep	  
brain	  stimulation	  procedures	  (Yanini	  et	  al.,	  2003).	  
	  
	  
While	  the	  first	  stereotactic	  frame	  (Figure	  4)	  was	  invented	  by	  Robert	  Clarke	  in	  1908,	  the	  
breakthrough	  in	  the	  development	  of	  human	  stereotactic	  surgery	  did	  not	  come	  until	  
1947,	  when	  ventriculography	  was	  introduced.	  	  Drs.	  Spiegel	  and	  Wycis	  introduced	  the	  
stereo-­‐encephalotome,	  which	  used	  landmarks	  within	  the	  brain,	  rather	  than	  the	  skull	  
(Yianni	  et	  al.,	  2003).	  	  This	  allowed	  for	  the	  use	  of	  thermal	  lesion	  or	  injection	  of	  alcohol	  
into	  specific	  targets,	  such	  as	  the	  thalamus,	  ansa	  lenticularis,	  and	  pallidum.	  	  Using	  the	  
stereo-­‐encephalotome,	  Dr.	  Spiegel	  and	  Wycis	  performed	  the	  first	  human	  stereotactic	  
surgeries	  (Figure	  4)	  for	  psychiatric	  illnesses	  and	  Huntington’s	  chorea.	  	  From	  then	  on,	  





In	  1952,	  Dr.	  Cooper	  stumbled	  upon	  the	  benefits	  of	  globus	  pallidal	  lesioning	  during	  an	  
attempted	  pedunculotomy	  for	  Parkinsonism	  (Birdno	  et	  al.,	  2008).	  	  The	  procedure	  was	  
aborted	  due	  to	  bleeding,	  which	  was	  controlled	  by	  ligating	  the	  anterior	  choroidal	  artery,	  
but	  caused	  the	  infarction	  of	  the	  globus	  pallidus.	  	  The	  patient	  survived	  with	  the	  
extinction	  of	  his	  tremors	  and	  no	  other	  deficits.	  	  While	  Dr.	  Cooper	  went	  on	  to	  adopt	  
stereotactic	  approaches	  to	  pallidal	  lesioning,	  which	  yielded	  favorable	  results	  and	  
reduced	  surgical	  mortalities	  (3%),	  other	  surgeons	  chose	  to	  lesion	  the	  globus	  pallidus	  by	  
injecting	  alcohol	  into	  it	  and	  followed	  by	  thermocoagulation.	  	  Some	  have	  chosen	  to	  
improve	  on	  Dr.	  Cooper’s	  work	  by	  placing	  the	  lesion	  more	  posteriorly	  and	  ventrally	  
within	  the	  internal	  segment	  of	  the	  globus	  pallidus.	  	  	  
	  
In	  1963,	  Dr.	  Spiegel	  explored	  campotomy	  as	  a	  means	  of	  correcting	  tremor	  and	  rigidity	  in	  
PD.	  	  Campotomy	  is	  the	  stereotaxic	  surgical	  technique	  of	  making	  a	  lesion	  in	  the	  fibers	  of	  
the	  pallidofugal,	  rubrothalamic,	  corticofugal,	  and	  hypothalamofugal	  pathways	  within	  
the	  H	  fields	  of	  Forel	  (beneath	  the	  thalamus).	  	  Despite	  of	  the	  success	  of	  campotomy,	  
thalamotomy,	  especially	  that	  of	  the	  ventral	  intermediate	  (Vim)	  nucleus	  within	  the	  
thalamus,	  emerged	  as	  the	  surgical	  procedure	  of	  choice	  because	  of	  the	  consistent	  tremor	  
control	  it	  provided.	  	  Although	  most	  surgeries	  for	  PD	  ceased	  after	  the	  introduction	  of	  L-­‐
DOPA	  in	  1967,	  small	  numbers	  of	  thalamotomies	  were	  performed	  for	  medically	  
refractory	  tremor	  during	  the	  next	  25	  years,	  until	  1992.	  	  At	  the	  time,	  a	  Swedish	  





including	  a	  reduction	  in	  L-­‐DOPA	  induced	  dyskinesia	  (CNS	  Clinic	  Jordan,	  2003).	  	  From	  
then	  on,	  neuroablation	  was	  seen	  as	  an	  effective	  solution	  once	  again.	  	  Moreover,	  
transplantation	  of	  fetal	  dopamine	  cells	  and	  adrenal	  medullary	  grafts	  in	  the	  striatum	  
yielded	  such	  unpredictable	  results	  that	  lesional	  surgery	  was	  seen	  as	  a	  more	  preferable	  
surgical	  treatment.	  
	  
As	  for	  deep	  brain	  stimulation	  (DBS),	  it	  had	  been	  in	  use	  during	  the	  1960s	  as	  a	  means	  of	  
preparing	  the	  brain	  targets	  for	  ablative	  surgery,	  and	  to	  identify	  the	  optimal	  site	  for	  
thalamic	  lesioning.	  	  It	  had	  been	  observed	  that	  high	  frequency	  VIM	  (ventrointermediate	  
nucleus	  of	  thalamus)	  stimulation	  suppressed	  tremors.	  	  By	  the	  late	  1970s	  and	  early	  
1980s,	  however,	  DBS	  was	  used	  for	  its	  therapeutic	  rather	  than	  its	  diagnostic	  effects	  
(Limousin	  et	  al.,	  2008).	  	  In	  1997,	  the	  FDA	  approved	  thalamic	  deep	  brain	  stimulation	  for	  
treating	  essential	  tremors	  and	  PD	  related	  tremors.	  	  Subthalamic	  and	  globus	  pallidal	  DBS	  
were	  subsequently	  approved	  for	  PD,	  primary	  generalized	  and	  segmental	  dystonia	  in	  
2003.	  	  Finally,	  DBS	  was	  approved	  for	  treating	  obsessive	  compulsive	  disorder	  in	  2009.	  	  
DBS	  is	  also	  used	  to	  treat	  Tourette	  syndrome,	  depression,	  epilepsy,	  headaches,	  pain,	  
vegetative	  states,	  addiction,	  obesity,	  dementia,	  and	  acceleration	  of	  stroke	  recovery	  
although	  the	  FDA	  has	  not	  approved	  its	  use	  in	  these	  cases.	  	  More	  research	  are	  done	  to	  
understand	  the	  mechanisms	  of	  DBS	  in	  hopes	  of	  using	  it	  for	  treating	  more	  psychiatric	  






Neural	  Pathophysiology	  of	  Parkinson’s	  disease:	  
	  
Neural	  ablations	  and	  deep	  brain	  stimulation	  both	  target	  the	  same	  neural	  regions	  and	  an	  
understanding	  of	  the	  basal	  ganglia	  pathways	  is	  crucial	  for	  the	  efficacy	  of	  both	  
techniques.	  	  The	  primary	  function	  of	  the	  basal	  ganglia	  is	  to	  provide	  feedback	  to	  the	  
cerebral	  cortex	  to	  initiate	  and	  control	  motor	  responses.	  	  If	  this	  feedback	  loop	  is	  
disrupted,	  the	  basal	  ganglia	  discharge	  patterns	  will	  become	  excessive,	  and	  induce	  
abnormal	  slowing	  of	  movements	  (Spiegel	  2011).	  	  Lesions	  to	  the	  basal	  ganglia	  will	  
decrease	  output	  and	  cause	  dyskinesia,	  which	  are	  abnormal	  involuntary	  movements	  
during	  periods	  of	  rest.	  	  
	  
Figure	  5.	  Basal	  Ganglia	  in	  a	  Coronal	  View	  of	  the	  Brain	  (Pereira	  et	  al.,	  2006).	  This	  figure	  
shows	  the	  locations	  of	  the	  basal	  ganglia	  nuclei	  in	  relation	  to	  each	  other	  and	  the	  rest	  of	  
the	  brain.	  	  While	  it	  cannot	  be	  seen	  here,	  the	  globus	  pallidus	  and	  the	  striatum	  are	  
situated	  more	  near	  anterior	  brain	  and	  the	  subthalamic	  nucleus	  and	  the	  substantia	  





globus	  pallidus;	  GPi,	  internal	  globus	  pallidus;	  Th,	  thalamus;	  STN,	  subthalamic	  nucleus;	  
SNr,	  substantia	  nigra	  pars	  reticulate;	  SNc,	  substantia	  nigra	  pars	  compacta	  	  
	  
	  
The	  basal	  ganglia	  is	  composed	  of	  the	  subthalamic	  nucleus,	  the	  substantia	  nigra,	  the	  
neostriatum,	  which	  consists	  of	  the	  caudate	  and	  putamen	  nuclei,	  and	  the	  globus	  pallidus	  
(Figure	  5),	  which	  can	  be	  divided	  into	  the	  external	  and	  internal	  segments.	  	  In	  general,	  the	  
movement	  control	  feedback	  loop	  starts	  with	  inputs	  going	  from	  the	  cerebral	  cortex	  to	  
the	  basal	  ganglia,	  input	  processing	  within	  the	  basal	  ganglia	  nuclei,	  and	  then	  outputs	  
from	  the	  basal	  ganglia	  to	  the	  thalamus.	  	  Finally,	  to	  complete	  the	  loop,	  the	  thalamus	  
sends	  the	  final	  outputs	  to	  the	  cerebral	  cortex.	  	  	  
	   	  
	  
Figure	  6:	  Significant	  Connections	  within	  the	  BasalGanglia	  (Spiegel,	  2011).	  	  
The	  three	  most	  significant	  connections	  for	  processing	  inputs	  from	  the	  cerebral	  cortex	  
include:	  (1)	  from	  striatum	  to	  globus	  pallidus,	  (2)	  reciprocal	  connections	  between	  
striatum	  and	  substantia	  nigra	  (link	  from	  striatum	  to	  substantia	  nigra	  pars	  reticulate	  
not	  shown	  here)	  and,(3)	  reciprocal	  links	  between	  the	  globus	  pallidus	  (GPe	  and	  GPi)	  
and	  the	  subthalamic	  nucleus	  (STN).	  After	  processing,	  output	  signal	  from	  globus	  





In	  the	  basal	  ganglia,	  the	  caudate	  and	  putamen	  nuclei	  receive	  most	  of	  the	  inputs.	  
Afterwards,	  the	  inputs	  have	  to	  go	  through	  the	  extensive	  internal	  connections	  within	  the	  
basal	  ganglia.	  	  The	  three	  most	  significant	  connections	  (Figure	  6)	  include	  (1)	  the	  one	  way	  
link	  from	  the	  striatum	  to	  the	  globus	  pallidus,	  (2)	  the	  reciprocal	  connections	  between	  the	  
striatum	  and	  the	  substantia	  nigra,	  as	  well	  as	  (3)	  the	  reciprocal	  GABAergic	  pathways	  
between	  the	  globus	  pallidus	  and	  the	  subthalamic	  nucleus.	  	  In	  the	  (1)	  connection,	  the	  
neostriatum	  sends	  signals	  to	  the	  medial	  (internal)	  pallidal	  segment	  and	  the	  lateral	  
(external)	  pallidal	  segment	  via	  the	  neurotransmitter	  GABA.	  	  In	  the	  (2)	  connection,	  the	  
neostriatum	  projects	  signals	  to	  the	  substantia	  nigra	  pars	  reticulata	  [one	  of	  the	  two	  parts	  
of	  the	  substantia	  nigra:	  the	  pars	  compacta,	  and	  the	  pars	  reticulate,	  which	  is	  a	  region	  just	  
ventral	  and	  lateral	  to	  the	  pars	  compacta]	  via	  the	  neurotransmitters	  GABA	  and	  substance	  
P.	  	  For	  the	  reciprocal	  pathway	  of	  (2),	  signals	  go	  from	  the	  substantia	  nigra	  pars	  compacta	  
back	  to	  the	  neostriatum	  via	  the	  neurotransmitter	  dopamine.	  In	  the	  (3)	  pathway,	  the	  
external	  globus	  pallidus	  projects	  GABAergic	  neurons	  to	  the	  subthalamic	  nucleus,	  but	  the	  
reciprocal	  connection	  from	  the	  subthalamic	  nucleus	  to	  the	  globus	  pallidus	  is	  mediated	  






	   	  
Figure	  7.	  Ansa	  Lenticularis	  and	  Lenticular	  Fasciculus	  Pathways	  (Hamani	  et	  al.,	  2004).	  
The	  figure	  shows	  the	  relative	  locations	  of	  the	  basal	  ganglia	  nuclei,	  as	  well	  as	  the	  two	  
output	  pathways	  of	  the	  ansa	  lenticularis	  (AL),	  and	  the	  lenticular	  fasciculus	  (LF).	  	  
Targets	  of	  the	  neural	  ablations	  are	  the	  thalamus	  (Thal),	  subthalamic	  nuclei	  (STN),	  and	  
the	  internal	  globus	  pallidus	  (GPi).	  	  These	  three	  nuclei	  are	  also	  targeted	  by	  DBS	  
treatment.	  	  Novel	  DBS	  targets	  include	  the	  pedunculopontine	  nucleus	  (PPN),	  and	  the	  
caudal	  zona	  incerta	  nucleus	  (ZI)	  due	  to	  efficacy	  in	  controlling	  L-­‐DOPA	  independent	  PD	  
symptoms.	  	  	  	  
Legend:	  Thal:	  thalamus,	  Put:	  putamen,	  IC:	  internal	  capsule,	  GPe:	  external	  globus	  
pallidus,	  GPi:	  internal	  globus	  pallidus,	  ZI:	  zona	  incertus,	  LF:	  lenticularis	  fasciculus,	  AL:	  




Two	  output	  pathways	  from	  the	  basal	  ganglia	  arise	  from	  the	  medial	  pallidal	  segment	  and	  
supply	  the	  ventral	  anterior,	  ventrolateral	  and	  centromedian	  nuclei	  of	  the	  thalamus.	  	  The	  
first	  pathway,	  ansa	  lenticularis,	  goes	  from	  the	  ventral	  part	  of	  the	  medial	  pallidal	  
segment,	  passes	  caudally	  towards	  the	  red	  nucleus	  and	  then	  turns	  rostrally	  to	  enter	  the	  
thalamus.	  	  The	  second	  pathway,	  lenticular	  fasciculus,	  starts	  from	  the	  medial	  pallidal	  
segment,	  exits	  the	  globus	  pallidum	  dorsally,	  runs	  caudally	  in	  direction	  of	  midbrain	  and	  





then	  approaches	  the	  red	  nucleus	  and	  turns	  abruptly	  rostrally	  to	  enter	  the	  thalamus	  
(Spiegel,	  2011).	  	  	  
	  
In	  addition	  to	  the	  two	  pathways	  of	  the	  ansa	  lenticularis	  and	  the	  lenticular	  fasciculus,	  
motor	  functions	  are	  also	  controlled	  by	  outputs	  coming	  from	  the	  substantia	  nigra.	  	  The	  
pars	  reticulata	  gives	  rise	  to	  two	  GABAergic	  pathways,	  one	  of	  which	  goes	  to	  the	  ventral	  
anterior	  and	  ventrolateral	  nuclei	  of	  the	  thalamus,	  and	  the	  other	  projects	  to	  the	  superior	  
colliculus	  (Spiegel,	  2011).	  	  Because	  the	  superior	  colliculus	  is	  involved	  in	  the	  integration	  
of	  saccadic	  eye	  movements	  and	  tracking,	  the	  basal	  ganglia	  can	  influence	  motor	  
functions	  related	  to	  reflex	  and	  voluntary	  control	  of	  eye	  movements.	  	  
	  
	  
Figure	  8a:	  Direct	  Pathway	  
	  
In	  direct	  pathway,	  signals	  from	  the	  cerebral	  cortex	  feed	  into	  the	  neostriatum	  via	  
glutamate.	  The	  neostriatum	  uses	  GABA	  to	  send	  inhibitory	  signals	  to	  the	  medial	  globus	  
pallidus,	  which	  also	  uses	  GABA	  to	  send	  inhibitory	  signals	  to	  the	  thalamus.	  	  This	  
pathway	  finally	  sends	  excitatory	  signals	  to	  the	  motor	  parts	  of	  the	  cerebral	  cortex,	  






Figure	  8b:	  Indirect	  Pathway	  
In	  the	  indirect	  pathway,	  signals	  from	  the	  cerebral	  cortex	  get	  modified	  as	  they	  go	  
through	  first	  the	  neostriatum,	  the	  lateral	  or	  external	  globus	  pallidus,	  the	  subthalamic	  
nucleus,	  the	  medial	  or	  internal	  globus	  pallidus,	  the	  thalamus,	  and	  finally	  back	  to	  the	  




Putting	  everything	  together	  results	  in	  the	  following	  two	  circuitries	  for	  motor	  response	  
control.	  	  In	  the	  direct	  pathway	  (Figure	  8a),	  information	  from	  the	  cerebral	  cortex	  is	  sent	  
to	  the	  neostriatum;	  from	  the	  neostriatum	  to	  the	  medial	  globus	  pallidus;	  then	  from	  the	  
globus	  pallidus	  back	  to	  the	  thalamus;	  and	  finally	  from	  the	  thalamus	  back	  to	  the	  cortex.	  	  
As	  for	  the	  indirect	  pathway	  (Figure	  8b),	  information	  goes	  from	  the	  cortex	  to	  the	  
neostriatum;	  from	  the	  neostriatum	  to	  the	  lateral	  globus	  pallidus;	  then	  from	  the	  lateral	  
globus	  pallidus	  to	  the	  subthalamic	  nucleus;	  from	  the	  subthalamic	  nucleus	  to	  the	  internal	  
globus	  pallidus;	  from	  the	  internal	  globus	  pallidus	  back	  to	  the	  thalamus;	  and	  finally,	  from	  
the	  thalamus	  back	  to	  the	  cortex.	  	  The	  outcomes	  of	  both	  pathways	  are	  very	  different.	  	  
The	  direct	  pathway	  results	  in	  excitation	  of	  the	  motor	  regions	  of	  the	  cortex	  and	  facilitates	  










Figure	  9a:	  Normal	  Basal	  Ganglia	  Feedback	  Loop	  with	  Dopamine	  Input	  
Figure	  9b:	  Basal	  Ganglia	  Feedback	  Loop	  with	  Lack	  of	  Dopamine	  (Spiegel,	  2011)	  
In	  PD,	  neuronal	  deaths	  in	  the	  substantia	  nigra	  pars	  compacta	  leads	  to	  significantly	  
diminished	  dopamine	  levels,	  which	  then	  decrease	  both	  inhibitory	  and	  excitatory	  
inputs	  to	  the	  neostriatum.	  	  This	  leads	  to	  two	  consequences;	  excessive	  inhibition	  of	  
external	  globus	  pallidus	  and	  lack	  of	  inhibition	  of	  the	  internal	  globus	  pallidus.	  	  
Excessive	  inhibition	  of	  the	  GPL	  leads	  to	  excitation	  of	  the	  Sth,	  leading	  to	  excessive	  
excitation	  of	  the	  GPM.	  	  This	  causes	  excessive	  inhibition	  of	  the	  thalamus	  and	  
subsequent	  movements.	  	  This	  manifests	  as	  the	  PD	  motor	  symptoms.	  	  Dopamine	  inputs	  
from	  the	  substantia	  nigra	  can	  either	  excite	  or	  inhibit	  the	  neostriatum	  depending	  on	  
the	  receptor	  (D1	  excites,	  D2	  inhibits).	  	  Neostriatum	  inhibits	  external	  globus	  pallidus,	  





thalamus	  (VA/VL).	  	  Thalamus	  excites	  frontal	  lobe.	  	  Ultimately,	  addition	  of	  dopamine	  
results	  in	  facilitation	  of	  movement.	  
	  
Figure	  9a,	  b:	  GPL=	  External	  Globus	  Pallidus,	  GPM	  =	  Internal	  Globus	  Pallidus,	  Sth	  =	  
subthalamic	  nucleus,	  SN	  =	  substantia	  nigra,	  VA/VL	  =	  ventral	  anterior	  and	  ventrolateral	  
nuclei	  of	  thalamus,	  Neostriatum	  includes	  caudate	  and	  putamen	  nuclei.	  
	  
5A:	  normal	  circuit	  enhanced	  by	  dopamine	  from	  SN	  results	  in	  movement	  (big	  gray	  arrow)	  
5B:	  loss	  of	  dopamine	  -­‐>	  reduced	  enhancement	  -­‐>	  slowing	  of	  movement	  (thin	  gray	  
arrow)	  
	  
The	  aforementioned	  direct	  and	  indirect	  basal	  ganglia	  pathways	  can	  be	  modulated	  by	  
other	  systems,	  the	  most	  significant	  one	  being	  that	  of	  the	  dopamine	  connection	  between	  
the	  substantia	  nigra	  and	  the	  neostriatum.	  	  Dopamine	  excites	  the	  direct	  pathway	  via	  its	  
excitatory	  effects	  on	  dopamine	  D1	  receptors	  in	  regions	  of	  the	  neostriatum	  that	  project	  
to	  the	  medial	  pallidal	  segment.	  	  Dopamine	  inhibits	  the	  indirect	  pathway	  via	  dopamine	  
D2	  receptors	  in	  the	  neostriatum	  (Figure	  9a,	  Spiegel,	  2011).	  	  Loss	  of	  dopamine	  in	  cases	  
like	  PD	  will	  inhibit	  movement	  (Figure	  9b,	  Spiegel,	  2011).	  Surgical	  treatments	  target	  the	  
nuclei	  involved	  in	  this	  pathway	  in	  hopes	  of	  slowing	  down	  the	  progression	  of	  the	  effects	  
















Figures	  10a	  (den	  Dunnen,	  2013)	   Figure	  10b	  (den	  Dunnen,	  2013)	  
	  
Figure	  10a:	  Basal	  Ganglia	  Feedback	  Loop	  under	  Normal	  Conditions	  (den	  Dunnen,	  2013)	  
Dopamine	  inputs	  from	  the	  substantia	  nigra	  can	  either	  excite	  or	  inhibit	  the	  neostriatum	  
depending	  on	  the	  receptor	  (D1	  excites,	  D2	  inhibits).	  	  Neostriatum	  inhibits	  external	  
globus	  pallidus,	  which	  inhibits	  Sth.	  	  Sth	  then	  excites	  internal	  globus	  pallidus,	  which	  
then	  inhibits	  thalamus	  (VA/VL).	  	  Thalamus	  excites	  frontal	  lobe.	  	  Ultimately,	  addition	  of	  
dopamine	  results	  in	  facilitation	  of	  movement.	  Legend:	  GPe,	  external	  globus	  pallidus;	  
GPi,	  internal	  globus	  pallidus;	  STN,	  subthalamic	  nucleus;	  SN,	  substantia	  nigra;	  Thal,	  
thalamus	  
	  
Figure	  10b:	  Basal	  Ganglia	  Feedback	  Loop	  under	  PD	  Conditions	  (den	  Dunnen,	  2013)	  
In	  PD,	  neuronal	  deaths	  in	  the	  substantia	  nigra	  pars	  compacta	  leads	  to	  significantly	  
diminished	  dopamine	  levels,	  which	  then	  decrease	  both	  inhibitory	  and	  excitatory	  
inputs	  to	  the	  neostriatum.	  	  This	  leads	  to	  two	  consequences;	  excessive	  inhibition	  of	  
external	  globus	  pallidus	  and	  lack	  of	  inhibition	  of	  the	  internal	  globus	  pallidus.	  	  
Excessive	  inhibition	  of	  the	  GPL	  leads	  to	  excitation	  of	  the	  Sth,	  leading	  to	  excessive	  
excitation	  of	  the	  GPM.	  	  This	  causes	  excessive	  inhibition	  of	  the	  thalamus	  and	  
subsequent	  movements.	  	  This	  manifests	  as	  the	  PD	  motor	  symptoms.	  
	  
Two	  downstream	  effects	  of	  substantia	  nigra	  degeneration	  and	  dopamine	  deficiency	  in	  
PD	  are	  excessive	  subthalamic	  nucleus	  excitation	  of	  internal	  globus	  pallidus	  and	  excessive	  
globus	  pallidal	  inhibition	  of	  the	  thalamus	  (Figures	  10a	  and	  10b,	  dan	  Dunnen	  et	  al.,	  





mediate	  the	  PD	  symptoms	  of	  akinesia	  and	  rigidity.	  	  Thus,	  the	  mentioned	  nuclei	  are	  
targeted	  in	  surgical	  treatments.	  
Mechanism	  of	  Deep	  Brain	  Stimulation:	  
	  
While	  the	  effects	  of	  DBS	  on	  patients	  with	  late	  stage	  or	  refractory	  PD	  are	  well	  known,	  its	  
exact	  mechanism	  remains	  shrouded	  in	  mystery.	  	  Much	  work	  had	  been	  done	  to	  shed	  
light	  on	  it	  in	  hopes	  of	  improving	  the	  tuning	  process	  for	  each	  patient,	  using	  it	  for	  treating	  
L-­‐DOPA	  independent	  PD	  symptoms	  and	  other	  psychiatric	  disorders.	  	  According	  to	  
current	  research,	  the	  effectiveness	  of	  DBS	  depends	  heavily	  on	  the	  target	  nuclei,	  the	  
frequency,	  and	  whatever	  is	  near	  the	  target	  nuclei.	  	  The	  most	  effective	  target	  nuclei	  for	  
L-­‐DOPA	  resistant	  PD	  include	  the	  subthalamic	  nucleus	  and	  the	  globus	  pallidus.	  	  The	  
ventral	  intermediate	  nucleus	  is	  only	  good	  for	  tremors.	  	  The	  pedunculopontine	  and	  the	  
caudal	  zona	  incerta	  nuclei	  are	  under	  research	  for	  treating	  L-­‐DOPA	  independent	  PD	  
symptoms.	  
	  









Figure	  11:Tremor	  Generation	  (Poston	  et	  al.,	  2011).	  
In	  PD,	  lack	  of	  dopamine	  leads	  to	  a	  hyperactive	  putamen	  and	  internal	  globus	  pallidus.	  	  
At	  the	  same	  time,	  there	  is	  an	  increased	  connection	  between	  the	  internal	  globus	  
pallidus	  and	  the	  cerebello-­‐thalamic	  circuit,	  leading	  to	  the	  generation	  of	  tremors	  
(Poston	  et	  al.,	  2011).Legend:	  GPe:	  external	  globus	  pallidus,GPi:	  internal	  globus	  
pallidus,	  SNc:	  substantia	  nigra	  par	  compacta,	  	  	  DA:	  dopamine;	  MC:	  motor	  cortex;	  VIM:	  
ventral	  intermediate	  thalamic	  nucleus;	  VOp:	  thalamic	  ventralis	  oralis	  posterior	  
nucleus;	  CBLM:	  cerebellum	  
	  
It	  is	  known	  that	  DBS	  of	  the	  ventral	  intermediate	  nucleus	  of	  the	  thalamus	  relieves	  
essential	  and	  Parkinsonian	  tremor,	  but	  not	  akinesia	  and	  rigidity.	  	  This	  is	  because	  two	  
different	  neural	  circuits	  produce	  the	  three	  mentioned	  symptoms.	  	  Tremor	  generation	  in	  
PD	  is	  associated	  with	  discrete	  functional	  changes	  in	  the	  cerebello-­‐thalamo-­‐cortical	  
pathways	  (Figure	  11),	  while	  akinesia	  and	  rigidity	  is	  caused	  by	  dysfunction	  in	  the	  cortico-­‐
striato-­‐pallido-­‐thalamo-­‐cortical	  pathways.	  	  This	  is	  supported	  by	  data	  from	  cerebral	  
blood	  flow	  and	  glucose	  metabolism	  functional	  imaging	  studies	  on	  ventral	  intermediate	  





According	  to	  the	  cerebello-­‐thalamo-­‐cortical	  pathway	  theory,	  the	  lack	  of	  dopamine	  in	  PD	  
increases	  output	  from	  the	  putamen,	  which	  then	  enhances	  output	  from	  the	  internal	  
globus	  pallidus.	  	  At	  the	  same	  time,	  there	  is	  also	  increased	  connectivity	  between	  the	  
internal	  globus	  pallidus	  and	  the	  VIM-­‐MC-­‐CBLM	  circuit	  (blue),	  and	  the	  basal	  ganglia	  are	  
activated	  at	  critical	  time	  points	  in	  the	  tremor	  cycle	  (Poston	  et	  al.,	  2011).	  
	  
It	  was	  hypothesized	  that	  thalamic	  DBS	  would	  serve	  to	  inhibit	  or	  block	  the	  output	  of	  VIM	  
in	  a	  way	  similar	  to	  that	  of	  thalamotomy.	  	  However,	  research	  findings	  contradicted	  this	  
theory.	  	  While	  DBS	  does	  inhibit	  target	  nuclei,	  it	  does	  so	  only	  at	  high	  frequencies	  
(frequency	  >	  125	  Hz).	  	  Patients	  who	  received	  DBS	  at	  a	  frequency	  of	  125	  Hz	  or	  higher	  
showed	  significant	  improvement	  in	  bradykinesia,	  as	  well	  as	  the	  entire	  motor	  subset	  of	  
the	  Unified	  Parkinson’s	  Disease	  Rating	  Scale	  (UPDRS).	  	  Patients	  who	  received	  DBS	  at	  a	  
frequency	  of	  10	  Hz	  showed	  worsened	  bradykinesia	  and	  UPDRS	  motor	  scores.	  	  Strangely	  
enough,	  DBS	  at	  frequencies	  of	  5	  Hz,	  20	  Hz,	  and	  45	  Hz	  did	  not	  worsen	  or	  improve	  
bradykinesia	  or	  UPDRS	  motor	  scores	  (Birdno	  et	  al.,	  2008).	  The	  current	  consensus	  is	  that	  
deep	  brain	  stimulation	  works	  by	  overriding	  the	  pathological	  bursts,	  low	  frequency	  
oscillations,	  and	  irregular	  low	  frequency	  firing	  patterns	  found	  in	  movement	  disorders	  
and	  replacing	  them	  with	  a	  more	  regularized	  firing	  pattern.	  	  	  





Deep	  Brain	  Stimulation	  of	  the	  Subthalamic	  Nucleus:	  
	  
	  
Figure	  12:	  Parasagittal	  slice	  thru	  Brain	  at	  L7	  Level	  (Devergnas	  et	  al.,	  2011).	  
The	  figure	  shows	  some	  of	  the	  major	  pathways	  that	  can	  be	  affected	  by	  subthalamic	  
DBS	  due	  to	  their	  proximity	  and	  that	  electrical	  impulses	  spread	  indiscriminately	  from	  
the	  target	  to	  the	  surroundings,	  leading	  to	  side	  effects,	  which	  will	  be	  discussed	  in	  a	  
later	  section.	  	  Excitatory	  glutamatergic	  pathways	  are	  shown	  as	  red	  lines,	  inhibitory	  
GABA-­‐ergic	  ones	  in	  black	  lines,	  and	  modulatory	  dopaminergic	  fibers	  as	  green	  lines.	  	  
The	  blue	  circles	  represent	  the	  spread	  of	  the	  electrical	  stimulation	  of	  the	  STN.	  Legend:	  
CM:centromedian	  nucleus;	  DLG:	  lateral	  geniculate	  body;	  FF:	  Fields	  of	  Forel;	  IC:	  internal	  
capsule;	  GPe:	  external	  globus	  pallidus;	  GPi:	  internal	  globus	  pallidus;	  OT:	  optic	  tract;	  
Put:	  putamen;	  SN:	  substantia	  nigra;	  STN:	  subthalamic	  nucleus;	  VA:	  ventral	  anterior	  
nucleus;	  VL:	  ventrolateral	  nucleus:	  ZI:	  zona	  incerta	  	  
	  
The	  subthalamic	  nucleus	  receives	  GABAergic	  inhibitory	  afferents	  from	  the	  globus	  
pallidus	  externus	  as	  well	  as	  neuromodulatory	  inputs	  from	  the	  substantia	  nigra	  (Figure	  
22).	  	  Then,	  it	  sends	  excitatory	  outputs	  to	  the	  striatum,	  the	  substantia	  nigra,	  and	  both	  
parts	  of	  the	  globus	  pallidus.	  	  In	  fact,	  there	  are	  strong	  reciprocal	  connections	  between	  





nuclei	  are	  the	  fastest	  spiking	  pacemakers	  in	  the	  basal	  ganglia,	  they	  are	  designated	  as	  the	  
“central	  pacemaker	  of	  the	  basal	  ganglia”	  with	  synchronous	  bursts.	  	  This	  system	  is	  
hypothesized	  to	  play	  a	  key	  role	  in	  the	  generation	  of	  patterns	  of	  activity	  found	  in	  PD	  
(Poston	  et	  al.,	  2010).	  	  
	  
In	  studies	  of	  rat	  brain	  slices,	  three	  key	  observations	  of	  the	  intracellular	  electrical	  
recordings	  of	  subthalamic	  neurons	  were	  found.	  	  First,	  the	  majority	  of	  the	  cells	  
spontaneously	  fire	  in	  the	  absence	  of	  current	  injections	  or	  synaptic	  stimulations.	  	  
Secondly,	  the	  same	  cells	  can	  transiently	  fire	  at	  very	  high	  frequencies	  (80-­‐90	  Hz).	  	  Finally,	  
when	  the	  cells	  are	  transiently	  depolarized	  after	  being	  hyperpolarized	  below	  -­‐65mV	  
(Poston	  et	  al.,	  2010),	  they	  engage	  voltage-­‐gated	  calcium	  and	  sodium	  currents	  to	  fire	  
bursts	  of	  action	  potentials.	  
	  
In	  PD,	  the	  neurons	  of	  the	  subthalamic	  nucleus	  are	  impaired	  by	  pathologically	  
synchronized	  oscillatory	  activity	  at	  a	  frequency	  between	  11	  and	  30	  Hz	  that	  disrupts	  
normal	  signaling.	  	  This	  signaling	  is	  almost	  nonexistent	  in	  healthy	  individuals.	  	  Low	  
frequencies	  (20	  Hz)	  will	  exacerbate	  PD	  symptoms.	  	  	  High	  frequency	  DBS	  suppresses	  the	  
synchronized	  activity	  both	  locally	  in	  and	  around	  the	  subthalamic	  nucleus,	  and	  over	  other	  
functionally	  connected	  elements	  of	  the	  cortex-­‐basal	  ganglia	  network	  (Eusebio	  et	  al.,	  





Surprisingly,	  L-­‐DOPA	  medication	  also	  has	  the	  same	  effect	  as	  subthalamic	  nucleus	  DBS	  on	  
these	  pathologic	  oscillations.	  	  
	  
Mechanism	  of	  DBS	  of	  the	  Globus	  Pallidus:	  
	  
Historically,	  GPi	  has	  been	  the	  preferred	  target,	  especially	  since	  the	  resurgence	  of	  
pallidotomy	  in	  the	  early	  1990s	  and	  the	  subsequent	  success	  of	  pallidal	  DBS	  for	  PD.	  	  The	  
globus	  pallidus	  is	  a	  neural	  structure	  that	  is	  involved	  in	  the	  regulation	  of	  voluntary	  
movement	  on	  the	  subconscious	  level.	  	  The	  globus	  pallidus	  has	  a	  primarily	  inhibitory	  
action	  that	  is	  intended	  to	  balance	  the	  excitatory	  one	  from	  the	  cerebellum;	  imbalances	  
result	  in	  tremors,	  jerks,	  and	  other	  movement	  problems	  (Chiken	  et	  al.,	  2013).	  	  	  
	  
Synchronized	  disruptive	  oscillations	  between	  3	  and	  20	  Hz	  are	  found	  in	  neurons	  of	  the	  
globus	  pallidus,	  and	  DBS	  suppresses	  them.	  	  In	  a	  study	  done	  on	  monkeys,	  high	  frequency	  
stimulation	  was	  found	  to	  inhibit	  the	  spontaneous	  firings	  (or	  oscillations)	  of	  the	  internal	  
globus	  pallidus	  neurons	  by	  activation	  of	  GABA-­‐A	  and	  GABA-­‐B	  receptors.	  	  Single-­‐pulse	  
stimulation	  is	  mediated	  by	  the	  GABA-­‐A	  receptors	  while	  repetitive	  stimulation	  is	  
mediated	  by	  both	  the	  GABA-­‐A	  and	  GABA-­‐B	  receptors.	  	  It	  is	  postulated	  that	  stimulation	  
activates	  GABAergic	  axon	  terminals	  and	  subsequent	  GABA	  release.	  	  The	  released	  GABA	  
binds	  to	  postsynaptic	  GABA-­‐A	  receptors.	  	  Repetitive	  stimulation	  releases	  enough	  GABA	  
to	  activate	  the	  postsynaptic	  GABA-­‐B	  receptors;	  accumulated	  GABA	  spills	  out	  of	  synapses	  





External	  globus	  pallidal	  neurons	  exhibited	  a	  different	  response.	  	  Single	  pulse	  stimulation	  
resulted	  in	  biphasic	  responses	  that	  may	  be	  due	  to	  excitation	  of	  both	  GABAergic	  and	  
glutamatergic	  axon	  terminals.	  	  Chiken	  et	  al.	  hypothesized	  that	  inhibition	  of	  the	  external	  
globus	  pallidus	  was	  due	  to	  excitation	  through	  the	  GPe-­‐STN	  reciprocal	  connections;	  local	  
GPe	  stimulation	  inhibits	  GPe	  activity	  and	  causes	  disinhibition	  of	  excitatory	  STN-­‐GPe	  
pathways.	  (Chiken	  et	  al.,	  2013)	  
	  
Deep	  Brain	  Stimulation	  of	  the	  Pedunculopontine	  Nucleus:	  
	  
While	  DBS	  is	  a	  standard	  therapy	  in	  the	  treatment	  of	  PD,	  it	  does	  not	  inhibit	  the	  
progression	  of	  the	  condition,	  apart	  from	  the	  cardinal	  motor	  signs,	  dysautonomia,	  and	  
psychiatric	  symptoms.	  	  Some	  patients	  also	  do	  not	  respond	  to	  the	  neuro-­‐modulatory	  
treatment	  for	  motor	  disturbances,	  especially	  those	  with	  severe	  axial	  symptoms	  such	  as	  
postural	  instability	  and	  gait	  difficulty	  (PIGD).	  	  Hence,	  research	  had	  been	  done	  to	  find	  
new	  anatomical	  and	  physiological	  targets	  to	  increase	  the	  efficacy	  of	  DBS.	  	  One	  of	  the	  
promising	  targets	  is	  the	  pedunculopontine	  nucleus	  (PPN),	  and	  the	  simultaneous	  
stimulation	  of	  the	  PPN	  and	  STN	  proved	  effective	  in	  treating	  PIGD.	  This	  is	  because	  PPN	  
projections	  to	  the	  brainstem	  and	  the	  spinal	  cordplay	  an	  important	  role	  in	  the	  genesis	  of	  
axial	  symptoms	  in	  Parkinson’s	  disease	  (Tykocki	  et	  al.,	  2011).	  
	  
The	  PPN	  is	  part	  of	  the	  mesencephalic	  locomotor	  region	  (MLR),	  which	  is	  functionally	  





MLR	  enable	  coordination	  of	  limbs	  and	  postural	  movements.	  	  Furthermore,	  the	  PPN	  
cholinergic	  neurons	  are	  part	  of	  the	  motivation	  and	  reward	  circuit	  and	  are	  combined	  
with	  the	  limbic	  and	  brainstem	  motivational	  system.	  	  The	  PPN	  receives	  inputs	  from	  limbic	  
system	  and	  the	  striatum,	  acting	  as	  a	  selective	  and	  coordinative	  center	  for	  the	  affective	  
impulses,	  preparing	  a	  programmed	  motor	  reaction,	  appropriate	  to	  the	  emotional	  status.	  	  
The	  PPN	  is	  afferently	  connected	  with	  the	  dorsolateral	  ventral	  globus	  pallidum	  (dVP)	  and	  
sends	  two	  projections:	  1)	  to	  the	  spinal	  cord	  through	  the	  brainstem	  motor	  nuclei;	  2)	  to	  
the	  ventral	  tegmentum	  area,	  which	  mediate	  dopaminergically	  to	  the	  nucleus	  
accumbens	  and	  dVP,	  which	  close	  the	  loop	  (Tykocki	  et	  al.,	  2011).	  
	  
The	  PPN	  is	  part	  of	  the	  reticular	  activating	  system	  (RAS)	  that	  modulates	  ascending	  
projections	  through	  the	  thalamus	  and	  descending	  projections	  through	  the	  pons	  and	  
medulla.	  	  	  	  The	  PPN	  is	  most	  active	  during	  waking	  and	  paradoxical	  sleep,	  and	  is	  composed	  
of	  different	  populations	  of	  cholinergic,	  glutamatergic	  and	  GABAergic	  neurons.	  	  PPN	  
neurons	  increase	  firing	  during	  REM	  sleep	  or	  both	  waking	  and	  REM	  sleep,	  but	  decrease	  
during	  slow-­‐wave	  sleep,	  suggestive	  of	  increased	  excitation	  during	  activated	  states	  
(Garcia-­‐Rill	  et	  al.,	  2011).	  
	  
The	  PPN	  is	  also	  part	  of	  primary	  acoustic	  startle	  reactions.	  	  A	  single	  acoustic	  stimulus	  
activates	  the	  ventral	  cochlear	  nucleus	  and	  PPN,	  which	  send	  cholinergic	  inhibitory	  signals	  





sensorimotor	  gating	  information	  from	  the	  forebrain	  (Tykocki	  et	  al.,	  2011).	  
	  
Neuropathology	  of	  PPN:	  
The	  symptoms	  of	  postural	  instability	  and	  gait	  difficulty	  reflect	  an	  insufficiency	  of	  output	  
from	  the	  PPN	  in	  PD	  patients.	  	  Since	  it	  is	  not	  clear	  if	  the	  cause	  is	  the	  same	  as	  that	  of	  
dopaminergic	  insufficiency	  from	  the	  substantia	  nigra,	  research	  had	  been	  done	  to	  
differentiate	  if	  the	  insufficiency	  is	  caused	  by	  neurodegeneration	  or	  functional	  inhibition.	  	  
Analyses	  of	  post	  mortem	  brain	  sections	  of	  three	  groups	  –	  PD	  patients	  without	  balance	  
deficit	  or	  falls,	  PD	  patients	  with	  balance	  deficits	  and	  falls,	  and	  healthy	  control	  –	  showed	  
that	  the	  number	  of	  cholinergic	  and	  dopaminergic	  neurons	  was	  significantly	  lower	  in	  
patients	  with	  balance	  deficits	  and	  falls	  than	  patients	  in	  the	  other	  two	  groups.	  	  However,	  
the	  lack	  of	  difference	  in	  the	  number	  of	  cuneiform	  nuclei	  [The	  cuneiform	  nucleusis	  
another	  MLR	  nuclei	  that	  is	  responsible	  for	  locomotion,	  and	  is	  located	  dorsal	  to	  the	  
pedunculopontine	  nucleus	  (Allen	  et	  al.,	  1996)]	  in	  both	  groups	  of	  PD	  patients	  suggests	  
that	  PPN	  inhibition	  rather	  than	  the	  extent	  of	  degeneration	  causes	  PIGD	  symptoms	  
(Tykocki	  et	  al.,	  2011).	  
	  
In	  PD	  patients	  with	  PIGD	  symptoms,	  it	  was	  found	  the	  pedunculopontine	  nucleus	  either	  
had	  too	  many	  connections	  with	  the	  inappropriate	  neural	  regions	  or	  no	  connections	  at	  
all.	  	  Post	  PPN	  DBS	  diffusion	  MRI	  results	  showed	  normalization	  of	  cortical	  and	  brainstem	  





pontine	  connectivity	  was	  reduced	  and	  reorganized,	  so	  that	  the	  dominant	  connectivity	  
was	  with	  the	  pre-­‐frontal	  cortical	  areas,	  instead	  of	  the	  primary	  motor	  cortex.	  	  
Discrepancy	  of	  PPN	  connection	  in	  different	  subtypes	  of	  PD	  patients	  was	  found.	  	  Imaging	  
with	  diffusion	  MRI	  detected	  absence	  of	  PPN	  connectivity	  to	  any	  part	  of	  the	  cerebellum	  
in	  PIGD	  patients,	  whereas	  non-­‐PIGD	  PD	  group	  displayed	  significant	  connectivity	  with	  the	  
cerebellum	  (Tykocki	  et	  al.,	  2011).	  	  
DBS	  of	  Caudal	  Zona	  Incerta	  Nucleus	  (cZI):	  
	  
In	  addition	  to	  the	  pedunculopontine	  nucleus,	  the	  caudal	  zona	  incerta	  nucleus	  is	  another	  
target	  under	  exploration	  for	  deep	  brain	  stimulation.	  	  
	  





This	  figure	  shows	  the	  connections	  the	  caudal	  zona	  incerta	  has	  with	  other	  basal	  ganglia	  
nuclei.	  	  ZI	  receives	  key	  afferent	  connections	  from	  the	  globus	  pallidus,	  cerebral	  cortex,	  
cingulated	  cortex,	  and	  the	  reticular	  activating	  system;	  at	  the	  same	  time,	  ZI	  sends	  
outputs	  to	  the	  thalamus,	  the	  globus	  pallidus,	  the	  substantia	  nigra,	  and	  the	  cerebral	  
cortex.	  	  These	  connections	  allow	  for	  its	  physiological	  functions	  of	  visceral	  control,	  
arousal,	  attention,	  and	  generation	  of	  axial	  and	  proximal	  limb	  locomotion	  (Plaha	  et	  al.,	  
2006).	  Legend:	  White	  arrows:	  afferent	  fibers;	  Red,	  green	  arrows:	  efferent	  fibers;	  PUT:	  
putamen,	  GPe:	  globus	  pallidus	  externus,	  GPi:	  globus	  pallidus	  internus,	  SNr:	  substantia	  
nigra	  reticulate,	  STN:	  subthalamic	  nucleus,	  RAS:	  reticular	  activating	  system,	  MEA:	  
midbrain	  extrapyramidal	  area,	  ZI:	  zona	  incerta,	  CM/Pf:	  centromedian	  and	  
parafascicular	  nucleus	  of	  thalamus,	  VA/VL:	  ventral	  anterior,	  lateral	  nucleus	  of	  
thalamus,	  MC:	  Motor	  cortex,	  PMC:	  premotor	  cortex	  
	  
	  
The	  zona	  incerta	  lies	  at	  the	  base	  of	  the	  dorsal	  thalamus,	  and	  is	  composed	  of	  four	  parts:	  
rostral,	  dorsal,	  ventral,	  and	  caudal.	  	  The	  rostral	  part	  extends	  over	  the	  dorsal	  and	  medial	  
surface	  of	  the	  STN	  whilst	  its	  caudal	  or	  motor	  part	  lays	  posteromedial	  to	  the	  subthalamic	  
nucleus.	  	  The	  ZI	  nucleus	  receives	  afferents	  from	  the	  basal	  ganglia	  output	  nuclei	  (globus	  
pallidus	  internus	  and	  substantia	  nigra	  reticulate),	  the	  ascending	  reticular	  activating	  
system,	  and	  also	  motor,	  associative	  and	  limbic	  areas	  of	  the	  cortex,	  which	  are	  known	  to	  
facilitate	  and	  modulate	  motor	  behavior	  (Figure	  13).	  	  The	  ZI	  sends	  efferents	  to	  the	  
centromedian	  and	  parafascicular	  nuclei	  (CM/Pf)	  of	  the	  thalamus,	  the	  ventral	  anterior	  
(VA)	  and	  ventral	  lateral	  (VL)	  nuclei	  of	  the	  thalamus,	  the	  mid-­‐brain	  extrapyramidal	  area,	  
basal	  ganglia	  output	  nuclei	  and	  the	  cortex.	  	  	  
	  
The	  ZI	  is	  thought	  to	  have	  several	  physiological	  functions.	  	  Its	  rostral	  sector	  has	  been	  
associated	  with	  visceral	  control,	  its	  dorsal	  sector	  with	  arousal,	  its	  ventral	  sector	  with	  





of	  axial	  and	  proximal	  limb	  movements	  including	  locomotion	  (Plaha	  et	  al.,	  2006).	  	  	  
	  
Abnormal	  burst	  firing	  as	  well	  as	  synchronized	  oscillations	  in	  the	  3-­‐7,	  13-­‐20,	  20-­‐35	  Hz,	  60-­‐
100	  Hz,	  and	  300	  Hz	  bands	  have	  been	  the	  recorded	  in	  the	  GPi	  and	  STN	  of	  PD	  patients.	  	  It	  
is	  likely	  that	  these	  abnormal	  patterns	  of	  neuronal	  firing	  are	  transmitted	  to	  the	  ZI	  via	  
afferents	  from	  the	  basal	  ganglia	  output	  nuclei	  and	  the	  motor	  cortex;	  abnormal	  
oscillations	  with	  burst	  firing	  at	  4,	  20	  Hz,	  and	  other	  frequencies	  have	  been	  recorded	  in	  
the	  ZI	  (Plaha	  et	  al.,	  2006).	  	  The	  ZI	  nucleus	  will	  then	  transmit	  these	  oscillations	  via	  its	  
efferent	  connections	  to	  the	  thalamus,	  the	  brainstem	  locomotor	  center	  and	  back	  to	  the	  
basal	  ganglia	  output	  nuclei	  (GPI,	  SNr)	  and	  the	  cortex.	  	  These	  oscillations	  subsequently	  
disrupt	  normal	  information	  processing	  in	  the	  striatum	  and	  the	  basal	  ganglia	  output	  
nuclei.	  	  The	  ZI’s	  direct	  connections	  with	  the	  ventral	  intermediate	  nucleus	  of	  the	  
thalamus	  may	  be	  the	  cause	  of	  tremor	  generation.	  	  The	  abnormal	  firing	  patterns	  
transmitted	  from	  the	  cZI	  to	  the	  midbrain	  extrapyramidal	  area	  in	  PD	  may	  also	  contribute	  
to	  the	  symptoms	  of	  impaired	  locomotion,	  axial	  and	  gross	  limb	  movements.	  It	  is	  
speculated	  that	  high	  frequency	  stimulation	  of	  cZI	  would	  override	  these	  abnormal	  
oscillations,	  and	  be	  much	  more	  effective	  at	  controlling	  PD	  symptoms	  than	  stimulation	  of	  
the	  subthalamic	  nucleus	  (Plaha	  et	  al.,	  2006).	  	  
	  





The	  Surgical	  Procedure	  of	  Neural	  Ablations	  and	  Deep	  Brain	  Stimulation	  
	  
There	  is	  no	  one	  best	  method	  for	  performing	  stereotactic	  surgery.	  Hence,	  surgeons	  need	  
to	  modify	  general	  approaches	  to	  target	  localization	  to	  suit	  their	  own	  preferences	  and	  to	  
take	  advantage	  of	  whatever	  equipment	  they	  have	  at	  their	  disposal.	  	  Currently	  accepted	  
techniques	  involve	  frame-­‐based	  anatomical	  localization	  supported	  by	  intraoperative	  
physiological	  confirmation	  of	  proper	  targeting	  (CNS	  Clinic	  Jordan,	  2003).	  
	  
Neural	  Structural	  Anatomical	  Targeting	  Techniques:	  
In	  the	  pre-­‐L-­‐DOPA	  era,	  positive	  contrast	  and	  air	  ventriculography	  were	  used	  to	  localize	  
the	  foramen	  of	  Monro	  and	  the	  anterior	  and	  posterior	  commissures.	  	  The	  stereotactic	  
coordinates	  of	  therapeutic	  targets	  were	  determined	  from	  their	  relationship	  to	  these	  
structures	  as	  described	  in	  stereotactic	  atlases.	  	  Targeting	  accuracy	  was	  limited	  by	  the	  
inaccuracies	  of	  the	  atlases.	  	  While	  ventriculography	  has	  been	  currently	  supplanted	  by	  
the	  noninvasive	  techniques	  of	  CT	  and	  MRI,	  it	  is	  still	  employed	  by	  many	  stereotactic	  
surgeons	  (CNS	  Clinic	  Jordan,	  2003).	  Due	  to	  the	  deep	  location	  of	  the	  nuclei,	  direct	  
surgical	  approaches	  are	  not	  feasible.	  	  “Instead,	  a	  combination	  of	  image-­‐guided	  
stereotactic	  techniques	  and	  intraoperative	  neurophysiology	  is	  required	  to	  place	  the	  
therapeutic	  lesions	  or	  stimulating	  electrodes	  with	  acceptable	  accuracy	  and	  safety.	  	  
Unlike	  tumors,	  which	  are	  relatively	  large	  and	  easily	  identified	  on	  CT	  (computed	  
tomography)	  or	  MRI	  (magnetic	  resonance	  imaging),	  functional	  neurosurgical	  targets	  are	  





these	  are	  physiologic	  as	  much	  as	  anatomic	  targets,	  image-­‐based	  targeting	  may	  
incompletely	  identify	  the	  desired	  location	  (CNS	  Clinic	  Jordan,	  2010).	  	  Thus,	  image-­‐based	  
targeting	  alone	  is	  insufficient.	  	  	  	  	  	  	  
	  
Compared	  with	  CT	  based	  techniques,	  MRI	  based	  ones	  provide	  better	  resolution,	  as	  well	  
as	  multiplanar	  images	  with	  minimal	  frame-­‐related	  disturbances.	  Non-­‐reformatted	  MRI	  
wonderfully	  delineates	  the	  commissures,	  the	  thalamus,	  and	  most	  of	  the	  basal	  ganglia	  
structures.	  	  These	  features	  allow	  for	  the	  direct	  stereotactic	  localization	  of	  the	  surgical	  
target.	  	  The	  major	  weakness	  of	  MRI	  based	  techniques	  is	  the	  potential	  for	  image	  
distortion	  created	  by	  nonlinearities	  within	  the	  magnetic	  field	  (CNS	  Clinic	  Jordan,	  2003).	  	  
Misrepresentations	  can	  be	  induced	  by	  various	  factors,	  including	  the	  presence	  of	  
ferromagnetic	  objects	  in	  the	  field,	  imperfections	  in	  the	  scanner’s	  magnets,	  and	  most	  
commonly,	  patient	  movements.	  	  Thus,	  targeting	  errors	  are	  usually	  greater	  in	  the	  
periphery	  than	  in	  the	  center	  of	  the	  magnetic	  field	  and	  stereotactic	  space	  (CNS	  Clinic	  
Jordan,	  2003).	  In	  contrast,	  CT	  based	  techniques	  maintain	  linear	  accuracy,	  thus	  reducing	  
image-­‐induced	  targeting	  errors.	  However,	  metallic	  artifacts	  can	  impede	  visualization	  of	  
the	  commissures;	  CT	  tissue	  resolution	  is	  worse	  than	  that	  of	  the	  MRI	  ones.	  	  Unlike	  MRI	  
techniques,	  CT	  techniques	  provide	  only	  axial	  images.	  	  While	  it	  is	  possible	  to	  fuse	  CT	  and	  






Physiological	  confirmation,	  also	  known	  as	  physiological	  localization,	  is	  another	  method	  
for	  targeting	  the	  neural	  nuclei.	  	  Physiological	  targeting	  utilizes	  microelectrode	  
recordings	  of	  electrical	  signal	  patterns	  given	  off	  by	  the	  nuclei	  to	  find	  the	  targets	  (Guridi	  
et	  al.,	  1999).	  	  This	  works	  better	  than	  anatomical	  targeting	  because	  the	  nuclei	  of	  the	  
basal	  ganglia	  structure	  are	  not	  evenly	  distributed	  throughout	  the	  structure.	  	  For	  
instance,	  the	  nuclei	  responsible	  for	  motor	  symptoms	  are	  located	  in	  the	  posteroventral	  
region	  of	  the	  internal	  globus	  pallidus.	  	  Thus,	  physiological	  confirmation	  is	  coupled	  with	  
anatomical	  targeting	  for	  successful	  surgeries	  (Guridi	  et	  al.,	  1999).	  	  
	  
As	  for	  the	  actual	  process,	  the	  surgeon	  makes	  a	  cut	  (about	  2	  inches	  long)	  according	  to	  the	  
target	  coordinates	  and	  then	  inserts	  a	  hollow	  probe	  through	  a	  small	  hole	  drilled	  into	  the	  
skull	  to	  the	  specific	  location.	  Different	  methods	  can	  be	  used	  to	  kill	  the	  brain	  cells,	  
including	  circulating	  	  liquid	  nitrogen	  inside	  the	  probe	  destroying	  the	  targeted	  brain	  
tissue	  or	  by	  inserting	  an	  electrode	  heated	  up	  to	  near	  200°	  Fahrenheit	  to	  burn	  the	  cells	  
(Fields	  et	  al.,	  2000).	  	  Although	  the	  surgery	  usually	  requires	  only	  about	  a	  2-­‐day	  hospital	  














DEEP	  BRAIN	  STIMULATION	  APPARATUS	  
	  
	  
Figure	  14A:	  Radiograph	  of	  DBS	   Figure	  14B:	  Body	  View	  of	  DBS	  Apparatus	  
Figures	  from	  (Kringelbach	  et	  al.,	  2008).	  	  Both	  of	  these	  figures	  show	  the	  positioning	  of	  
the	  DBS	  apparatus	  within	  the	  patient.	  	  Pacemaker	  (red)	  is	  placed	  at	  near	  the	  clavicle;	  
the	  electrodes	  are	  inserted	  deep	  inside	  the	  brain	  via	  sterotactic	  surgery;	  and	  finally,	  
wires	  connecting	  the	  two	  parts	  go	  under	  the	  skin	  that	  covers	  the	  neck	  and	  the	  skull.	  	  
The	  right	  figure	  also	  shows	  the	  holes	  where	  the	  surgery	  was	  performed.	  
	  
DBS	  is	  an	  established	  treatment	  for	  patients	  in	  late	  stage	  PD,	  especially	  when	  they	  
become	  refractory	  to	  all	  available	  medications.	  	  It	  uses	  electrical	  impulses	  to	  stimulate	  a	  
targeted	  area	  of	  the	  brain	  to	  alleviate	  symptoms.	  	  DBS	  is	  an	  alternative	  to	  the	  
mentioned	  surgical	  treatments	  for	  managing	  parkinsonian	  tremors,	  and	  unlike	  those	  
from	  neural	  ablation,	  the	  effects	  of	  deep	  brain	  stimulation	  are	  reversible.	  	  Different	  
brain	  nuclei	  are	  targeted	  for	  different	  pathological	  conditions.	  	  	  In	  the	  case	  of	  PD,	  the	  
thalamus,	  the	  globus	  pallidus	  and	  the	  subthalamic	  nuclei	  are	  the	  targets	  because	  of	  






DBS	  had	  been	  used	  since	  the	  1960s	  as	  a	  means	  of	  preparing	  the	  brain	  targets	  for	  
ablative	  surgery,	  and	  to	  identify	  the	  optimal	  site	  for	  thalamic	  nuclei	  destruction.	  	  By	  the	  
late	  1970s	  and	  early	  1980s,	  however,	  deep	  brain	  stimulation	  was	  used	  for	  its	  
therapeutic	  rather	  than	  its	  diagnostic	  effects.	  	  After	  the	  resurrection	  of	  surgery	  as	  a	  
viable	  solution	  in	  1992,	  the	  Food	  and	  Drug	  Administration	  approved	  deep	  brain	  
stimulation	  as	  a	  treatment	  for	  essential	  tremor,	  PD,	  dystonia,	  and	  obsessive	  compulsive	  
disorder	  in	  1997,	  2002,	  2003	  and	  2009	  respectively.	  	  DBS	  is	  also	  used	  to	  treat	  chronic	  
pain,	  major	  depression,	  Tourette	  syndrome,	  headaches,	  epilepsy,	  vegetative	  states,	  
addiction,	  obesity,	  dementia,	  and	  improving	  stroke	  recovery	  although	  the	  FDA	  has	  not	  
approved	  its	  use	  in	  these	  cases.	  
	  
DBS	  involves	  the	  implantation	  of	  a	  medical	  device	  called	  a	  “brain	  pacemaker”,	  which	  
sends	  electrical	  impulses	  to	  specific	  parts	  of	  the	  brain	  and	  ultimately	  creates	  an	  electric	  
field	  that	  suppresses	  the	  brain’s	  erratic	  electrical	  signals	  associated	  with	  PD	  symptoms.	  	  
As	  shown	  above	  (Figures	  20A,	  20B),	  the	  DBS	  system	  consists	  of	  the	  pacemaker,	  also	  
known	  as	  the	  implanted	  pulse	  generator	  (IPG),	  the	  lead,	  and	  the	  extension.	  	  All	  three	  
components	  are	  surgically	  implanted	  inside	  the	  body	  under	  anesthesia.	  	  The	  leads	  are	  
implanted	  in	  a	  way	  that	  is	  similar	  to	  that	  used	  for	  microelectrodes	  used	  in	  the	  
mentioned	  neural	  ablations.	  	  The	  right	  side	  of	  the	  brain	  is	  stimulated	  to	  address	  
symptoms	  on	  the	  left	  side	  of	  the	  body	  and	  vice	  versa	  due	  to	  the	  crossover	  of	  





The	  pacemaker	  is	  a	  battery-­‐powered	  neurostimulator	  encased	  in	  a	  titanium	  shell,	  which	  
sends	  the	  electrical	  pulses	  to	  the	  brain.	  	  The	  lead	  is	  a	  coiled	  wire	  insulated	  in	  
polyurethane	  with	  four	  platinum	  iridium	  electrodes	  and	  is	  placed	  in	  one	  of	  the	  three	  
areas	  of	  the	  brain.	  	  The	  lead	  is	  connected	  to	  the	  IPG	  by	  the	  extension,	  an	  insulated	  wire	  
that	  runs	  from	  the	  head,	  down	  the	  side	  of	  the	  neck,	  behind	  the	  ear	  to	  the	  IPG.	  	  The	  
pacemaker	  is	  usually	  placed	  subcutaneously	  below	  the	  clavicle	  or	  in	  certain	  cases,	  the	  
abdomen.	  	  The	  IPG	  needs	  to	  be	  calibrated	  to	  optimize	  symptom	  suppression	  and	  reduce	  
adverse	  events.	  The	  battery	  usually	  lasts	  between	  three	  to	  five	  years,	  and	  is	  replaced	  in	  
an	  outpatient	  process	  (Limousin	  et	  al.,	  2008).	  
	  
The	  leads	  are	  placed	  in	  the	  brain	  according	  to	  the	  type	  of	  symptoms	  the	  patient	  
presents.	  	  For	  non-­‐PD	  essential	  tremor,	  the	  ventrointermediate	  nucleus	  of	  the	  thalamus	  
is	  targeted.	  	  For	  dystonia	  and	  other	  PD	  symptoms,	  which	  include	  rigidity,	  bradykinesia,	  
akinesia,	  and	  tremor,	  the	  lead	  can	  be	  placed	  in	  either	  the	  globus	  pallidus	  or	  subthalamic	  
nucleus.	  	  The	  stimulator	  can	  be	  placed	  unilaterally	  or	  bilaterally,	  but	  for	  most	  patients	  
with	  PD,	  surgery	  has	  to	  be	  done	  on	  both	  sides	  of	  the	  brain	  unless	  the	  patient	  has	  only	  
unilateral	  symptoms	  (Limousin	  et	  al.,	  2008).	  	  
	  
The	  implantation	  procedure	  is	  usually	  done	  over	  the	  span	  of	  a	  month,	  and	  may	  vary	  for	  
each	  patient.	  	  The	  process	  is	  usually	  split	  into	  three	  stages,	  with	  the	  first	  two	  stages	  for	  





surgery	  begins,	  the	  patient	  is	  screened	  for	  any	  factors	  or	  conditions	  that	  would	  
adversely	  affect	  either	  the	  procedure	  itself	  or	  the	  aftermath	  because	  deep	  brain	  
stimulation	  may	  not	  be	  suitable	  for	  all	  patients.	  	  Factors	  that	  contraindicate	  DBS	  include	  
PD	  that	  is	  not	  responsive	  to	  L-­‐DOPA	  or	  dopamine	  agonists,	  difficulties	  with	  speech,	  
walking,	  or	  balance	  that	  are	  not	  relieved	  by	  medications,	  confusion,	  memory	  problems,	  
any	  psychiatric	  disorders,	  depression,	  anxiety,	  and	  age	  over	  70	  years	  old.	  	  After	  passing	  
the	  initial	  screening,	  the	  patient	  will	  undergo	  the	  first	  stage,	  which	  involves	  the	  
stereotactic	  implantation	  of	  the	  leads	  at	  the	  target	  nuclei.	  	  The	  patient	  will	  be	  
hospitalized	  for	  about	  one	  to	  two	  days	  and	  watched	  for	  complications	  such	  as	  seizures.	  	  	  
The	  second	  stage,	  which	  involves	  implanting	  the	  rest	  of	  the	  deep	  brain	  stimulation	  
system,	  usually	  occurs	  10	  to	  14	  days	  after	  the	  first	  stage.	  	  Since	  this	  part	  takes	  only	  a	  few	  
hours	  to	  complete,	  the	  patient	  can	  go	  home	  on	  the	  same	  day.	  	  Programming	  of	  the	  
pacemaker	  takes	  place	  about	  two	  to	  four	  weeks	  after	  the	  implantation	  and	  the	  patient	  
will	  have	  to	  make	  multiple	  appointments	  in	  order	  to	  get	  the	  best	  stimulator	  settings.	  	  
The	  patient	  will	  be	  given	  a	  magnet	  for	  turning	  the	  stimulator	  on	  and	  off.	  	  Even	  so,	  it	  will	  
take	  some	  time	  before	  the	  patient	  will	  actually	  receive	  adequate	  symptom	  relief	  
(Lozano	  et	  al.,	  2004).	  
	  
The	  Benefits	  and	  Adverse	  Events	  of	  Neural	  Ablations	  and	  Deep	  Brain	  Stimulation:	  
	  
Thalamotomy:	  





the	  target	  location	  is	  always	  on	  the	  side	  opposite	  that	  with	  the	  worst	  tremors.	  	  	  	  While	  
both	  types	  of	  procedures	  immediately	  relieve	  tremors,	  they	  do	  not	  help	  with	  
bradykinesia,	  which	  becomes	  the	  most	  important	  symptom	  over	  time	  in	  PD	  patients.	  	  
Unilateral	  thalamotomy	  may	  be	  associated	  with	  some	  loss	  of	  fine	  dexterity.	  	  Bilateral	  
thalamotomy	  are	  poorly	  tolerated	  due	  to	  increased	  complications	  and	  risks,	  including	  
vision	  and	  speech	  problems;	  unilateral	  ones	  are	  preferred	  instead	  (CNS	  Clinic	  Jordan,	  
2003).	  	  	  
	  
Pallidotomy:	  
Posteroventral	  pallidotomy	  improves	  tremor,	  rigidity,	  and	  L-­‐DOPA	  induced	  dyskinesia	  in	  
patients	  with	  medically	  refractory,	  moderately	  advanced	  PD.	  	  Unilateral	  pallidotomy	  is	  
effective	  and	  relatively	  safe	  compared	  with	  medical	  therapy	  in	  patients	  with	  severe	  
dyskinesia	  and	  "on"	  and	  "off"	  fluctuations	  (Lai	  et	  al.,	  2000;	  Hallett	  et	  al.,	  1999).	  	  A	  
randomized	  trial	  found	  that	  those	  treated	  with	  unilateral	  pallidotomy	  (n	  =	  18)	  had	  
improvements	  in	  tremor,	  rigidity,	  bradykinesia,	  gait,	  and	  balance	  compared	  with	  those	  
treated	  medically	  (n	  =	  18),	  and	  subsequent	  follow-­‐up	  found	  that	  the	  benefits	  of	  
unilateral	  pallidotomy	  were	  sustained	  after	  two	  years	  (Vitek	  et	  al.,	  2003).	  	  The	  greatest	  
improvement	  occurred	  on	  the	  side	  contralateral	  to	  the	  lesion,	  but	  significant	  ipsilateral	  
improvement	  was	  also	  observed	  for	  bradykinesia,	  rigidity,	  and	  drug-­‐induced	  dyskinesia.	  	  
A	  systematic	  review	  of	  unilateral	  pallidotomy	  found	  that	  the	  risk	  of	  permanent	  adverse	  





hemorrhage	  occurred	  in	  4	  percent,	  and	  the	  associated	  mortality	  was	  1	  percent	  (de	  Bie	  
et	  al.,	  2002).	  Bilateral	  pallidotomy	  carries	  a	  high	  risk	  of	  permanent	  pseudobulbar	  speech	  
and	  swallowing	  impairment	  in	  patients	  already	  compromised	  in	  these	  functions	  (Hallett	  
et	  al.,	  1999).	  	  	  
	  
Subthalamotomy:	  
Results	  from	  several	  uncontrolled	  and	  unblinded	  studies	  suggest	  that	  unilateral	  
subthalamotomy	  is	  effective	  for	  the	  treatment	  of	  advanced	  PD	  (Tarsy	  et	  al.,	  2009).	  
Unilateral	  subthalamotomy	  appears	  to	  be	  as	  effective	  as	  bilateral	  subthalamotomy	  and	  
has	  been	  associated	  with	  fewer	  adverse	  effects.	  	  While	  unilateral	  subthalamotomy	  
produces	  shorter	  lasting	  ipsilateral	  improvements	  (Alvarez	  et	  al.,	  2009),	  it	  was	  
associated	  with	  significant	  motor	  benefit	  contralateral	  to	  the	  lesion	  (Alvarez	  et	  al.,	  
2009).	  	  The	  biggest	  downside	  to	  this	  procedure	  is	  the	  adverse	  neurologic	  effects,	  the	  
most	  common	  of	  which	  include	  a	  risk	  of	  stroke,	  confusion,	  speech	  and	  or	  visual	  
problems	  (Limousin	  et	  al.,	  2008).	  	  	  	  
	  
In	  a	  case	  series	  of	  89	  patients	  who	  underwent	  unilateral	  subthalamotomy,	  68	  patients	  
were	  available	  for	  evaluations	  after	  12	  months,	  36	  after	  24	  months	  and	  25	  patients	  after	  
36	  months.	  	  The	  UPDRS	  motor	  scores	  improved	  significantly	  and	  L-­‐DOPA	  daily	  doses	  
were	  significantly	  reduced	  by	  45%,	  36%	  and	  28%	  at	  12,	  24	  and	  36	  months	  post-­‐surgery.	  	  





four	  to	  12	  weeks	  in	  38	  cases	  (Alvarez	  et	  al.,	  2009).	  However,	  dyskinesia	  remained	  
unchanged	  for	  14	  patients	  (16	  percent)	  and	  was	  severe	  in	  eight	  of	  these,	  causing	  a	  
combination	  of	  hemiballism	  and	  hemichorea	  that	  failed	  to	  improve	  even	  after	  stopping	  
dopaminergic	  medications	  or	  treatment	  with	  dopamine	  antagonists.	  All	  eight	  patients	  
required	  pallidotomy	  within	  four	  weeks	  to	  two	  years	  after	  subthalamotomy	  to	  eliminate	  
dyskinesia	  (Alvarez	  et	  al.,	  2009).	  	  
	  
In	  an	  earlier	  study,	  eighteen	  advanced	  PD	  patients	  received	  staged	  or	  simultaneous	  
bilateral	  subthalamotomies.	  One	  patient	  subsequently	  developed	  multiple	  system	  
atrophy	  (MSA)	  signs	  and	  was	  excluded	  from	  further	  analysis.	  Motor	  improvements	  
compared	  to	  baseline	  were	  58%	  in	  the	  off	  state	  and	  63%	  in	  the	  ‘on’	  state.	  Daily	  L-­‐DOPA	  
dose	  was	  reduced	  by	  a	  mean	  of	  72%,	  with	  5	  patients	  receiving	  none.	  Three	  patients	  
developed	  severe	  chorea	  post-­‐operatively,	  which	  improved	  spontaneously	  at	  3–6	  
months	  (Alvarez	  et	  al.,	  2002).	  	  	  
	  
Adverse	  Effects	  of	  Deep	  Brain	  Stimulation	  in	  General:	  
	  
Non-­‐specific	  adverse	  effects	  common	  to	  all	  types	  of	  DBS	  include	  surgical	  and	  hardware	  
complications,	  which	  are	  rare.	  	  According	  to	  a	  2010	  study	  that	  examined	  the	  medical	  
records	  for	  141	  patients	  who	  had	  undergone	  a	  total	  of	  522	  DBS	  procedures	  over	  the	  
course	  from	  1998	  to	  2007,	  surgical	  complications	  –	  death,	  neurologic	  damage,	  infection,	  





leak,	  peripheral	  nerve	  injury,	  and	  venous	  infarction	  –	  were	  observed	  in	  5.6%	  of	  the	  
patients.	  	  Hardware	  complications,	  which	  include	  misplaced,	  broken,	  or	  malfunctioning	  
electrodes,	  damaged	  wire	  extensions	  or	  pulse	  generators,	  allergies	  to	  the	  hardware,	  
were	  observed	  in	  7%	  of	  the	  patients.	  Overall	  mortality	  was	  about	  0.7%.	  	  Thus,	  DBS	  can	  
be	  considered	  as	  a	  safe	  procedure	  with	  low	  rates	  of	  mortality,	  surgical,	  and	  hardware	  
complications	  (Vergani	  et	  al.,	  2010).	  
	  
Deep	  Brain	  Stimulation	  of	  the	  Subthalamic	  Nucleus:	  
For	  DBS	  of	  the	  subthalamic	  nucleus,	  general	  complications	  include	  hemorrhage	  (1-­‐2%)	  
and	  infections	  at	  the	  site	  of	  surgery	  (3-­‐5%);	  thus,	  the	  procedure	  is	  very	  safe	  overall	  
(Lozano	  2004).	  	  Despite	  of	  this,	  the	  procedure	  is	  difficult	  to	  tolerate	  for	  most	  patients.	  	  
In	  addition,	  patients	  experience	  acute	  side	  effects	  of	  stimulation	  when	  the	  electrode	  is	  
close	  to	  a	  surrounding	  structure.	  	  STN	  electrodes	  may	  stimulate	  the	  pyramidal	  tract	  to	  
cause	  a	  tonic	  contraction,	  the	  corticobulbar	  tract	  to	  produce	  dysarthria,	  or	  the	  medial	  
lemniscus	  to	  invoke	  parasthesias.	  	  There	  is	  also	  a	  slight	  decline	  in	  cognitive	  abilities	  post-­‐
surgery,	  including	  frontal-­‐executive	  dysfunction,	  and	  speech	  problems.	  	  Another	  serious	  
side	  effect	  seen	  only	  in	  DBS	  of	  the	  STN	  is	  that	  the	  leads	  might	  have	  the	  tendency	  to	  
spread	  currents	  into	  the	  associative	  and	  limbic	  regions	  of	  the	  STN	  nucleus,	  as	  well	  as	  
into	  the	  medial	  forebrain	  bundle,	  zona	  incerta,	  lateral	  hypothalamus,	  and	  other	  region	  






As	  for	  the	  benefits,	  subthalamic	  DBS	  helps	  to	  alleviate	  the	  PD	  motor	  symptoms	  of	  
rigidity,	  akinesia,	  tremors,	  and	  bradykinesia,	  as	  well	  as	  L-­‐DOPA-­‐induced	  dyskinesias.	  	  
Apart	  from	  dyskinesia,	  DBS	  of	  the	  STN	  results	  in	  effects	  that	  are	  similar	  in	  quality	  and	  
magnitude	  to	  the	  effects	  of	  L-­‐DOPA.	  	  STN	  DBS	  reduces	  motor	  scores	  of	  40-­‐60%;	  it	  also	  
results	  in	  reduction	  in	  ‘on-­‐off’	  fluctuations	  (Figure	  3;	  on-­‐off	  fluctuations	  refer	  to	  the	  
wearing	  off	  of	  L-­‐DOPA	  dose	  effects)	  because	  of	  improvement	  in	  symptoms	  during	  the	  
‘off’	  period.	  	  Improvements	  in	  activities	  of	  daily	  living	  and	  quality	  of	  life	  scores	  generally	  
accompany	  mentioned	  motor	  improvements.	  	  Oddly	  enough,	  these	  therapeutic	  effects	  
occur	  sequentially.	  	  Alterations	  to	  tremor	  occur	  over	  seconds-­‐to-­‐minutes,	  followed	  by	  
alteration	  in	  limb	  akinesia	  and	  rigidity	  over	  several	  minutes,	  and	  axial	  symptoms	  over	  
hours.	  
	  
An	  added	  bonus	  is	  that	  patients	  who	  received	  this	  type	  of	  DBS	  can	  reduce	  their	  dose	  of	  
L-­‐DOPA	  post	  surgery;	  this	  comes	  with	  the	  risk	  of	  increased	  depression,	  apathy	  (Robert	  et	  
al.,	  2011),	  suicidal	  ideation,	  and	  excessive	  gambling	  tendencies	  (Stamey	  et	  al.,	  2008)	  due	  
to	  the	  rapid	  reduction	  of	  L-­‐DOPA	  dosage.	  	  Patients	  also	  are	  angrier	  post	  surgery	  and	  this	  
is	  due	  to	  a	  possible	  lesional	  effect	  (Burdick	  et	  al.,	  2011).	  	  A	  new	  study	  (de	  Andrade	  et	  al.,	  
2012;	  Dellapina	  et	  al.,	  2012)	  showed	  that	  patients	  who	  received	  DBS	  of	  the	  STN	  have	  
increased	  pain	  thresholds,	  and	  thus	  feels	  less	  pain.	  	  Subthalamic	  DBS	  also	  improves	  
patients’	  temperature	  sensation,	  according	  to	  a	  2011	  study	  in	  Japan,	  but	  the	  mechanism	  





	  	  	  	  	  	  	   	  
Figure	  15:	  Ocular	  bradykinesia	  impairs	  visual	  exploration	  in	  Parkinson’s	  disease	  (Terao	  
et	  al.,	  2013).	  
The	  figures	  show	  color-­‐coded	  heat	  maps	  of	  the	  distribution	  of	  fixation	  when	  normal	  
subjects	  and	  PD	  patients	  view	  pictures	  of	  increasing	  complexity	  (from	  left	  to	  right).	  	  
Red	  color	  means	  longest	  duration	  of	  fixation	  while	  green	  means	  least	  duration	  of	  
fixation.	  	  In	  all	  images,	  the	  distribution	  of	  eye-­‐fixation	  position	  in	  PD	  patients	  was	  
narrower	  than	  that	  in	  normal	  subjects.	  
	  
Another	  benefit	  of	  the	  DBS	  of	  the	  STN	  is	  the	  improvement	  of	  impaired	  saccades	  that	  are	  
usually	  found	  in	  patients	  with	  Parkinson’s	  disease.	  	  Saccades	  are	  quick	  back	  and	  forth	  
movements	  of	  the	  eyes	  that	  are	  intended	  to	  help	  people	  form	  a	  spatial	  picture	  of	  their	  
environment,	  and	  develop	  a	  spatial	  awareness	  needed	  for	  postural	  stability.	  	  Saccades	  
can	  be	  both	  involuntary	  and	  voluntary.	  	  Patients	  with	  PD	  have	  decreased	  saccades	  of	  





instabilities.	  	  In	  early	  stages	  of	  the	  disease,	  patients	  are	  still	  able	  to	  compensate	  for	  this	  
decrease	  in	  spatial	  information	  with	  other	  types	  of	  movement,	  and	  as	  the	  disease	  
progresses,	  patients	  become	  unable	  to	  compensate	  for	  it	  any	  more	  (Terao	  et	  al.,	  2013).	  
	  
Figure	  16:	  Pathophysiology	  underlying	  saccade	  abnormalities	  in	  Parkinson’s	  Disease	  
(Terao	  et	  al.,	  2003).	  In	  normal	  healthy	  individuals,	  mostly	  excitatory	  signals	  reach	  the	  
superior	  colliculus	  and	  allow	  for	  saccadic	  movements	  of	  the	  eyes.	  	  In	  PD,	  decreased	  
dopaminergic	  input	  from	  SNc	  ultimately	  causes	  increased	  but	  unchecked	  inhibitory	  
signal	  (black)	  to	  the	  superior	  colliculus.	  Subsequent	  suppression	  of	  saccadic	  
movements	  of	  the	  eyes	  ensues	  (Terao	  et	  al.,	  2003).	  Legend.	  Cx:	  cerebral	  cortex,	  Cd:	  
caudate	  nucleus,	  GPe:	  external	  globus	  pallidus,	  STN:	  subthalamic	  nucleus,	  SNc:	  
substantia	  nigra	  pars	  compacta,	  SNr:	  substantia	  nigra	  pars	  reticulate,	  SC:	  superior	  
colliculus;	  Excitatory:	  red	  lines,	  Inhibitory:	  all	  other	  colors,	  Basal	  Ganglia	  Circuit:	  
dotted	  line	  loop	  
	  
Dopamine	  deficiency	  leads	  to	  decreased	  activity	  of	  the	  direct	  pathway	  and	  increased	  
activity	  of	  the	  inhibitory	  indirect	  pathway,	  especially	  of	  the	  subthalamic	  nucleus,	  
resulting	  in	  increased	  activity	  of	  GABAergic	  inhibitory	  projection	  neurons	  of	  the	  basal	  
ganglia	  output	  nuclei.	  	  Decreased	  activity	  of	  the	  direct	  pathway	  results	  in	  impaired	  





however,	  exhibit	  overactive	  tonic	  firing	  rates	  and	  excessively	  suppress	  the	  thalamus	  and	  
the	  superior	  colliculus,	  which	  is	  downstream	  from	  it.	  	  This	  prevents	  the	  thalamus	  from	  
producing	  quick	  movements	  of	  an	  appropriate	  scale,	  resulting	  in	  bradykinesia/akinesia.	  	  
The	  superior	  colliculus	  is	  excessively	  inhibited	  by	  the	  overactive	  substantia	  nigra	  and	  
that	  all	  types	  of	  saccades	  are	  suppressed.	  	  This	  leads	  to	  increased	  time	  or	  latency	  for	  
saccades	  to	  occur	  and	  ocular	  bradykinesia.	  	  L-­‐DOPA	  and	  dopamine	  agonists	  do	  not	  
improve	  this	  problem.	  	  DBS	  of	  the	  subthalamic	  nucleus,	  however,	  improves	  saccade	  
impairment,	  more	  so	  for	  voluntary	  saccades	  than	  reflexive	  saccades.	  	  DBS	  also	  improves	  
saccade	  initiation,	  reduces	  latencies,	  and	  increases	  amplitudes	  and	  velocities	  (Terao	  et	  
al.,	  2013).	  
	  
Unfortunately,	  these	  therapeutic	  effects	  of	  subthalamic	  DBS	  last	  only	  five	  years.	  	  	  This	  is	  
due	  to	  the	  progression	  of	  the	  disease	  and	  the	  manifestation	  of	  L-­‐DOPA	  independent	  
symptoms.	  	  In	  various	  long	  term	  studies	  of	  patients	  who	  received	  subthalamic	  deep	  
brain	  stimulation	  at	  2	  years,	  3	  years,	  4	  years,	  5	  years,	  9	  years,	  and	  even	  10	  years,	  it	  was	  
found	  that	  the	  motor	  improvement	  due	  to	  the	  surgery	  lasts	  for	  up	  to	  10	  years.	  	  Non-­‐
motor	  improvements	  such	  as	  mood	  improvements,	  quality	  of	  life,	  and	  activities	  of	  daily	  
living,	  last	  only	  for	  one	  year	  (Rodriguez-­‐Oroz	  et	  al.,	  2005;	  Castrioto	  et	  al.,	  2011;	  Zibetti	  et	  








Deep	  Brain	  Stimulation	  of	  the	  Globus	  Pallidus:	  
	  
Pallidal	  DBS	  is	  most	  beneficial	  for	  treating	  dyskinesias,	  ranging	  between	  50%	  and	  76%	  
improvement	  on	  dyskinesia	  scales	  in	  UPDRS;	  this	  effect	  lasts	  for	  at	  least	  4	  to	  5	  years	  
(Limousin	  2008).	  	  Unlike	  subthalamic	  DBS,	  patients	  who	  had	  received	  pallidal	  DBS	  
patients	  cannot	  reduce	  their	  post-­‐surgery	  dosage	  of	  L-­‐DOPA	  (Lai	  et	  al.,	  2000).	  	  Surgical	  
complications	  are	  similar	  to	  those	  of	  subthalamic	  DBS.	  	  Patients	  may	  experience	  acute	  
side	  effects	  of	  stimulation	  when	  the	  electrode	  is	  close	  to	  a	  surrounding	  structure.	  	  
Motor	  symptoms	  may	  occur	  with	  stimulation	  of	  the	  internal	  capsule,	  while	  photo-­‐opsias	  
and	  scotomata	  indicate	  proximity	  of	  the	  optic	  tract	  (CNS	  Clinic	  Jordan,	  2003).	  	  Adverse	  
events	  due	  to	  voltage	  include	  paresthesias,	  muscle	  contraction,	  and	  visual	  flashes.	  	  
Stimulation	  of	  the	  most	  ventral	  part	  of	  the	  globus	  pallidus	  in	  cases	  where	  the	  electrode	  
were	  misplaced,	  patients	  may	  have	  worsened	  akinesia,	  both	  on	  and	  off	  medication	  
(Limousin	  et	  al.,	  2008).	  	  Other	  side	  effects	  include	  dysarthria,	  weight	  gain,	  eyelid-­‐
opening	  apraxia,	  confusion,	  increased	  anger,	  suicidal	  ideation,	  and	  a	  slight	  decline	  in	  
cognitive	  abilities	  post-­‐surgery,	  including	  frontal-­‐executive	  dysfunction,	  and	  speech	  
problems.	  	  Psychiatric	  problems	  are	  usually	  rare	  (Limousin	  et	  al.,	  2008).	  
	  
Deep	  Brain	  Stimulation:	  Globus	  Pallidus	  vs.	  Subthalamic	  Nucleus	  
	  
Various	  randomized	  controlled	  trials	  comparing	  bilateral	  subthalamic	  DBS	  with	  bilateral	  
globus	  pallidal	  DBS	  show	  that	  at	  12	  months,	  subthalamic	  DBS	  is	  better	  than	  pallidal	  DBS	  





et	  al.,	  2005),	  but	  at	  24	  months,	  there	  were	  no	  significant	  differences	  between	  the	  two	  
treatments.	  	  By	  self-­‐report	  diaries,	  there	  was	  also	  no	  significant	  discrepancy	  between	  
the	  two	  groups	  in	  the	  time	  per	  day	  for	  states	  of	  good	  motor	  function,	  troublesome	  
dyskinesia,	  poor	  motor	  function,	  or	  sleep	  (Anderson	  et	  al.,	  2005).	  	  Similar	  results	  were	  
found	  by	  a	  2013	  study	  done	  in	  Netherlands	  comparing	  the	  efficacy	  of	  globus	  pallidal	  DBS	  
versus	  subthalamic	  DBS	  for	  18	  patients	  with	  advanced	  PD	  (Odekerken	  et	  al.,	  2013).	  
	  
However,	  another	  study	  in	  2009	  showed	  that	  unilateral	  pallidal	  DBS	  was	  better	  than	  
unilateral	  subthalamic	  DBS	  for	  improving	  UPDRS	  motor	  scores,	  quality	  of	  life,	  activities	  
of	  daily	  living,	  emotional	  well-­‐being,	  stigma,	  cognition	  and	  discomfort	  (Zahodne	  et	  al.,	  
2009).	  	  Unlike	  those	  who	  had	  bilateral	  subthalamic	  DBS,	  patients	  who	  received	  
unilateral	  subthalamic	  DBS	  do	  not	  reduce	  their	  post-­‐surgery	  L-­‐DOPA	  doses.	  	  The	  quality	  
of	  life	  improvement	  seen	  in	  unilateral	  pallidal	  DBS	  was	  partly	  due	  to	  the	  lack	  of	  decline	  
in	  speech	  fluency	  (Zahodne	  et	  al.,	  2009).	  	  
	  
Based	  on	  the	  results	  from	  aforementioned	  studies,	  subthalamic	  DBS	  would	  be	  the	  
treatment	  of	  choice	  if	  a	  bilateral	  procedure	  was	  needed,	  but	  DBS	  of	  the	  globus	  pallidus	  
should	  be	  preferred	  if	  a	  unilateral	  procedure	  was	  required	  instead.	  	  In	  the	  case	  of	  








Effects	  of	  Deep	  Brain	  Stimulation	  of	  PPN:	  
	  
Deep	  brain	  stimulation	  of	  the	  pedunculopontine	  nucleus	  is	  most	  effective	  when	  done	  
bilaterally	  at	  a	  frequency	  between	  20	  and	  80	  Hz	  (Garcia-­‐Rill	  et	  al.,	  2011),	  and	  in	  
conjunction	  with	  DBS	  of	  the	  subthalamic	  nucleus.	  	  Prior	  animal	  studies	  and	  pioneer	  
clinical	  trials	  of	  low	  frequency	  PPN	  DBS	  done	  by	  Jenkinson	  et	  al.	  showed	  significant	  
amelioration	  of	  gait	  and	  postural	  deficits	  in	  PD.	  	  Stimulation	  at	  a	  frequency	  of	  5	  Hz	  
showed	  increased	  motor	  activity	  in	  MPTP	  monkeys	  comparable	  to	  that	  observed	  after	  
levodopa	  treatment.	  	  	  A	  conflicting	  study	  done	  by	  Rauch	  et	  al.,	  2010,	  however,	  reported	  
a	  non-­‐uniform	  response	  to	  both	  high	  and	  low	  frequencies	  according	  to	  different	  motor	  
functions:	  locomotor	  activity,	  postural	  instability	  and	  limb	  use.	  	  	  
	  
It	  had	  been	  observed	  that	  PPN	  DBS	  affects	  the	  subthalamic	  nucleus	  firing	  rate.	  	  At	  a	  
frequency	  of	  25	  Hz	  (Tykocki	  et	  al.,	  2011),	  PPN	  DBS	  causes	  two	  conflicting	  STN	  neuronal	  
responses:	  decreased	  firing	  in	  bursting	  neurons	  and	  an	  excitatory	  effect	  in	  large	  tonic	  
neurons.	  	  Silence	  in	  burst	  neurons	  is	  in	  accord	  with	  a	  PPN	  therapeutic	  effect,	  but	  
increased	  tonic	  mode	  is	  not	  desired.	  	  Stimulation	  at	  a	  frequency	  of	  180	  Hz	  results	  in	  
motor	  deterioration.	  	  PPN	  DBS	  modulates	  descending	  basal	  ganglia-­‐brainstem	  
pathways.	  	  The	  PD	  patients	  present	  an	  increased	  Hoffman	  reflex	  (HR)	  [a	  finger	  flexor	  
reflex	  that	  if	  abnormal,	  reflects	  on	  abnormalities	  in	  locomotion	  control	  pathways	  of	  the	  
upper	  body]	  threshold;	  this	  abnormality	  was	  significantly	  reduced	  by	  DBS.	  	  It	  was	  found	  





threshold.	  	  The	  PPN	  DBS	  may	  act	  on	  spinal	  cord	  excitability	  by	  improving	  the	  
reticulospinal	  pathway	  transmission.	  	  So,	  the	  effectiveness	  of	  the	  stimulation	  might	  be	  
due	  not	  only	  to	  the	  modulation	  of	  the	  basal	  ganglia	  circuits,	  but	  also	  excitation	  of	  the	  
pontomedullary	  reticular	  formation	  and	  reticulospinal	  nuclei	  improving	  descending	  
spinal	  pathways.	  	  PET	  imaging	  of	  PD	  patients	  with	  unilateral	  PPN	  DBS	  revealed	  increased	  
regional	  blood	  flow	  in	  the	  thalamus,	  cerebellum,	  midbrain	  region	  and	  cortical	  areas	  
involving	  the	  medial	  sensorimotor	  cortex	  extending	  into	  the	  caudal	  supplementary	  
motor	  area.	  	  The	  PPN-­‐DBS	  significantly	  improved	  executive	  functions	  and	  working	  
memory	  and	  reduced	  sleep	  fragmentation	  and	  comfort.	  	  This	  effect	  is	  probably	  due	  to	  
activation	  of	  cholinergic	  muscarine	  receptor	  transmission	  from	  the	  PPN	  to	  the	  thalamus.	  
	  
According	  to	  studies	  done	  by	  (Mazzone	  et	  al.,	  2005)	  and	  (Plaha	  et	  al.,2005)	  in	  2005,	  
bilateral	  PPN	  DBS	  alone,	  without	  previous	  STN	  DBS	  or	  simultaneous	  implantation	  or	  
stimulation	  of	  STN,	  revealed	  improvement	  in	  the	  total	  UPDRS	  –	  53%	  and	  UPDRS	  motor	  
subscore	  –	  57%	  and	  L-­‐DOPA	  reduction	  of	  32.5%.	  The	  best	  clinical	  response	  was	  
observed	  at	  frequencies	  between	  20	  Hz	  and	  25	  Hz.	  	  Electrophysiological	  recordings	  
directly	  from	  the	  PPN	  during	  synchronous	  stimulation	  of	  STN	  produced	  only	  slight	  
changes	  in	  PPN	  firing	  activity	  while	  the	  same	  stimulation	  provoked	  increased	  SNr	  
activity.	  	  As	  for	  patients	  with	  PIGD	  dominancy,	  PPN	  DBS	  was	  more	  effective	  than	  STN	  
DBS	  alone	  but	  less	  than	  STN	  plus	  PN	  DBS	  in	  the	  OFF	  medication	  state.	  	  The	  combination	  





(PPN	  DBS	  72.4%,	  STN	  DBS	  75.8%,	  PPN	  and	  STN	  DBS	  83.5%)	  in	  comparison	  with	  any	  OFF	  
medication	  stimulation	  or	  with	  L-­‐DOPA	  alone	  (50.2%)	  (Tykocki	  et	  al.,	  2011).	  There	  were	  
also	  improvements	  of	  freezing	  and	  post-­‐surgery.	  	  It	  can	  be	  concluded	  that	  DBS	  of	  the	  
PPN	  and	  the	  STN	  nuclei	  together	  should	  be	  considered	  for	  treating	  PIGD	  symptoms,	  and	  
that	  DBS	  of	  the	  PPN	  alone	  may	  be	  a	  waste	  of	  time	  and	  money	  for	  the	  patient.	  
	  
Effects	  of	  Caudal	  Zona	  Incerta	  Deep	  Brain	  Stimulation:	  
	  
DBS	  of	  the	  caudal	  zona	  incerta	  nuclei	  provides	  PD	  patients	  with	  better	  relief	  of	  motor	  
symptoms	  than	  DBS	  of	  the	  subthalamic	  nucleus	  due	  to	  its	  direct	  connection	  with	  
thalamic	  nuclei	  (Figure	  13;	  Plaha	  et	  al.,	  2006).	  	  In	  a	  two-­‐year	  comparison	  study	  done	  
between	  2002	  and	  2004,	  DBS	  of	  the	  caudal	  zona	  incerta	  nucleus	  was	  explored	  (Plaha	  et	  
al.,	  2006).	  	  In	  this	  study,	  35	  patients	  were	  randomly	  assigned	  to	  either	  DBS	  of	  the	  
subthalamic	  nucleus,	  of	  the	  dorsomedial/medial	  to	  the	  STN,	  or	  of	  the	  caudal	  zona	  
incerta	  nucleus.	  	  The	  patients	  were	  evaluated	  with	  the	  contralateral	  UPDRS	  scale,	  
especially	  the	  parts	  for	  motor,	  tremor,	  bradykinesia,	  and	  rigidity.	  	  DBS	  of	  the	  caudal	  
zona	  incerta	  was	  superior	  to	  the	  other	  targets	  for	  reduction	  in	  UPDRS	  motor	  subscore:	  
76%	  reduction	  with	  cZI	  DBS,	  61%	  reduction	  with	  DBS	  of	  area	  dorsomedial	  or	  medial	  to	  
the	  STN,	  and	  55%	  reduction	  with	  STN	  DBS.	  	  Bradykinesia	  was	  markedly	  improved	  in	  the	  
cZI	  group	  than	  the	  others	  (cZI:	  65%	  reduction,	  area	  medial	  to	  STN:	  56%,	  and	  STN:	  59%).	  	  





medication	  reduction	  and	  stimulation	  parameters	  between	  the	  three	  groups	  (Plaha	  et	  
al.,	  2006).	  
	  
When	  Should	  Deep	  Brain	  Stimulation	  Be	  Used?	  
	  
Historically,	  surgical	  treatment	  is	  usually	  not	  considered	  until	  the	  patient	  develops	  
symptoms	  refractory	  to	  L-­‐DOPA	  and	  other	  anti-­‐PD	  treatments	  or	  unbearable	  side	  effects	  
due	  to	  medication	  use.	  	  Deep	  brain	  stimulation	  is	  used	  to	  help	  control	  those	  symptoms,	  
but	  is	  not	  a	  cure	  for	  PD.	  Hence,	  patients	  have	  to	  continue	  medications	  after	  surgical	  
treatment	  (Rodriguez-­‐Oroz	  et	  al.,	  2005).	  	  Studies	  have	  been	  done	  to	  compare	  the	  
efficacy	  of	  DBS	  alone	  and	  of	  DBS	  with	  medications	  with	  the	  best	  medical	  therapy.	  
	  
In	  a	  2009	  large	  multicenter	  controlled	  trial	  (Weaver	  et	  al.,	  2009)	  where	  a	  blinded	  
assessment	  was	  done	  with	  255	  adults	  with	  advanced	  PD	  and	  motor	  complications,	  
bilateral	  DBS	  of	  either	  subthalamic	  nucleus	  or	  globus	  pallidus	  was	  compared	  with	  best	  
medical	  therapy.	  	  At	  6	  months,	  the	  primary	  outcome	  measure	  of	  “on-­‐time”	  without	  
troubling	  dyskinesia	  improved	  by	  almost	  5	  hours	  for	  patients	  in	  the	  DBS	  groups	  and	  
improved	  by	  zero	  hours	  for	  those	  in	  the	  best	  medical	  therapy	  group.	  	  However,	  patients	  
in	  the	  DBS	  group	  had	  more	  serious	  adverse	  events	  than	  those	  in	  the	  best	  medical	  
therapy	  group	  (40%	  vs.	  15%),	  but	  most	  of	  these	  side	  effects	  can	  be	  attributed	  to	  risks	  of	  
surgery:	  postoperative	  headache	  and	  pain,	  and	  infections	  at	  the	  surgical	  site.	  	  There	  





implantation	  and	  another	  from	  lung	  cancer	  that	  was	  present	  even	  before	  the	  trial	  
began.	  	  At	  four	  to	  six	  months,	  patients	  in	  the	  DBS	  group	  had	  much	  less	  side	  effects	  but	  
more	  falls	  and	  dystonia,	  which	  may	  be	  cause	  by	  increased	  mobility	  and	  activity	  after	  
DBS.	  	  Patients	  in	  the	  DBS	  group	  had	  mildly	  diminished	  performance	  on	  several	  measures	  
of	  cognitive	  function,	  which	  includes	  working	  memory,	  processing	  speed,	  verbal	  fluency,	  
and	  delayed	  recall.	  	  In	  sum,	  for	  patients	  with	  advanced	  PD,	  DBS	  is	  more	  effective	  for	  
improving	  motor	  function	  and	  quality	  of	  life	  than	  best	  medical	  therapy	  in	  the	  short	  
term,	  but	  has	  an	  increased	  risk	  of	  surgery	  related	  complications	  (Weaver	  et	  al.,	  2009).	  	  
	  
In	  another	  randomized	  open	  label	  trial	  –	  the	  PD	  SURG	  trial	  –	  that	  took	  place	  at	  13	  
neurosurgical	  centers	  in	  the	  UK	  from	  2000	  to	  2006,	  it	  was	  found	  that	  patients	  who	  
received	  both	  DBS	  and	  best	  medical	  treatment	  did	  better	  than	  those	  who	  received	  best	  
medical	  therapy	  alone	  at	  1	  year	  post	  surgery.	  	  The	  mean	  improvement	  in	  PDQ-­‐39	  
(Parkinson’s	  disease	  Questionnaire	  39)	  score	  was	  5	  points	  and	  0.3	  points	  for	  patients	  
who	  had	  DBS	  plus	  best	  medical	  therapy	  and	  best	  medical	  therapy	  alone,	  respectively.	  	  
This	  score	  includes	  improvements	  in	  activities	  of	  daily	  living	  domain	  and	  in	  bodily	  
discomfort	  (Williams	  et	  al.,	  2010).	  	  
	  
Economics:	  
In	  order	  for	  any	  treatments	  to	  be	  successful,	  the	  quality	  of	  life,	  the	  cost	  and	  the	  cost	  





cannot	  afford	  them	  or	  end	  up	  unable	  to	  function	  properly	  due	  to	  a	  poor	  quality	  of	  life.	  	  
Deep	  brain	  stimulation	  is	  an	  expensive	  procedure,	  averaging	  about	  $50,000	  US	  dollars	  
per	  operation;	  the	  high	  cost	  is	  due	  to	  the	  use	  of	  microelectrode	  recording,	  which	  
enables	  accurate	  targeting	  of	  basal	  ganglia	  nuclei.	  	  The	  price	  varies	  a	  little	  based	  on	  the	  
type	  of	  DBS	  performed	  on	  the	  patient.	  	  For	  subthalamic	  DBS	  with	  microelectrode	  
recording	  done	  unilaterally,	  the	  current	  price	  is	  $26,764.79.	  	  Current	  costs	  for	  
simultaneous	  bilateral	  DBS	  and	  staged	  bilateral	  DBS	  are	  $33,481.43	  and	  $53,529.58,	  
respectively	  (McClelland	  et	  al.,	  2011).	  
	  
The	  price	  would	  amount	  up	  to	  $100,000	  if	  post-­‐surgery	  medical	  and	  care	  costs	  are	  taken	  
into	  account	  as	  well.	  While	  DBS	  is	  expensive,	  several	  European	  studies	  have	  found	  it	  to	  
be	  more	  cost	  effective	  than	  the	  best	  medical	  therapy	  and	  are	  worth	  it	  over	  time,	  if	  the	  
patient	  lives	  long	  enough	  and	  does	  not	  have	  other	  fatal	  complications	  such	  as	  cancer.	  
	  
A	  2005	  French	  study	  on	  the	  economic	  costs	  of	  subthalamic	  DBS	  found	  that	  the	  half-­‐a-­‐
year	  expenses	  of	  PD	  decreased	  from	  10,087	  Euros	  pre	  surgery	  to	  1673	  Euros	  post	  
surgery	  (Table	  3).It	  was	  concluded	  that	  subthalamic	  DBS	  provides	  patients	  who	  has	  L-­‐
DOPA	  induced	  motor	  complications	  with	  good	  outcomes	  with	  low	  risk	  and	  little	  cost	  







Table	  3.	  Cost	  of	  6	  months	  care	  of	  PD	  patients	  before	  and	  after	  subthalamic	  DBS	  (Fraix	  
et	  al.,	  2005).	  
	  
Cost	  before	  surgery	  totaled	  around	  10,087	  Euros	  and	  around	  1673	  Euros	  after	  DBS.	  	  
Most	  of	  the	  cost	  reduction	  was	  due	  to	  the	  reduction	  of	  hospitalizations	  linked	  to	  PD	  
and	  anti-­‐PD	  medications	  patients	  usually	  need.	  	  There	  is	  not	  much	  reduction	  in	  the	  
costs	  due	  to	  consultations,	  auxiliary	  care,	  and	  other	  medications	  (Fraix	  et	  al.,	  2005).	  
	  
In	  this	  same	  study,	  patients	  were	  also	  evaluated	  for	  post-­‐surgery	  effects	  on	  motor	  
symptoms,	  quality	  of	  life	  (QALYs),	  cognition,	  and	  behavior,	  as	  well	  as	  factors	  that	  could	  
be	  predictive	  of	  post-­‐surgery	  outcomes.	  	  110	  patients	  from	  four	  French	  centers	  were	  
assessed	  before	  surgery,	  at	  3	  and	  12	  months	  after	  surgery	  using	  the	  UPDRS	  scale.	  	  
Evaluations	  were	  performed	  in	  off-­‐medication	  condition	  after	  overnight	  fasting,	  and	  in	  
on-­‐medication	  condition	  during	  L-­‐DOPA	  challenge	  (L-­‐DOPA	  was	  withheld).	  	  	  The	  off	  
period	  symptoms	  greatly	  improved	  at	  the	  3-­‐month	  follow	  up;	  UPDRS	  motor	  scores	  
improved	  by	  51%	  in	  a	  blinded	  evaluation	  and	  by	  57%	  in	  a	  non-­‐blinded	  evaluation.	  	  This	  
improvement	  allowed	  for	  a	  major	  improvement	  in	  all	  aspects	  of	  the	  patient’s	  quality	  of	  
life,	  especially	  in	  the	  social	  functioning	  aspect.	  	  The	  patients	  had	  no	  cognitive	  
impairment,	  except	  for	  post-­‐surgery	  deterioration	  in	  verbal	  fluency.	  	  Some	  patients	  had	  
worsened	  motivation	  and	  or	  apathy,	  which	  is	  probably	  due	  to	  the	  large	  and	  abrupt	  





frequent	  in	  patients	  who	  had	  STN	  DBS	  compared	  to	  medically	  treated	  patients.	  	  Despite	  
of	  these	  results,	  the	  patients	  ended	  having	  520	  additional	  visits	  in	  addition	  to	  the	  
planned	  3-­‐month	  and	  12-­‐month	  follow-­‐ups,	  including	  121	  hospitalizations	  and	  399	  
outpatient	  visits	  for	  complications	  (Fraix	  et	  al.,	  2005).	  	  	  
	  
The	  cost	  of	  subthalamic	  deep	  brain	  stimulation	  was	  36,900	  Euros	  per	  patient,	  and	  this	  
included	  hospital	  stay	  of	  4-­‐5	  days,	  hospitalization	  for	  surgery	  (18-­‐31	  days),	  cost	  of	  
equipment,	  and	  cost	  of	  consultation.	  	  Comparing	  the	  total	  cost	  of	  six	  months	  before	  and	  
after	  surgery,	  the	  cost	  decreased	  from	  10,087Euros	  to	  1673	  Euros	  (Fraix	  et	  al.,	  2005).	  	  
Given	  this	  amount	  of	  savings	  in	  healthcare	  expenditure	  obtained	  in	  a	  6-­‐month	  period,	  
the	  cost	  of	  procedure	  allows	  for	  a	  return	  on	  investment	  over	  2.2	  years;	  deep	  brain	  
stimulation	  is	  cost	  effective	  over	  time.	  	  Despite	  of	  this	  promising	  data,	  there	  were	  
several	  limitations	  to	  this	  study.	  	  The	  researchers	  did	  not	  take	  into	  account	  the	  cost	  of	  
stimulator	  replacements,	  which	  is	  estimated	  at	  15,000	  Euros	  every	  5	  years,	  the	  long	  
term	  occurrence	  of	  L-­‐DOPA	  resistant	  symptoms	  and	  disabling	  symptoms	  such	  as	  
dementia,	  postural	  instability,	  speech	  deficits,	  and	  dysautonomia.	  	  	  	  
	  
This	  reduction	  in	  post-­‐surgery	  cost	  is	  supported	  by	  another	  2005	  2-­‐year	  study	  done	  in	  
Germany.	  	  According	  to	  this	  study,	  the	  average	  yearly	  expenses	  of	  antiparkinsonian	  
medications	  decreased	  from	  11,242	  Euros	  to	  3,760	  Euros	  after	  the	  first	  year	  (Meissner	  





to	  electrode	  implantation)	  but	  dropped	  by	  about	  50%	  two	  years	  after	  DBS	  surgery.	  	  It	  
was	  concluded	  that	  DBS	  was	  a	  cost	  effective	  therapy	  in	  the	  long	  run.	  	  
	  
In	  a	  2006	  one	  year	  Spanish	  prospective	  comparative	  study	  on	  the	  cost	  effectiveness	  of	  
subthalamic	  stimulation	  and	  best	  medical	  treatment,	  it	  was	  found	  that	  for	  patients	  with	  
advanced	  PD,	  DBS	  is	  more	  cost	  effective	  than	  best	  medical	  therapy	  because	  of	  its	  
improvement	  of	  PD	  and	  drastic	  reduction	  in	  the	  need	  for	  antiparkinsonian	  medications	  
(Valldeoriola	  et	  al.,	  2007).	  	  In	  this	  study,	  two	  cohorts	  of	  patients	  (total	  of	  29	  people)	  with	  
advanced	  PD	  were	  evaluated	  for	  a	  year.	  	  Patients	  were	  excluded	  if	  they	  were	  older	  than	  
75	  years	  old,	  had	  dementia	  or	  severe	  cognitive	  impairment,	  any	  conditions	  that	  
contraindicate	  surgery,	  marked	  brain	  atrophy,	  brain	  lesions	  on	  neuroimaging,	  or	  
invalidating	  remaining	  symptoms	  during	  the	  L-­‐DOPA	  on	  phase.	  	  The	  UPDRS	  and	  a	  
generic	  health	  related	  quality	  of	  life	  scale	  were	  used	  to	  assess	  the	  patients.	  	  Direct	  
medical	  costs	  included	  those	  for	  goods	  and	  services	  used	  in	  prevention	  of	  disease,	  
diagnosis,	  treatment	  and	  rehabilitation.	  	  Non-­‐medical	  costs	  included	  any	  expenses	  
related	  to	  the	  disease,	  such	  as	  transportation,	  social	  services,	  accommodations,	  and	  
special	  equipment	  and	  facilities.	  	  Cost-­‐effectiveness	  was	  measured	  by	  calculating	  life	  
years	  gained	  adjusted	  by	  health-­‐related	  quality	  of	  life	  and	  incremental	  cost-­‐







Table	  4.Cumulative	  Expenses	  of	  Best	  Medical	  Therapy	  (BMT)	  Compared	  to	  DBS	  
(Valldeoriola	  et	  al.,	  2007)	  
	  
Table	  4,taken	  from	  (Valldeoriola	  et	  al.,	  2007),	  shows	  a	  drastic	  reduction	  in	  the	  total	  
amount	  of	  expenditures	  for	  PD	  patients	  who	  had	  subthalamic	  DBS	  rather	  than	  best	  
medical	  therapy	  (BMT).	  	  This	  is	  due	  to	  a	  reduction	  in	  the	  need	  for	  L-­‐DOPA,	  dopamine	  
agonists,	  apomorphine,	  and	  COMT	  inhibitors	  (ICOMT).	  	  Values	  are	  in	  Euros.	  	  Based	  on	  
data	  from	  2006,	  1	  Euro	  =	  $1.255743	  US	  dollar	  (Year	  average	  data	  taken	  from	  
http://www.x-­‐rates.com/average/?from=EUR&to=USD&amount=1&year=2006).	  
	  
UPDRS	  scores	  improved	  more	  forsubthalamic-­‐DBS	  patients	  than	  those	  who	  had	  the	  best	  
medical	  treatment.	  	  Pharmacological	  costs	  in	  DBS	  patients	  were	  3799	  Euros	  compared	  
to	  that	  of	  patients	  using	  best	  medical	  treatment,	  which	  totaled	  to	  13,208	  Euros.	  	  (Table	  
4)	  At	  the	  beginning	  of	  the	  study,	  patients	  in	  both	  groups	  spent	  the	  same	  amount	  of	  
money	  on	  medications,	  but	  in	  the	  follow-­‐up	  period,	  DBS	  patients’	  spending	  on	  
medications	  was	  reduced	  by	  more	  than	  threefold	  compared	  to	  that	  of	  best	  medical	  
therapy	  patients.	  	  This	  is	  due	  to	  a	  drastic	  reduction	  in	  the	  use	  of	  PD	  medications	  and	  
apomorphine	  by	  patients	  who	  received	  subthalamic	  DBS.	  	  For	  patients	  who	  received	  
DBS,	  additional	  medical	  costs	  were	  1,280	  Euros	  compared	  to	  that	  of	  patients	  on	  best	  
medical	  treatment:	  4017	  Euros.	  	  The	  non-­‐direct	  medical	  costs	  of	  DBS	  and	  best	  medical	  
therapy	  was	  4,079	  Euros	  and	  2787	  Euros	  respectively	  (Valldeoriola	  et	  al.,	  2007).	  Patients	  





more	  money	  on	  physiotherapy,	  speech	  therapy,	  and	  home	  care	  assistance.	  	  Patients	  in	  
the	  best	  medical	  therapy	  group	  had	  more	  visits	  to	  the	  emergency	  room	  and	  
hospitalization	  days	  due	  to	  PD	  motor	  complications	  or	  medication	  adverse	  events.	  	  	  
	  
Deep	  Brain	  Stimulation	  For	  Younger	  Patients	  (Age	  <50):	  
Since	  its	  advent	  in	  the	  1960s,	  DBS	  had	  been	  considered	  only	  as	  a	  last	  resort	  treatment,	  
used	  only	  when	  patients	  become	  refractory	  to	  medications;	  this	  occurs	  after	  average	  
disease	  duration	  of	  14	  years.	  	  Research	  has	  shown	  that	  the	  effect	  of	  DBS	  on	  the	  neural	  
pathways	  is	  similar	  to	  that	  of	  the	  L-­‐DOPA	  medication,	  albeit	  through	  a	  different	  
mechanism.	  	  Although	  the	  current	  consensus	  is	  to	  put	  off	  surgery	  as	  long	  as	  possible	  
when	  medications	  work	  for	  patients,	  two	  recent	  studies	  had	  shown	  that	  deep	  brain	  
stimulation	  works	  even	  better	  than	  the	  best	  medical	  treatments	  in	  younger	  patients	  
with	  PD.	  	  	  
	  
A	  2006	  progressive	  and	  randomized	  study	  comparing	  the	  use	  of	  subthalamic	  DBS	  versus	  
best	  medical	  treatment	  for	  patients	  at	  an	  early	  stage	  of	  PD,	  it	  was	  found	  that	  DBS	  should	  
be	  a	  treatment	  option	  for	  such	  patients	  (Schupbach	  et	  al.,	  2006).	  	  In	  this	  study,	  all	  of	  the	  
twenty	  French	  patients	  are	  younger	  than	  55	  years	  old,	  and	  are	  afflicted	  with	  PD	  for	  a	  
short	  time;	  the	  time	  elapsed	  since	  the	  first	  parkinsonian	  symptom	  was	  about	  6.8	  +/-­‐	  1	  
years.	  	  These	  patients	  have	  mild	  to	  moderate	  motor	  signs	  (UPDRS	  “off	  medication”	  





number	  of	  patients	  matched	  for	  age,	  duration	  and	  severity	  of	  disease,	  and	  impairment	  
in	  socioprofessional	  functioning	  were	  randomly	  assigned	  either	  bilateral	  subthalamic	  
DBS	  or	  best	  medical	  treatment.	  	  The	  PD	  motor	  scales,	  quality	  of	  life	  scales,	  cognition,	  
psychiatric	  morbidity	  were	  used	  to	  assess	  the	  patients	  at	  inclusion,	  and	  at	  6,	  12,	  and	  18	  
months	  after	  treatment.	  	  Results	  showed	  that	  DBS	  was	  more	  beneficial	  than	  best	  
medical	  treatment	  for	  patients	  in	  early	  stages	  of	  PD.	  	  Quality	  of	  life	  was	  improved	  by	  
24%	  in	  surgical	  and	  0%	  in	  non-­‐surgical	  patients.	  	  After	  18	  months,	  the	  severity	  of	  PD	  
motor	  signs	  “off”	  medication,	  L-­‐DOPA-­‐induced	  motor	  complications,	  and	  daily	  L-­‐DOPA	  
dose	  were	  reduced	  by	  69%,	  83%,	  and	  57%	  in	  operated	  patients	  and	  increased	  by	  29%,	  
15%,	  and	  12%	  in	  the	  group	  with	  medical	  treatment	  only.	  	  Patients	  in	  the	  surgical	  group	  
had	  mild	  or	  transient	  adverse	  events,	  and	  improved	  overall	  psychiatric	  morbidity	  and	  
anxiety	  (Schupbach	  et	  al.,	  2006).	  	  	  
	  
In	  the	  EARLYSTIM	  study	  done	  between	  2007	  and	  2009	  in	  17	  specialized	  centers	  in	  
Germany	  and	  France,	  251	  patients	  were	  randomly	  assigned	  either	  subthalamic	  DBS	  or	  
best	  medical	  treatment.	  	  This	  study	  was	  done	  to	  test	  the	  hypothesis	  that	  deep	  brain	  
stimulation	  improves	  quality	  of	  life	  as	  early	  as	  the	  beginning	  of	  the	  intermediate	  phase,	  









Figure	  17:EARLYSTIM	  Study	  Hypothesis:	  Subthalamic	  DBS	  Provides	  More	  Benefits	  if	  
Used	  in	  Early	  PD.	  	  
	  
Figure	  17.	  Quality	  of	  life	  for	  PD	  patients	  gradually	  degenerates	  over	  time	  (black	  line)	  
even	  during	  the	  honeymoon	  period,	  which	  is	  the	  earliest	  stage	  of	  PD	  where	  dopamine	  
agonists	  and	  other	  medications	  keep	  all	  symptoms	  under	  control.	  	  Deep	  brain	  
stimulation	  works	  well	  for	  patients	  with	  advanced	  PD	  and	  can	  improve	  quality	  of	  life	  
up	  to	  25%	  (green	  line).	  	  The	  EARLYSTIM	  study	  hypothesizes	  that	  this	  improvement	  can	  
be	  seen	  much	  earlier	  in	  the	  disease	  (red	  line)	  when	  patients	  begin	  to	  have	  reductions	  
of	  life	  quality	  and	  are	  still	  psychosocially	  competent	  (Deuschl	  et	  al.,	  2012).	  	  
	  
Quality	  of	  life	  was	  the	  main	  outcome	  measure	  while	  a	  video-­‐based	  motor	  score	  was	  a	  
blinded	  secondary	  outcome.	  	  Motor,	  neuropsychological,	  psychiatric	  and	  psychosocial	  
aspects	  were	  assessed	  by	  scales	  or	  questionnaires	  specific	  for	  each	  aspect.	  	  In	  order	  to	  
reduce	  suicidal	  ideation	  and	  behavior,	  all	  patients	  had	  a	  semi-­‐structured	  psychiatric	  
interview	  repeated	  at	  follow-­‐up	  visits	  at	  least	  every	  8	  weeks.	  	  All	  patients	  were	  under	  61	  
years	  old,	  and	  the	  mean	  age	  was	  52.6	  years	  old.	  	  They	  all	  have	  mild	  L-­‐DOPA-­‐responsive	  





psychosocial	  competence,	  and	  had	  recently	  experienced	  the	  end	  of	  their	  honeymoon	  
period.	  	  However,	  the	  patients’	  disease	  duration	  was	  7.5	  years;	  the	  duration	  had	  be	  four	  
years	  or	  more	  to	  exclude	  any	  non-­‐idiopathic	  cases	  of	  PD.	  	  	  
Figure	  18A,	  B:	  Comparison	  of	  efficacy	  of	  DBS	  and	  Best	  Medical	  Therapy	  in	  Early	  Stage	  
PD	  Patients.	  
	  
Figure	  18A	  (Schuepbach	  et	  al.,	  2013):	  PDQ-­‐39	  is	  a	  subset	  of	  the	  UPDRS	  scale.	  
Figure	  18A	  shows	  the	  progression	  f	  the	  PDQ-­‐39	  Index	  Score	  for	  patients	  who	  had	  best	  
medical	  therapy	  (Blue)	  and	  patients	  who	  had	  DBS	  at	  early	  stage	  of	  PD	  (Red).	  	  Lower	  







Figure	  18B	  (Schuepbach	  et	  al.,	  2013):	  	  
Figure	  18B	  shows	  improvements	  in	  the	  scores	  for	  various	  domains	  of	  the	  PDQ-­‐39	  
questionnaire	  for	  patients	  who	  received	  either	  DBS	  or	  best	  medical	  therapy.	  	  Again,	  
patients	  who	  received	  DBS	  at	  an	  early	  stage	  of	  PD	  had	  major	  improvements	  (red	  bars)	  
in	  mobility,	  activities	  of	  daily	  living,	  emotional	  well-­‐being,	  stigma,	  bodily	  discomfort,	  
social	  support,	  and	  cognition.	  	  No	  difference	  in	  communication	  scores	  between	  the	  
two	  groups	  of	  patients.	  
	  
For	  the	  primary	  outcome	  of	  quality	  of	  life,	  the	  mean	  score	  for	  the	  neurostimulation	  
group	  improved	  by	  7.8	  points,	  and	  that	  for	  the	  medical	  therapy	  group	  worsened	  by	  0.2	  
points,	  as	  assessed	  by	  the	  summary	  index	  of	  the	  Parkinson’s	  Disease	  Questionnaire	  
(PDQ-­‐39).	  	  As	  for	  the	  other	  aspects,	  neurostimulation	  was	  superior	  to	  medical	  therapy	  
with	  respect	  to	  motor	  disability,	  activities	  of	  daily	  living,	  L-­‐DOPA-­‐induced	  motor	  
complications,	  and	  time	  with	  good	  mobility	  and	  no	  dyskinesia.	  	  There	  was	  also	  a	  lower	  
risk	  of	  suicide	  in	  the	  neurostimulation	  group	  than	  the	  medical	  treatment	  group.	  	  
However,	  serious	  side	  effects	  occurred	  in	  54.8%	  of	  patients	  in	  the	  neurostimulation	  







Parkinson’s	  disease	  is	  a	  progressively	  debilitating	  condition	  that	  affects	  about	  1%	  of	  the	  
world’s	  population.	  	  There	  are	  several	  types	  of	  PD,	  but	  the	  idiopathic	  L-­‐DOPA	  responsive	  
type	  makes	  up	  the	  majority	  of	  all	  cases	  of	  PD.	  	  The	  current	  bestmedical	  treatments	  
include	  dopamine	  agonists,	  L-­‐DOPA,	  MAO-­‐B	  inhibitors,	  and	  COMT	  inhibitors	  while	  the	  
best	  surgical	  therapies	  are	  mainlyDBS	  and	  pallidotomy	  (George	  et	  al.,	  2009).	  	  The	  
current	  consensus	  on	  treating	  idiopathic	  PD	  patients	  is	  to	  start	  with	  dopamine	  agonists	  
at	  early	  stages	  of	  the	  disease,	  then	  switch	  to	  the	  L-­‐DOPA	  medication,	  and	  finally	  to	  the	  
surgical	  methods	  of	  DBS	  when	  the	  patient	  becomes	  refractory	  to	  all	  medications.	  	  There	  
are	  several	  rationales	  to	  this	  consensus:	  the	  first	  is	  that	  surgical	  options	  are	  always	  last	  
resort	  treatments.	  	  Secondly,	  it	  is	  hypothesized	  that	  L-­‐DOPA	  is	  not	  neuroprotective,	  and	  
early	  use	  of	  it	  would	  increase	  production	  of	  oxidative	  radicals	  and	  expedite	  the	  
progression	  of	  PD.	  	  Hence,	  dopamine	  agonists	  are	  considered	  as	  a	  better	  option	  for	  
treating	  early	  PD.	  	  Thirdly,	  chronic	  use	  of	  L-­‐DOPA	  results	  in	  L-­‐DOPA	  induced	  dyskinesia,	  
dystonia,	  on-­‐off	  condition,	  and	  worsening	  of	  symptoms	  when	  the	  effects	  of	  L-­‐DOPA	  
wear	  off.	  	  As	  the	  disease	  progresses,	  the	  patient	  becomes	  refractory	  to	  all	  medications.	  	  	  
	   Deep	  Brain	  Stimulation	  should	  be	  used	  earlier	  when	  the	  patient	  has	  the	  first	  sign	  
of	  wearing	  off	  of	  L-­‐DOPA	  rather	  than	  at	  a	  stage	  where	  the	  patient	  is	  refractory	  to	  all	  
medications.	  	  DBS	  offers	  the	  patient	  relief	  from	  all	  of	  the	  cardinal	  symptoms	  of	  PD;	  it	  
also	  alleviates	  the	  motor	  side	  effects	  of	  L-­‐DOPA	  usage.	  	  However,	  the	  procedure	  is	  





psychiatric	  disorders.	  	  Surgical	  adverse	  events	  include	  infections	  at	  surgical	  sites,	  
seizures,	  hemorrhages	  24	  hours	  after	  the	  operation,	  and	  the	  occasional	  misplacement	  
of	  the	  electrode	  within	  the	  brain.	  	  Psychiatric	  disorders	  would	  include	  increased	  suicide	  
ideations	  and	  attempts,	  increased	  apathy	  and	  depression,	  and	  excessive	  gambling	  
behavior	  for	  some	  patients.	  	  In	  addition	  to	  these	  problems,	  patients	  using	  DBS	  have	  to	  
replace	  the	  battery	  every	  three	  to	  five	  years.	  	  Despite	  of	  all	  of	  these	  adverse	  events	  of	  
DBS,	  studies	  have	  shown	  that	  deep	  brain	  stimulation	  is	  far	  superior	  to	  the	  best	  medical	  
treatment	  for	  improving	  patients’	  mobility,	  quality	  of	  life,	  activities	  of	  daily	  living,	  
emotional	  well	  being,	  and	  UPDRS	  motor	  scores	  whether	  the	  patients	  are	  in	  the	  
advanced	  or	  early	  stages	  of	  PD.	  	  The	  number	  of	  suicides	  decreases	  if	  DBS	  was	  done	  at	  an	  
earlier	  stage	  of	  PD.	  	  Moreover,	  certain	  studies	  have	  found	  that	  even	  though	  most	  of	  the	  
therapeutic	  effects	  of	  DBS	  abruptly	  wear	  off	  one	  year	  post	  surgery,	  and	  disappear	  
altogether	  by	  five	  years,	  the	  alleviating	  effect	  of	  DBS	  on	  motor	  symptoms,	  dyskinesia,	  
and	  dystonia,	  remains	  up	  to	  ten	  years	  post-­‐surgery.	  	  While	  DBS	  is	  expensive,	  certain	  
European	  studies	  have	  found	  that	  its	  drastic	  reduction	  in	  motor	  symptoms	  and	  the	  need	  
for	  medications	  post-­‐surgery	  make	  it	  much	  more	  cost	  effective	  over	  time	  than	  the	  best	  
medical	  treatment.	  	  Based	  on	  current	  research	  data,	  it	  is	  strongly	  recommended	  that	  
DBS	  should	  be	  used	  much	  earlier	  to	  treat	  PD	  patients	  who	  are	  at	  an	  earlier	  stage	  of	  the	  
disease;	  however,	  since	  there	  had	  been	  only	  two	  studies	  done	  on	  using	  DBS	  for	  patients	  
at	  an	  earlier	  stage	  of	  the	  disease,	  more	  studies	  should	  be	  done.	  	  Last	  but	  not	  least,	  in	  





the	  globus	  pallidus	  –	  is	  affected	  per	  surgery.	  	  While	  DBS	  of	  the	  subthalamic	  and	  globus	  
pallidus	  nuclei	  are	  only	  good	  for	  L-­‐DOPA	  responsive	  symptoms,	  recent	  research	  have	  
shown	  that	  DBS	  of	  either	  the	  pedunculopontine	  or	  the	  caudal	  zona	  incerta	  nuclei	  is	  
effective	  for	  controlling	  L-­‐DOPA	  independent	  symptoms.	  	  Hence,	  it	  may	  be	  beneficial	  to	  
conduct	  further	  research	  on	  stimulating	  more	  targets	  simultaneously	  so	  that	  both	  L-­‐
DOPA	  responsive	  and	  independent	  symptoms	  can	  be	  controlled	  together.	  
	  





APPENDIX I: Unified Parkinson’s Disease Rating Scale 
Scale taken from (Parkinson Study Group, 2004) 
 
UNIFIED PARKINSON'S DISEASE RATING SCALE 
I. MENTATION, BEHAVIOR AND MOOD 
0 = None. 
1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties. 
2 = Moderate memory loss, with disorientation and moderate difficulty handling complex problems. Mild 
but definite 
impairment of function at home with need of occasional prompting. 
3 = Severe memory loss with disorientation for time and often to place. Severe impairment in handling 
problems. 
4 = Severe memory loss with orientation preserved to person only. Unable to make judgements or solve 
problems. 
Requires much help with personal care. Cannot be left alone at all. 
1. Intellectual Impairment 
(Due to dementia or drug intoxication) 
0 = None. 
1 = Vivid dreaming. 
2 = "Benign" hallucinations with insight retained. 
3 = Occasional to frequent hallucinations or delusions; without insight; could interfere with daily activities. 
4 = Persistent hallucinations, delusions, or florrid psychosis. Not able to care for self. 
2. Thought Disorder 
1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks. 
2 = Sustained depression (1 week or more). 
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of interest). 
4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent. 
3. Depression 
0 = Normal. 
1 = Less assertive than usual; more passive. 
2 = Loss of initiative or disinterest in elective (nonroutine) activities. 
3 = Loss of initiative or disinterest in day to day (routine) activities. 
4 = Withdrawn, complete loss of motivation. 
4. Motivation/Initiative 
II. ACTIVITIES OF DAILY LIVING (for both "on" and "off") 
0 = Normal. 
1 = Mildly affected. No difficulty being understood. 
2 = Moderately affected. Sometimes asked to repeat statements. 
3 = Severely affected. Frequently asked to repeat statements. 
4 = Unintelligible most of the time. 
5. Speech 
0 = Normal. 
1 = Slight but definite excess of saliva in mouth; may have nighttime drooling. 
2 = Moderately excessive saliva; may have minimal drooling. 
3 = Marked excess of saliva with some drooling. 
4 = Marked drooling, requires constant tissue or handkerchief. 
6. Salivation 
0 = Normal. 
1 = Rare choking. 
2 = Occasional choking. 
3 = Requires soft food. 
4 = Requires NG tube or gastrotomy feeding. 
7. Swallowing 
0 = Normal. 
1 = Slightly slow or small. 
2 = Moderately slow or small; all words are legible. 
3 = Severely affected; not all words are legible. 
4 = The majority of words are not legible. 
8. Handwriting 





1 = Somewhat slow and clumsy, but no help needed. 
2 = Can cut most foods, although clumsy and slow; some help needed. 
3 = Food must be cut by someone, but can still feed slowly. 
4 = Needs to be fed. 
9. Cutting food and handling utensils 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Occasional assistance with buttoning, getting arms in sleeves. 
3 = Considerable help required, but can do some things alone. 
4 = Helpless. 
10. Dressing 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Needs help to shower or bathe; or very slow in hygienic care. 
3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom. 
4 = Foley catheter or other mechanical aids. 
11. Hygiene 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can turn alone or adjust sheets, but with great difficulty. 
3 = Can initiate, but not turn or adjust sheets alone. 
4 = Helpless. 
12. Turning in bed and adjusting bed clothes 
0 = None. 
1 = Rare falling. 
2 = Occasionally falls, less than once per day. 
3 = Falls an average of once daily. 
4 = Falls more than once daily. 
13. Falling (unrelated to freezing) 
0 = None. 
1 = Rare freezing when walking; may have starthesitation. 
2 = Occasional freezing when walking. 
3 = Frequent freezing. Occasionally falls from freezing. 
4 = Frequent falls from freezing. 
14. Freezing when walking 
0 = Normal. 
1 = Mild difficulty. May not swing arms or may tend to drag leg. 
2 = Moderate difficulty, but requires little or no assistance. 
3 = Severe disturbance of walking, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
15. Walking 
(Symptomatic complaint of tremor in any part of body.) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Moderate; bothersome to patient. 
3 = Severe; interferes with many activities. 
4 = Marked; interferes with most activities. 
16. Tremor 
0 = None. 
1 = Occasionally has numbness, tingling, or mild aching. 
2 = Frequently has numbness, tingling, or aching; not distressing. 
3 = Frequent painful sensations. 
4 = Excruciating pain. 
17. Sensory complaints related to parkinsonism 
III. MOTOR EXAMINATION 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
18. Speech 





1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 1/4 inch or more. 
19. Facial Expression 
(head, upper and lower extremities) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
20. Tremor at rest 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
21. Action or Postural Tremor of hands 
(Judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be 
ignored.) 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
22. Rigidity 
(Patient taps thumb with index finger in rapid succession.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 
4 = Can barely perform the task. 
23. Finger Taps 
(Patient opens and closes hands in rapid succesion.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 
4 = Can barely perform the task. 
24. Hand Movements 
(Pronation-supination movements of hands, vertically and horizontally, 
with as large an amplitude as possible, both hands simultaneously.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 
4 = Can barely perform the task. 
25. Rapid Alternating Movements of Hands 
(Patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should be at least 
3 inches.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 
4 = Can barely perform the task. 
26. Leg Agility 
(Patient attempts to rise from a straightbacked chair, with arms folded across chest.) 
0 = Normal. 
1 = Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up without help. 





27. Arising from Chair 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
4 = Marked flexion with extreme abnormality of posture. 
28. Posture 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or 
propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
29. Gait 
(Response to sudden, strong posterior displacement produced by pull on shoulders while patient 
erect with eyes open and feet slightly apart. Patient is prepared.) 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
30. Postural Stability 
(Combining slowness, hesitancy, decreased armswing, small amplitude, and 
poverty of movement in general.) 
0 = None. 
1 = Minimal slowness, giving movement a deliberate character; could be normal for some persons. 
Possibly reduced 
amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some 
reduced 
amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
31. Body Bradykinesia and Hypokinesia 
IV. COMPLICATIONS OF THERAPY (In the past week) 
A. DYSKINESIAS 
(Historical information.) 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
32. Duration: What proportion of the waking day are dyskinesias present? 
(Historical information; may be modified by office examination.) 
0 = Not disabling. 
1 = Mildly disabling. 
2 = Moderately disabling. 
3 = Severely disabling. 
4 = Completely disabled. 
33. Disability: How disabling are the dyskinesias? 
0 = No painful dyskinesias. 
1 = Slight. 
2 = Moderate. 
3 = Severe. 
4 = Marked. 
34. Painful Dyskinesias: How painful are the dyskinesias? 
(Historical information.) 
0 = No 
1 = Yes 
35. Presence of Early Morning Dystonia 
B. CLINICAL FLUCTUATIONS 





1 = Yes 
36. Are "off" periods predictable? 
0 = No 
1 = Yes 
37. Are "off" periods unpredictable? 
0 = No 
1 = Yes 
38. Do "off" periods come on suddenly, within a few seconds? 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
39. What proportion of the waking day is the patient "off" on average? 
C. OTHER COMPLICATIONS 
0 = No 
1 = Yes 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
1 = Yes 
41. Any sleep disturbances, such as insomnia or hypersomnolence? 
( Record the patient's blood pressure, height and weight on the scoring form) 
0 = No 
1 = Yes 
42. Does the patient have symptomatic orthostasis? 
V. MODIFIED HOEHN AND YAHR STAGING 
STAGE 0 = No signs of disease. 
STAGE 1 = Unilateral disease. 
STAGE 1.5 = Unilateral plus axial involvement. 
STAGE 2 = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically independent. 
STAGE 4 = Severe disability; still able to walk or stand unassisted. 
STAGE 5 = Wheelchair bound or bedridden unless aided. 
VI. SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
100% = Completely independent. Able to do all chores without slowness, difficulty or impairment. 
Essentially normal. 
Unaware of any difficulty. 
90% = Completely independent. Able to do all chores with some degree of slowness, difficulty and 
impairment. Might 
take twice as long. Beginning to be aware of difficulty. 
80% = Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness. 
70% = Not completely independent. More difficulty with some chores. Three to four times as long in 
some. Must spend 
a large part of the day with chores. 
60% = Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; 
some impossible. 
50% = More dependent. Help with half, slower, etc. Difficulty with everything. 
40% = Very dependent. Can assist with all chores, but few alone. 
30% = With effort, now and then does a few chores alone or begins alone. Much help needed. 
20% = Nothing alone. Can be a slight help with some chores. Severe invalid. 
10% = Totally dependent, helpless. Complete invalid. 
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